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Abstract

THE ROLE OF TUMOR AND TUMOR MICROENVIRONMENT ON BREAST CANCERASSOCIATED ADIPOCYTE PLASTICITY
By Janina Vaitkus Pearce, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy in Clinical and Translational Research, Cancer and Molecular Medicine at
Virginia Commonwealth University.
Virginia Commonwealth University, 2019
Director: Francesco S. Celi
Professor, Department of Internal Medicine
Division Chair, Division of Endocrinology, Diabetes, and Metabolism

Cancer-associated cachexia is a condition defined by a sustained net-negative energy
imbalance. Although the different types of adipose tissue – white, beige, and brown –
have been implicated in contributing to cancer-associated cachexia, the mechanisms of
these maladaptive changes and their impact on whole-body energy expenditure have
not been fully elucidated. Using breast cancer as our model, we demonstrate white
adipose tissue browning in murine and human breast cancer; furthermore, we
demonstrate that this effect is extremely localized and takes place early in tumor
progression. We utilized in vitro cell culture techniques and demonstrate that cancer
secreted factors and cross-talk with white adipocytes decrease expression of classic
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white adipose tissue-related genes. We also demonstrate in murine and human culture
models that cancer secreted factors reduce white adipocyte lipid droplet size, and
cross-talk between cancer cells and adipocytes results in an increase in lipolysis-related
gene expression. Interestingly, our results strongly suggest that in mice, neither cancer
secreted factors nor cross talk with adipocytes can induce white adipose tissue
browning, indicate that this process likely occurs independently of direct cancer
interactions with local white adipocytes. We demonstrate that interleukin 6, a cytokine
with previous implications in white adipose tissue browning, induces interleukin 6mediated signaling; however, that signaling alone is not enough to directly induce white
adipose tissue browning. We present preliminary data suggesting that immune cell
population shifts within the white adipose tissue of mice with breast cancer tumors may
be source of white adipose tissue browning. We show that the Virginia Commonwealth
University Health System has an identifiable population of patients with cancer with
what we hypothesize as maladaptive thermogenic adipose tissue activity, and discuss
ongoing experiments aimed at understanding the implications of these changes on
whole body energy expenditure in human patients. Lastly, in a case of autoimmune
diabetes mellitus in the setting of an extra-adrenal paraganglioma, we demonstrate that
the interaction between cancer and whole-body metabolism is multifaceted. Together,
these experiments demonstrate that adipose tissue plasticity occurs in breast cancer
(and other cancers), and that different drivers for individual changes exist within the
tumor microenvironment. We predict that further exploration of the exact mechanisms
and translational implications will provide useful information to lead to new therapeutic
treatments for patients with cancer-associated cachexia.
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Chapter 1: Background
Please note that some of the material within this Chapter comes from our previously
published article, DOI 10.1177/1535370216683282. The final, definitive version of this
paper has been published in Exp Biol Med (Maywood), Volume 242/Issue 5, March
2017 published by SAGE Publishing [1].

1.1 Energy balance
The First Law of Thermodynamics, also referred to as the Law of Conservation of
Energy, states that energy cannot be created or destroyed [2]. In the context of
metabolism, energy balance is defined as the difference between energy intake and
energy expenditure (EE). Taken together with the Law of Conservation of Energy,
changes in an individual’s weight must be attributed to an imbalance in either energy
intake or expenditure. A positive energy balance, where energy intake is greater than
energy expended, causes weight gain; a negative energy balance, where energy intake
is less than energy expended, results in weight loss (Figure 1). However, this balance
is more complex than simply dietary intake and exercise; the classic “static,” or “linear,”
model of energy balance is being replaced by the concept of “dynamic” energy balance,
in which factors such as genetics, early life events, mood, stress, and metabolic and
hormonal signaling also contribute to the regulation of an individual’s energy balance
[3].
In present-day society, the effects of sustained positive energy balance are seen
in the global obesity pandemic, where rates of obesity have roughly tripled in the past
35 years [4]. While some individuals with obesity may be classified as ‘metabolically
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healthy’ [5], obesity is often associated with other health problems and increases the
risk for development of comorbidities such as diabetes, cardiac disease, liver disease,
and reproductive dysfunction, and cancer [6]. Obesity and its associated health
problems also come with a substantial economic cost: in 2008 in the United States
alone, the costs associated with obesity and its associated health problems were
estimated to be about $147 billion [7].
Deleterious effects can also be seen in cases of sustained negative energy
balance. Severe burns, trauma, and sepsis can all result in a negative energy balance
that causes undesirable health consequences [8-10]. While obesity increases the risk of
cancer development [6], sustained negative energy balance in the context of cancer can
result in cancer-associated cachexia (CAC), discussed in detail in section 1.4.
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Figure 1. Conceptual overview of energy balance
Energy balance is a complex, dynamic process with multiple contributing factors. Imbalances result in
weight gain (positive balance, on left) or weight loss (negative balance, on right).
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1.2 Measuring energy expenditure
Collectively, total energy expenditure (TEE) represents the total amount of
energy used in daily functioning. TEE is comprised of resting energy expenditure (REE,
also known as basal energy expenditure or BEE), activity energy expenditure (AEE),
and thermic effects of food, or diet-induced thermogenesis (DIT). REE is the energy
required to maintain basic cell and organ functions such as respiration and regulation of
body temperature [11]. AEE is the energy used to perform exercise and non-exercise
related tasks [12], and DIT is the energy used to metabolize substrates consumed in the
diet [11]. Similar to energy balance, TEE is influenced by a large range of factors,
including but not limited to age, body composition, thyroid hormone, catecholamines,
pharmacologic therapies, and diseases [12].
Measuring energy expenditure (EE) is a useful tool in animal and human studies
and can provide a point-estimate of energy utilization at rest, after eating, during
exercise, and under other experimental conditions. Predictive equations, such as the
Harris-Benedict equation, are historically based on specific patient populations. This is
problematic, as our population’s phenotype is changing over time and therefore
invalidates many of these older predictive equations [11, 12].
There are several approaches to measuring EE. Heat, carbon dioxide, and
oxygen are products of substrate utilization:
𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 + 𝑂  𝑜𝑥𝑖𝑑𝑎𝑡𝑖𝑜𝑛 𝐶𝑂 + 𝑂 + ℎ𝑒𝑎𝑡.
Direct calorimetry is a technique used to calculate EE by directly measuring heat loss
[13, 14]. Subjects enter a sealed chamber to measure body heat production, and
software is then used to calculate EE. While this can provide accurate measurements, it
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is burdened with several limitations, the most significant that subjects cannot bring any
devices that will increase heat production and confound results [11, 14]. Indirect
calorimetry can overcome these disadvantages.
Indirect calorimetry is a technique that utilizes the other products of substrate
utilization – by measuring CO2 and O2 gas exchange – to indirectly measure EE [13].
There are several different methods by which indirect calorimetry can be performed.
Portable methods, which include a mouthpiece and mask attached to a small backpackencased analyzer, allow for subjects to maintain relatively unrestricted mobility;
however, they may be uncomfortable for the patient and limit the length of study design
due to battery life constraints [14]. Metabolic carts using facemasks, mouthpieces, or
‘domed hoods’ are not limited by battery life and are fast and accurate in data collection;
however, these are often uncomfortable for patients and limit patient mobility [14].
Whole-room indirect calorimeters – also known as “respiration chambers” or
“metabolic chambers,” allow for maximum patient mobility and comfort. These are
rooms that vary in size from small (fitting a twin sized bed or exercise bike, for example)
to large (fitting a bed, toilet, sink, and exercise equipment simultaneously), providing the
capability for a range of experimental designs (Figure 2 shows the VCUHS small and
large open-circuit whole-room indirect calorimeters). While these large volumes can
increase the equilibration time, our lab has demonstrated robust temporal accuracy in
these systems [15]. Sleep studies, exercise studies, resting EE studies, combinations
of these, and more are possible using these systems. Additional procedures such as
blood and urine collection can be added to protocols using the whole-room indirect
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calorimeters, and additional equipment can be used within the calorimeters to acquire
additional data, such as accelerometers to measure movement.
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Figure 2. Whole-room indirect calorimeters at VCUHS
(A) Small and (B) Large whole-room indirect calorimeters located in the Clinical Research Service Unit
(CRSU) in North Hospital at the Virginia Commonwealth University Health System (VCUHS).
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1.3 Adipose tissue
Adipose tissue, previously viewed as an inert fat depot in isolated areas within
the body, is now regarded as a large, interactive, multi-compartment organ with clear
organization and anatomy [16-18]. Additionally, the secretomes of these depots can act
locally (paracrine organ function) and systemically (endocrine organ function) [19, 20].
The composition of adipose tissue includes mature adipocytes, as well as other
cell types that are important for each adipose tissue depots’ function. These include
vascular endothelial cells which provide the necessary vascular supply to the tissue,
nerve endings from the sympathetic nervous system, adipocyte precursor cells, and a
variety of immune cells [21-23].
Mature adipocytes are terminally differentiated cells, although recent evidence
suggests that they can be reprogrammed [24]. Turnover of adipocytes is quite low, but
de novo differentiation does occur [25].

1.3.1 White adipose tissue (WAT)
The largest component of adipose tissue is white adipose tissue (WAT), which
primarily consists of large, spherical adipocytes with a unilocular lipid droplet consuming
most of the cell volume [18]. WAT is found in both subcutaneous and visceral depots,
and increased visceral WAT mass is associated with increased metabolic risk [26, 27].
WAT has important endocrine and paracrine roles throughout the body [18, 28, 29], and
in general terms, functions to store energy, mainly in the form of triglycerides [30, 31].
Developmentally, white adipocytes are derived from myogenic factor 5 (MYF5)-negative
precursors (Figure 3).
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1.3.2 Brown adipose tissue (BAT)
In contrast to WAT, brown adipose tissue (BAT) primarily functions to expend
energy [30]. Until recently, functionally-significant BAT was thought to be present only in
neonates, undergoing rapid involution with age [30, 32-35], despite early reports that
indicated the presence of BAT in adult humans [33, 34, 36]. The development and use
of positron-emission tomography (PET) allowed for visualization of BAT in adult humans
[37], and in combination with other functional analyses [38, 39], sparked the recent
resurgence in interest in BAT’s function in health and disease. Details of WAT and BAT
development and gene signature are discussed elsewhere [30, 40, 41], but it is
important to note that, at least in mice, anatomically-defined BAT adipocytes are derived
from a cell lineage different from WAT, which instead share a lineage with myocytes
(muscle cells) which are MYF5-positive [42, 43]. Adult human BAT depots are located
near the aorta and within the supraclavicular region of the neck [18]. These adipocytes
contain multilocular lipid droplets, and their ability to expend uniquely great amounts of
energy is largely due to the presence and activation of a proton leakage pathway [44]
mediated by uncoupling protein 1 (UCP1) – the hallmark of BAT function [33, 45].
UCP1 uncouples oxidative phosphorylation from ATP synthesis in the inner
mitochondrial membrane (Figure 4) to dissipate energy in the form of heat [46, 47].
UCP1 is one of several members of the uncoupling protein family; of these, UCP2 and
UCP3 are most similar to UCP1 in homology. UCP1 is found specifically in thermogenic
adipocytes, UCP2 is expressed in many cell types [48], and UCP3 is expressed more
selectively, most notably in skeletal muscle [49]. Both UCP2 and UCP3 are important in
several cellular processes, for example, in regulating the cell’s response to reactive
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oxygen species-mediated oxidative stress and in fatty acid metabolism (reviewed by
[48, 50, 51]; however, interestingly, of the uncoupling protein family, only UCP1 is able
to confer a thermogenic phenotype – neither UCP2 nor UCP3 are capable of eliciting
this effect [52, 53]. The UCP1 gene in humans is located on chromosome 4 and has two
regulatory elements in the 5’ non-coding region that regulate its transcription. These
bind to key transcriptional regulators such as peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PPARGC1A) and PR domain zinc finger protein 16
(PRDM16) (reviewed by [54]). UCP1 is regulated post-translationally as well. Free long
chain fatty acids and purine nucleotides have been shown to serve opposing functions:
purine nucleotides inhibit UCP1 activity, and free long chain fatty acids removing that
purine-mediated inhibition to activate UCP1 function [55].

1.3.3 Beige adipose tissue
More recently, an additional type of adipocyte, defined as ‘brite’ (brown-in-white)
[56] or ‘beige’ [57], was identified. These adipocytes are located within and share cell
lineage with white adipocytes [30] but express UCP1 and function like brown adipocytes
[56] (Figure 3A). While some authors suggest that beige cells develop de novo [58], the
model of transdifferentiation – development of beige adipocytes from pre-existing white
adipocytes [59] – predominates [18]. Interestingly, in addition to sustained exposure to
cold, multiple different pathways promote the white-to-beige transition leading to a
similar cellular phenotype, reviewed by Giralt [30]. Importantly, beige adipose tissue can
expand in response to several mediators and is a target of both endocrine and
paracrine stimuli [60].
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This relatively ‘new’ beige adipose tissue has generated a great deal of
excitement, as its function is similar to classical BAT in expending energy and may have
additional protective roles against obesity [30]. On the other hand, its capability of
developing, expanding, and activating under local stimuli, including extracellular matrix
components [61], make this tissue a potential driver of CAC in response to tumor
microenvironment.
Together, all three adipose tissue types (Figure 3A), as well as their
differentiation and maintenance (Figure 3B), are clearly important in the energy balance
that is disrupted in CAC.
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Figure 3. White, beige, and brown adipose tissue
(A) White adipose tissue (‘White’ in image) has the lowest thermogenic activity, while brown adipose
tissue (‘Brown’ in image) has the highest. White and beige adipocytes share the same Myf5-negative
lineage, but beige and brown adipose tissue share increased UCP1 expression which confers
thermogenic activity. (B) General overview of process of adipogenesis and transdifferentiation of white to
beige adipocytes (“WAT browning”). Abbreviations defined in List of Abbreviations.
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Figure 4. Uncoupling protein 1 (UCP1) is the hallmark of thermogenic adipose tissue
UCP1 is located within the inner mitochondrial membrane. Normally, protons generated by the electron
transport chain (complexes I through IV as indicated in image) move through the ATP synthase to
generate ATP; however, when UCP1 is activated, the proton gradient is collapsed via proton transport
through UCP1, which generates heat.
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1.4 Cancer-associated cachexia (CAC)
1.4.1 History, definition, and staging
Changes in metabolism and altered energy requirements have been documented
in patients with cancer as early as the 1950s [62], yet it was not until the 1970s that the
multifaceted nature of cancer-associated cachexia (CAC, also referred to as cancer
cachexia) was appreciated [63, 64]. While early studies suggested that CAC was the
result of tumor-driven anorexia alone [65], it is now established that CAC is not solely
the result of decreased food intake; other contributing factors such as malabsorption
and altered metabolism play a role as well [63, 64]. In the early 2000s, increased
emphasis was placed on consolidating clinical and basic research findings to develop
guidelines for defining, staging, and treating CAC.
CAC, according to a recent international consensus developed by Fearon and
Strasser, is defined as a “multifactorial syndrome defined by an ongoing loss of skeletal
muscle mass (with or without loss of fat mass)” [66]. Almost all cancers can be
associated with CAC, although some more commonly than others [67]. Classically, CAC
is described in three stages: precachexia, cachexia, and refractory cachexia. Several
assessment criteria were proposed and described in detail by Fearon [66]; the most
obvious is the degree of weight loss a patient experiences, but others include catabolic
drive and loss of muscle mass and strength. The consensus guidelines were quickly
applied to and validated in clinical practice, and additional assessment and
management algorithms were proposed [68, 69].
While these guidelines represent significant improvements, there is still a lack of
simple clinical indicators and markers to allow for earlier and straightforward
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classification of CAC [69]. Despite increased awareness of this condition, CAC is still
very common and treatments are inadequate [70], suggesting that a comprehensive
understanding of the molecular and physiologic pathways leading to the development
and progression of CAC is still lacking. The large inter-individual variability in the
prevalence and severity of CAC in patients with the same tumor type [71, 72] further
supports the need for improving the knowledge of the pathophysiologic mechanisms
responsible for CAC. Given the high prevalence of obesity in the general population,
early stages of CAC may be missed when the diagnosis is based purely on weight loss
criteria (referred to as the ‘obesity paradox’ [72]). This factor demonstrates the need for
improvement in the early diagnosis of this condition.

1.4.2 Prognosis, effects, and treatment options
The inverse association between weight loss and survival in patients with cancer
is well known [73]. Recent estimates propose that CAC affects 60-80% of all patients
with advanced cancer [69], and is directly implicated in at least 20% of cancer-related
deaths [74], demonstrating that CAC is an independent risk factor for poor prognosis.
The loss of body mass and altered body composition in CAC leaves patients vulnerable
to increased toxicity from anti-tumor therapies such as chemotherapy [69, 75, 76]. This
may directly result in increased morbidity and mortality, and may indirectly affect
morbidity and mortality as the increased toxicity requires clinical treatment delays and
dose reductions in therapy. Not surprisingly, patients with CAC additionally experience
loss of physical function and decreased quality of life [69, 75].
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Clinical advancements in defining and staging CAC have not been matched by
similar improvements in treatment options and patient outcomes. Some studies suggest
that CAC may be reversible if caught in the precachexia or cachexia stages [68, 76].
The main therapeutic strategies utilized in these stages include exercise, intense
nutritional support, and removing any direct tumor causes (such as obstruction causing
malabsorption) [68, 69]. Unfortunately, many cases are clinically diagnosed in the
refractory cachexia stage, when CAC is often irreversible [66, 68] and nutritional
support, current drug therapies, and other measures are ineffective in restoring a netneutral or positive energy balance [77, 78]. In the past, many studies investigating
therapeutic drugs to combat CAC, such as eicosapentaenoic acid diester [79] and
bortezomib [80] have failed to demonstrate favorable outcomes. While experiments and
studies investigating new potential therapeutic targets have been ongoing, when Fearon
published his article in 2011, there were no active clinical drug trials for CAC [66]; since
then, several drugs in the pipeline have entered into the clinical trial phases. A review
by Dingemans and colleagues in 2014 identified 12 phase II clinical trials with 11
compounds [81]. Each of these drugs are expected to help combat CAC via one of the
following mechanisms: increasing appetite, improving digestion, decreasing systemic
inflammation, and improving the muscle synthesis-versus-degradation ratio [81]. Other
drugs have recently entered phase III trials, but difficulties in meeting multiple clinical
endpoints indicate the need for a more comprehensive approach. Anamorelin, a ghrelinreceptor agonist, demonstrated an ability to improve lean body mass in a phase II
clinical trial with patients with non-small cell lung cancer and CAC [82]. However, this
phase II trial, and a subsequent phase III trial, reported that while lean body mass
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improved, functional improvements in hand grip strength did not [82, 83] – highlighting
the potential discrepancy between proxies of end-organ effect and patient-centered
significant outcomes. Enobosarm, a selective androgen receptor modulator, showed a
significant increase in total lean body mass in phase II studies [84], but according to
information thus far presented in abstract format, it has not yielded consistent endpoint
results in phase III trials [85, 86]. As described below, there are many contributing
factors to CAC, so the development of these drugs is certainly a step in the right
direction. However, few compounds make it past phase II and III studies, and those that
have (and will) may not fully address the spectrum of pathophysiologic components of
CAC to be effective in mitigating or reversing all of the clinical components of CAC.

1.4.3 Contributing factors
The factors contributing to the development and maintenance of CAC are
grounded in the axiom of energy balance: weight loss or gain only occurs when there is
a sustained imbalance between energy intake and energy expenditure [64, 87]. In the
case of CAC, there is a persistent net-negative energy balance, with components linked
to both decreased energy intake and increased energy expenditure. Decreased energy
intake may occur via several mechanisms, including anorexia caused by chemosensory
distortions, malabsorption, and early satiety [66, 68, 71, 75]. Increased energy
expenditure may result from inflammation, increased tumor metabolism, and
altered/increased metabolism [68, 71, 72, 77]. To this end, the heterogeneity of adipose
tissue is particularly relevant in the pathophysiology of CAC. Adipose tissue
metabolism, aside from its more obvious role in obesity and diabetes, has been
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demonstrated to play a role in other states of metabolic dysfunction such as CAC. As
such, we identify and discuss the specific contributions of adipose tissue to the
development and progression of CAC.

1.4.4 Adipose tissue contributions to CAC: lipolysis
The breakdown of adipose tissue – lipolysis – is perhaps the most evident
component of adipose tissue’s contribution to CAC [88]. Fat loss observed in patients
with CAC is thought to occur via breakdown of adipose tissue (mainly WAT) in response
to a negative energy balance due to cancer-associated anorexia and other pathologic
factors recently reviewed by Ebadi and Mazurak [89, 90]. The importance of lipolysis in
CAC was demonstrated in a study that showed that the inhibition of lipid mobilization
can improve the CAC state [91]. A murine model of animals implanted with murine
adenocarcinoma 16 tumors reported changes in adipose tissue that included shrunken
adipocytes and decreased expression of adipose tissue transcription factors [92]. In
2018, investigators demonstrated early adipose tissue wasting in a new murine model
of CAC in pancreatic cancer [93].
From a clinical perspective, a critical component of the body mass loss observed
in CAC is the depletion of muscle mass, which usually precedes the observation of
significant changes in adipose tissue mass and is associated with decrease in muscle
function and mobility. Fearon and Strasser’s consensus findings highlight that skeletal
muscle loss is a necessity for a clinical diagnosis of CAC, but that adipose tissue loss
may or not be present [66]. However, lipolysis and lipid wasting may occur to an extent
before muscle loss [91]. Additionally, studies in a mouse model of colon cancer
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demonstrated an increase in protein kinase-A mediated lipolysis in early stage cachexia
[94], and this ‘early’ lipolysis was implicated in 1) the inception of a negative energy
balance that worsens over the course of CAC progression, and 2) a direct loss of
skeletal muscle [95]. Lipolysis results in increased free fatty acids in circulation, which
then get taken up by skeletal muscle; the excess of intramuscular free fatty acids results
in several biochemical changes, such as the expression of ubiquitin lipases Atrogin-1
and MuRF [96], that lead to skeletal muscle atrophy [97]. Indeed, Stephens showed a
positive association between the extent of body weight loss in cancer patients and the
amount of lipid droplet accumulation within skeletal muscle cells [98]. In a study of latestage CAC, protein kinase-A mediated lipolysis was not observed as in early stages, but
instead more lipases were observed and contributed to skeletal muscle dysfunction and
atrophy [99]. These findings suggest that there are likely different stages of lipid
metabolic responses in CAC. Physiologically, one would expect that lipolysis and
resulting loss of WAT mass would stimulate other pathways in the body to drive
anabolism and energy intake, such as leptin. Leptin is produced by WAT and its levels
are positively correlated to a patient’s state of adiposity, regardless of age or body mass
index (BMI) [89]. Low levels of leptin are expected in patients exhibiting fat loss with
CAC, which should result in increased activation of orexigenic pathways; however,
studies demonstrate that this feedback may be disrupted in cancer, resulting in an
undesirable decrease in signaling pathways such as neuropeptide Y [100]. It is
important to recognize that inflammation is known to be a key player in lipolysis and the
general increased catabolic drive observed in CAC (reviewed by Penet [77]). Since
adipose tissue depots have interspersed lymphocytes [18] and macrophages [101],
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there may be a functional relationship between lipolysis and increased inflammation.
However, CAC can present even in the absence of frank systemic inflammation [66],
and therapies targeting inflammatory cytokines such as tumor necrosis factor-alpha and
eicosapentaenoic acid diester have not been successful in ameliorating CAC [79, 102].
This finding is consistent with the multifactorial nature of CAC.

1.4.5 Adipose tissue contributions to CAC: beige and brown adipose tissue expansion
and activation
Several studies highlight increased resting energy expenditure in animal models
as well in humans affected by CAC, and point to adipose tissue as a culprit [103-105].
While lipolysis literally represents a loss of adipose tissue (especially WAT) mass, BAT
and beige adipose tissue depots appear to contribute to CAC via increased energy
expenditure.
BAT was first proposed as a contributor to CAC in 1989 [106], but this hypothesis
was not investigated further until the rediscovery of functional BAT in adult humans [38].
In a mechanistic study, Tsoli and colleagues found that activation of BAT (via increased
Ucp1 expression) contributed to the development of CAC in mice with cachectic colon
cancer cell line injections [103]. Interestingly, CAC and BAT activation were not present
in mice with non-cachectic colon cancer cell line injections [103]. In another study, BAT
activity was measured via 18F-fluorodeoxylucose positron emission
tomography/computed tomography (FDG PET/CT) in human patients with cancer, and
was found to correlate positively with cancer stage [107]. However, classical BAT is
relatively limited in mass, localized to relatively small depots within the body, therefore
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severely limiting its capacity to offer substantial contributions to energy expenditure and
CAC in humans [108, 109]. More studies are needed to provide a quantitative
assessment of classical BAT’s contributions to CAC [110].
WAT, however, has much larger depots, so the expansion of beige adipose
tissue within WAT depots may confer greater increases in energy expenditure, and may
contribute significantly to CAC. Not surprisingly, WAT browning was identified in
patients with pheochromocytomas [111], neuroendocrine tumors that secrete
norepinephrine, a known trigger of white-to-beige trans-differentiation. However, WAT
browning has also been observed in other tumor models beyond catecholaminesecreting tumors. Mechanistic studies in mice include genetic models of Kras-lung,
Kras-pancreatic, and K5-SOS carcinomas [112], chemically induced liver carcinoma
[112], graft/injection models of B16 melanoma [112] and Lewis lung carcinoma [112,
113], C26 colon carcinoma with and without interleukin 6 (IL6) expression [112], and
human pancreatic carcinoma xenografts [112]. In these models, investigators reported
the presence of WAT browning and its contribution to the observed CAC. This was
demonstrated by increased expression of Ucp1 mRNA and UCP1 protein [112, 113],
and also through increased expression of other genes crucial for beige adipose tissue
development, such as Prdm16 and Ppargc1a [113]. The authors also performed
functional analyses of the proposed beige adipose tissue to demonstrate increased
energy expenditure using oxygen consumption rate assays as well as body weight,
tissue weight, physical activity, oxygen uptake (VO 2), carbon dioxide production (VCO2),
respiratory exchange ratio (RER), and heat generation measurements [112, 113].
Additionally, two drivers of white-to-beige trans-differentiation were identified: IL6 [112]
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and parathyroid hormone-related peptide (PTH-rp) [113]. These are the first studies to
identify causative agents secreted by tumors that contribute to WAT browning and result
in increased energy expenditure, which contributes to CAC. importantly, WAT browning
was observed early in the progression of CAC, before skeletal muscle atrophy occurred
(consistent with the observations in lipolysis studies [91, 94]), suggesting that adipose
tissue dysfunction may occur prior to clinically-evident adipose tissue loss, contributing
to the development of CAC. Furthermore, Petruzzelli and colleagues examined, via
immunohistochemistry, adipose tissue samples acquired from human patients with CAC
and a multitude of cancers: Kaposi’s sarcoma, melanoma, cholangiocarcinoma, colon
adenocarcinoma, pancreatic neuroendocrine cancer, pleomorphic lung carcinoma, and
lung adenocarcinoma [112]. Results showed that many of the WAT samples had
increased UCP1 expression and adipocyte atrophy. While there is still much to
understand, these results clearly support the role of WAT browning in the development
and progression of CAC.
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Figure 5. Adipose tissue in CAC
A summary of adipose tissue contributions to cancer-associated cachexia (CAC). Cancer and its
microenvironment (top) influence white, beige, and brown adipose tissue (colored respectively). WAT
undergoes lipolysis, which results in a direct loss of adipose tissue mass and also contributes to skeletal
muscle mass loss. As the process progresses, skeletal muscle loss may act as positive feedback for
further adipose tissue lipolysis. WAT may also undergo browning to undergo trans-differentiation to beige
adipose tissue, expressing uncoupling protein 1 (UCP1) and thereby expending greater amounts of
energy. Similarly, existing classical brown adipose tissue may be activated, resulting in greater UCP1
expression with a resulting increase in energy expenditure. Collectively, these changes result in a netnegative energy balance, which contributes to the development and progression of CAC.
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1.4.6 The other side of the coin: the role of adipose tissue in promoting cancer
progression
It is important to recognize that the adipose tissue-cancer interactions also go in
the opposite direction. Cancer may directly and indirectly affect adipose tissue, and
adipose tissue may directly and indirectly affect cancer growth and survival, as well
[114]. Recent studies demonstrated that adipose-derived fibroblasts and cancerassociated adipocytes can contribute to cancer progression [19, 115, 116], and another
study demonstrated that increased beige and brown adipose tissue contributes to tumor
progression [117]. Since higher rates of lipolysis and browning are strongly correlated
with later-stage CAC, the hypothesized cross-talk between tumor and adipose tissue
may generate a positive feedback loop facilitating cancer progression and the clinical
impact of CAC.

1.4.7 Potential therapeutic strategies to restore adipose tissue homeostasis in CAC
As mentioned previously, aberrations in adipose tissue metabolism and
homeostasis in malignancy result in a decrease in both adipose tissue and muscle
mass. An ideal therapeutic approach would improve both adipose tissue and lean
muscle mass; however, this has not been successful due to the differences in cell
lineage of muscle and WAT. Their common precursor is the mesenchymal stem cell, but
adipogenesis and myogenesis have very different differentiation signals and pathways,
such differences in Wnt signaling [118]. Differences are also observed mechanically, as
softer substrates promote adipogenesis while stiffer substrates promote myogenesis
[119]. These differences, and subsequent lack of overlapping triggers, make the
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development of a single therapeutic aimed at increasing both WAT and muscle mass
incredibly difficult.
This relationship between adipose tissue changes and muscle loss is observed in
other non-malignancy states as well: in postmenopausal women with type 2 diabetes
mellitus, for example, increased intramuscular adipose tissue was associated with
decreased hand grip strength [120]. In the elderly population, increased thigh muscle
lipid content, represented by lower skeletal muscle attenuation coefficients on computed
tomography images, was demonstrated to be negatively associated with muscle
attenuation and strength [121]. Even in patients without metabolic disease, increased
thigh intramuscular adipose tissue is associated with predictors of increased metabolic
syndrome risk [122]. Current clinical trials investigating potential therapeutic agents for
patients with CAC are promising, but the drugs being tested do not directly address the
contributions of white, beige, and brown adipose tissue to CAC (such as reducing the
release of free fatty acids from WAT, or inhibiting the white-to-beige transition). AR-42,
a histone deacetylase, has recently demonstrated preclinical success in reducing levels
of MuRF1 and Atrogin-1 lipases and decreasing muscle degradation [123]. So, while
still mostly speculative, it is possible that restoring adipose tissue homeostasis by
targeting these areas of dysfunction will contribute to further improvements in patientcentered outcomes. For example, inhibition of WAT lipolysis and its downstream effects
on skeletal muscle atrophy could lead to improvement of hand-grip strength (used as a
proxy for overall muscle strength and function) and assessments of physical activity
(usually via patient-reported rating of physical functioning). Patients’ self-reported
quality of life and psychosocial status will likely improve if adipose tissue mass loss (and
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skeletal muscle, as well) was dampened – in part because patients may feel that they
are in better control of their weight and can keep their strength, and also in part because
conservation of adipose tissue mass would likely result in a decrease in anti-tumor
therapy toxicities. While studies investigating a ketogenic diet demonstrate improved
quality of life in patients with advanced cancer [124], to our current knowledge, no
studies have investigated the capability to restore adipose tissue mass and the
subsequent effect of restoring adipose tissue mass on CAC. A comprehensive
understanding of the physiology and pathophysiology of adipose tissue, cancer, and
CAC will hopefully lead to the discovery of key components and drivers within the
development and progression of CAC that can be manipulated and targeted to benefit
the patient. This is not a simple task, but as research progresses, the future applicability
to patients suffering from CAC must always be considered a primary endpoint.

1.5 Breast cancer
1.5.1 Epidemiology and rationale for use
Changes in normal breast tissue can be malignant or benign. While benign
conditions, such as fibroadenomas, fibrocystic changes of the breast, and cysts, are
estimated to account for approximately 80% of breast conditions, malignant breast
changes – breast cancer – have a staggering prevalence and impact on human health.
Worldwide, breast cancer is the most common cancer type diagnosed, and the most
common cause of cancer death in women [125]. Among women in the United States,
breast cancer is the most common cancer diagnosed and the second-leading cause of
cancer death [126, 127]. In the United States alone, an estimated 266,120 new cases of
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breast cancer will have been diagnosed in women in 2018. About 20% of patients with
breast cancer die from the disease, often due to incurable metastatic disease [126].
A 2009 study including over 2000 patients with breast cancer showed that
approximately 25% of patients with breast cancer are diagnosed with cachexia [128].
Although the percentage of patients with CAC in other cancers was found to be greater,
such as in gastric and esophageal cancer (with 41.5 and 41.9% of patients with CAC,
respectively [128]), the enormous prevalence of breast cancer relative to these other
cancers reinforces the importance of studying CAC and WAT browning within this
cancer type. A tabular visualization of these numbers is included in Table 1.
While the high prevalence of breast cancer, both in the United States and worldwide, serves as justification for the clinical importance of studying CAC in breast cancer,
there are advantages to utilizing breast cancer for mechanistic studies of WAT browning
in cancer in vitro and in vivo. Breast cancer is usually immediately adjacent to breast
adipose tissue based on basic breast anatomy, which allows for local, mechanistic
studies. Additionally, because localized breast cancer and breast tissue does not
immediately interact with other systems, using breast cancer as a model to study WAT
browning in cancer eliminates the confounding variables seen in other models (such as
malabsorption in gastrointestinal-related cancers).
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Table 1. Burden of cancer-associated cachexia (CAC) in breast cancer

Estimated number of
new patients (men and
women) diagnosed with
disease in 2018 [126]

Percentage of
patients with any
one of the cachexia
definitions [128]

General breast
cancer CAC burden
(estimated new
cases x percentage
with cachexia)

Breast

268,670

24.8%

66,630

Gastric

26,240

41.5%

10,890

Esophageal

17,290

41.9%

7,245

Cancer
type
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1.5.2 Pathophysiology
The breasts, or mammary glands, comprise a specialized organ with specialized
function in women: to produce milk to provide nutrients and passive immunity to their
nursing offspring after childbirth. The glands’ anterior border is comprised of the
epidermis (skin) and superficial facia of the anterior thoracic wall, and the posterior
border consists of the deep fascia of the anterior thoracic wall, retromammary bursa,
and pectoralis muscles. Each gland contains approximately of 10-20 lobes connected
by ducts, ultimately forming the lactiferous sinus which then exits through the nipple
anteriorly. The lobes are supported by fibrous stroma, Cooper ligaments, and adipose
tissue. The tissue also contains well-organized vasculature, innervation, and lymphatic
drainage (detailed in [129]).
Risk factors for the development and progression of breast cancer have been
studied extensively, and include nulliparity, familial history, history of benign breast
disease, and obesity [130, 131]. Considering that the ducts and lobules comprise the
mammary glands, it is not surprising that the two main types of breast cancer are ductal
and lobular. These cancers are further classified into subtypes based on several
molecular markers: estrogen receptor (ER), progesterone receptor (PR); and human
epidermal growth factor receptor 2 (HER2). The four main subtypes of breast cancer
are: luminal A (ER and/or PR+, HER2-); luminal B (ER and/or PR+, HER2+); HER2enriched (ER-, PR-, and HER2+), and triple negative (ER-, PR-, and HER2-). It is
important to note that the presence of other receptors and markers, such as androgen
receptor, Ki67, B-Myb, and Twist can be useful, and studies are ongoing to understand
the predictive values of these more recent, novel markers [132].
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Tumor size (T), lymph node spread and extent (N), and extent of metastases (M)
are the three criterion that make up the TNM staging algorithm, which create a staging
‘score’ ranging from 0 (representing breast cancer in-situ) to IV (representing the most
advanced breast cancer) [131]. Breast cancer most commonly metastasizes to the
bone, lung, brain, and liver [133]. Treatment options for breast cancer are variable
depending on the type and extent of disease. Surgery, radiation, and chemotherapy are
all therapeutic options, and hormonal and targeted therapies can be used as well [131].

1.6 Tumor microenvironment (TME)
1.6.1 General concepts
The tumor microenvironment (TME) has several features that distinguish it from
normal, healthy tissue. In addition to the presence of tumor (cancer) cells, the TME
often has mesenchymal stem cells abnormally recruited as well as activation of cancerassociated fibroblasts. The TME is often characterized by necrosis, hypoxia, and an
acidic pH, with increased interstitial pressure, abnormal extracellular matrix deposition,
and abnormal, disorganized, and often ‘leaky’ vasculature with increased blood flow
[134, 135]. This leaky vasculature facilitates increased infiltration of a variety of immune
cells, many of which are implicated in cancer-related processes [136]. As described
already in sections 1.4.4 through 1.4.6, changes in adipocytes and adipose tissue
depots may also contribute to cancer progression.
In breast cancer, key changes within the TME are known to aid in tumor
progression and metastasis [137]. Mitochondrial function (or dysfunction) in different
TME compartments has been shown to contribute to breast cancer growth [138].
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Altered signaling induced by breast cancer cells promotes tumor-beneficial processes
such as angiogenesis, resistance to therapy, and cell proliferation [139]. The TME is
associated with dynamic changes in inflammatory status, with many different
chemokines and cytokines involved. Interleukin 6 (IL6) is one such cytokine.

1.6.2 Interleukin 6 (IL6)
IL6 is a glycosylated protein comprised of 184 amino acids, synthesized and
secreted by a variety of cells, such as neutrophils, macrophages, smooth muscle cells,
T cells, monocytes, fibroblasts, endothelial cells, and even preadipocytes [140-143].
There are three IL6-initiated signaling cascades: the janus kinase (JAK)/signal
transducer and activator of transcription (STAT) pathway, the mitogen-activated protein
kinase (MAPK) pathway, and the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)
pathway (reviewed by [21]). We focus on the JAK/STAT pathway due to its implicated
role in other models of WAT browning [144]. JAKs are constitutively associated with the
cytoplasmic tail of GP130 [140]; after the IL6:IL6RA complex binds GP130, JAKs are
then activated by autophosphorylation and function to phosphorylate tyrosine residues
in the cytosolic portion of GP130. This recruits STAT transcription factors to propagate
target effects, and suppressors of cytokine signaling (SOCS) which act as feedback
inhibitors [145].
Signaling initiated by IL6 is a multi-step process. First, IL6 must bind to a specific
receptor, IL6 receptor alpha (IL6RA; also known as IL6R, or cluster of differentiation
CD126). IL6RA can be either membrane-bound or soluble; if soluble, it is usually the
result of proteolytic cleavage from the membrane (although translation of alternatively
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spliced mRNA may also be a source) [146-148]. IL6RA is not ubiquitously expressed;
instead, it is cell-specific, primarily found on hepatocytes, neutrophils, monocytes, and T
cells [149]. After IL6 binds to IL6RA, this IL6:IL6RA complex then associates with the
transmembrane protein glycoprotein 130 (GP130; also known as IL6 signal transducer
IL6ST, IL6RB, or cluster of differentiation CD130) [150]. IL6 alone will not bind to GP130
without first associating with IL6RA [151]. Unlike IL6RA, GP130 is expressed on all cells
within the body [152, 153]. Dimerization of GP130 serves as the signal transducer for
propagation of the JAK/STAT pathway [151].
IL6 is an inflammatory cytokine with pleiotropic actions, and has various roles in
the breast and tumor environment, which includes cancer cells and adipocytes as well
as adipocyte precursors, endothelial cells, and macrophages [154]. Elevated IL6 levels
increase protein catabolism and skeletal muscle wasting which contributes to CAC
[155]. Through its canonical signaling pathway via signal transducer and activator of
transcription 3 (STAT3), the role of IL6 in CAC has been expanded to include other
organ systems beyond skeletal muscle, including adipose tissue (reviewed by [156]).
IL6 is thought to be involved in the dedifferentiation and inflammatory characteristics of
breast cancer-associated adipocytes [157] and has been shown to stimulate WAT
lipolysis [158]; however, its roles in BAT activation and WAT browning are only of recent
interest. Increased BAT activity and WAT browning occurs in cancer and may contribute
to CAC [103, 112, 113]. Specifically, IL6 has been implicated as a direct driver of WAT
browning in models of colon cancer [112, 158].
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1.7 Summary
Sustained net-negative energy imbalance, as seen in CAC, represents a
substantial clinical burden. White, beige, and brown adipose tissues are known to be
involved in the development and progression of CAC, although exact mechanisms are
not fully understood for all processes, especially in breast cancer. Breast cancer
represents an ideal model to study the interactions between tumor, tumor
microenvironment (especially IL6), and white adipose tissue.
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Chapter 2: Materials and Methods

All mice were bred and maintained in Virginia Commonwealth University animal
facilities and utilized in accordance with protocols approved by the Institutional Animal
Care and Use Committee (IACUC) at VCU: AM10309 (Dr. Xianjun (Frank) Fang
laboratory), AD10000814 (Dr. Charles Clevenger laboratory), AD10001219 (Dr. Paula
Bos laboratory), AM10065 (Dr. Daniel Conrad, now Dr. Rebecca Martin laboratory),
AD10001447 (Dr. Francesco Celi laboratory).
All human subjects research was performed in accordance with VCU IRB and
PRMC-approved protocols (HM20009089 and MCC-17-13470, respectively).

2.1 Tissue acquisition
2.1.1 Mouse tissue acquisition
In collaboration with Dr. Frank Fang, female B6.FVB-Tg(MMTVPyVT)634Mul/LellJ mice (also referred to as “C57BL/6J MMTV-PyVT” mice, Jackson
Laboratory, stock #022974) at approximately 4 months of age were euthanized via
isofluorane and cervical dislocation before being transferred to our lab for tissue
extraction. Bilateral adipose tissue pads (interscapular, axillary, inguinal, and ovarian)
were harvested and used for immunohistochemistry (see section 2.2) and gene
expression analysis (see section 2.14). For axillary and inguinal adipose tissue pads,
when tumor was present, some of the adjacent tumor was included with the adipose
tissue that was placed in formalin for downstream immunohistochemistry.
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In collaboration with the lab of Dr. Charles Clevenger, female PyMT FVB/N-Tg
(MMTV-PyMT) 634 Mul/J mice (also referred to as “FVB MMTV-PyMT” mice, Jackson
Laboratory, stock #002374) at approximately 4 and 13 weeks of age, as well as agematched female control FVB/NJ mice (Jackson Laboratory, stock #001800), were
euthanized before transfer to our lab for tissue extraction. Bilateral adipose tissue pads
(interscapular and inguinal) were harvested and used for gene expression and protein
analyses (see sections 2.14 and 2.15, respectively).
C57BL/6J wild-type mice (Jackson Laboratory, stock #000664) and BALB/cJ
wild-type mice (Jackson Laboratory, stock #000651) were euthanized at approximately
3 weeks of age via isoflurane. Inguinal white adipose tissue pads were removed under
sterile conditions in a cell culture hood and used to isolate primary stromal vascular
fraction cells for cell culture (see section 2.4.1).

2.1.2 Human tissue acquisition
Benign breast tissue from women undergoing elective breast reduction surgeries
was obtained through the VCU Tissue and Data Acquisition and Analysis Core
(TDAAC). Deidentified samples were then moved under the cell culture hood, fibrous
and connective tissue was removed, and adipose tissue was used for
immunohistochemistry (see section 2.2.2) and isolation of primary stromal vascular
fraction cells for cell culture (see section 2.4.2).
Slides with deidentified human samples of breast cancer with adjacent adipose
tissue were obtained from the TDAAC for use in immunohistochemistry.
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2.2 Immunohistochemistry (IHC)
2.2.1 Mouse IHC
Bilateral adipose tissue pads (interscapular, axillary, inguinal, and ovarian), with
tumor when applicable, were harvested from female B6.FVB-Tg(MMTVPyVT)634Mul/LellJ mice at approximately 4 months of age and immediately placed into
10% buffered formalin (Fisher Chemical) for 6 days. Tissues were then transferred to
70% ethanol until embedding and sectioning was performed by the VCU Massey
Cancer Center’s Cancer Mouse Model Shared Resource. All tissues were embedded
with paraffin using a standard dehydration, clearing, and paraffin infiltration program via
a Sakura Tissue Tek automated processor, and were sectioned at 5µm thickness.
Mouse UCP1 expression in the tissues was detected via immunohistochemistry
using the SuperPicture 3rd Gen IHC Detection Kit (Invitrogen 87-8973) reagents and
slight protocol modifications. Slides were deparaffinized in xylene and rehydrated in a
graded series of ethanol, ending with distilled water and finally PBST. Slides were then
placed in citrate buffer (Sigma-Aldrich C9999) diluted to 1X in distilled water and heated
in a microwave for antigen retrieval. Peroxidase quenching solution (included in kit) was
placed on slides and incubated for 10 minutes. After washing with PBST, slides were
covered with 5% BSA (Fisher Scientific BP1600-100, diluted in TBST) for one hour. The
slides were incubated in UCP1 primary antibody (abcam 10983; diluted 1:500 in 1%
BSA) or 1% BSA (to serve as post-antibody negative control) at 4°C in a dark cold room
overnight. The next day, after washing with PBST, HRP Polymer Conjugate (included in
kit) was added to cover the tissue area and left to incubate for 30 minutes. Slides were
washed in PBST and DAB Chromogen (included in kit) was added for approximately 2
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minutes to visualize binding. Slides were then washed with tap water and
counterstained with diluted Hematoxylin Solution Gill No.2 (Sigma-Aldrich GHS232) for
30 seconds. After washing with tap water, slides were dehydrated using a reversegraded series of ethanol, ending with xylene, and glass slides were mounted using
HistoChoice Mounting Media (Amresco/VWR H157).
Slides were digitally scanned using the NanoZoomer 2.0-HT Whole Slide Imager
Digital Pathology Slide Scanner (Meyer Instruments) by the Department of Pathology.
2.2.2 Human IHC
Slides were stained by the VCU Massey Cancer Center’s Cancer Mouse Model
Shared Resource Core for UCP1 using primary antibody (abcam ab155117, diluted
1:200). Stained slides were scanned at 20X magnification by the Core facility. Slide
images were captured using Phenochart 1.0.9 software.

2.3 IHC staining intensity: qualitative and quantitative measures
Qualitative assessment of IHC intensity was determined via blinded scoring by
Dr. Trang Le in the Division of Endocrinology, Diabetes, and Metabolism. Images were
assigned random number labels and sent to Dr. Le for scoring. For each sample, Dr. Le
assigned a numerical value to grade the average staining intensity in the adipose tissue
at 1) the tumor-adipose tissue interface and 2) the adipose tissue furthest from the
tumor. The following numerical scale was used: 0 = no staining; 1 = weak staining; 2 =
moderate staining; 3 = strong staining. These values were used to calculate the gradient
of staining intensity.
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Quantitative assessment was performed by computation analysis. The IHC
images were processed and analyzed in MATLAB 2017a. A customized algorithm was
developed to automatically detect the brown pixels and count the number of brown
pixels by columns of each IHC image. The counts were plotted against the column
index (which indicates the distance to the tumor cells) for curve fitting.

2.4 Isolation of primary stromal vascular fraction (SVF) cells from adipose tissue
Stromal vascular fraction (SVF) isolation was performed according to established
protocol [159] with slight modifications for both mouse and human white adipose tissue.
See Figure 6 for visual representation of this process.

2.4.1 Mouse SVF
For each C57BL/6 or BALB/c mouse, left and right inguinal fat pads were
homogenized and combined into one tube, then digested in 1mg/mL Collagenase A
(Roche 10103586001) in sterile PBS at 37°C for 90 minutes with gentle inversion of
tubes every 10-15 minutes. After digestion, the cell solution was filtered through a
100µm cell strainer to remove any large, undigested tissue. The remaining cell solution
was centrifuged at 200g for 10 minutes at room temperature. Supernatant was
removed (including floating lipids) to leave a pellet of SVF. This SVF pellet was
resuspended in 5mL of basal cell culture medium consisting of DMEM/F12+Glutamax
(Thermo Fisher 10565-018), 10% fetal bovine serum (FBS; Thermo Fisher 10082-147),
200U/mL penicillin, 0.2mg/mL streptomycin, and 25μg/mL amphotericin B (Sigma
Aldrich A5955) and 100μg/mL Normacin (InvivoGen ant-nr-1, lot NOL-39-05A) and
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plated on to a T25 tissue flask (Cellstar 690175). Cells were kept in a cell incubator
(HERAcell 150i) at 37°C and 5% CO2 from this point forward. Cell culture medium was
changed after 4 hours to remove cells that had not adhered (especially red blood cells).
Cell culture medium was changed the next day and then every 2 days until cells
reached 90% confluency, at which point they were passaged with Trypsin (Gibco
25200-056) and expanded to T75s (Corning 430641U) or frozen in basal cell culture
medium and 10% DMSO (Sigma D2650).

2.4.2 Human SVF
Adipose tissue was cut into small pieces and SVF pellet was obtained using
methods described in section 2.4.1. The resulting human SVF pellet was resuspended
in 5mL of basal cell culture medium consisting of DMEM/F12+Glutamax, 200U/mL
penicillin, 0.2mg/mL streptomycin, and 25μg/mL amphotericin B, supplemented with
either 1) 10% FBS or 2) components included in Fibroblast Growth Kit-Low serum
(ATCC, PCS-201-041) and plated on to a T25 tissue flask. Cells were kept in a cell
incubator and cared for using same methods described in section 2.4.1.
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Figure 6. Process of SVF isolation for mouse and human adipose tissue samples
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2.5 Immortalization of murine stromal vascular fraction cells
SVF cells were isolated from the inguinal fat pad of a 1-month old male
C57BL/6J mouse as described above in section 2.4.1. SVF cells were immortalized with
SV40 Large T antigen (Addgene plasmid #1780) as published previously [160].
Immortalized SVF cells were cultured in basal medium consisting of DMEM/F12
GlutaMAX supplemented with 200 U/mL penicillin/streptomycin and 10% FBS. These
immortalized SVF cells are also referred to as mouse immortalized white preadipocytes,
‘mIWPA,’ throughout the text.

2.6 Differentiation of mature adipocytes
2.6.1 Mouse immortalized white preadipocytes (mIWPA) differentiation
mIWPA cells were grown in basal cell culture medium as described above in
section 2.5. Cells were plated on cell culture plates coated with 0.1% gelatin solution
(Sigma-Aldrich G1393) according to manufacturer protocol and grown to confluency in
basal cell culture medium before differentiation. For white adipocyte differentiation, an
induction cocktail comprised of basal medium, supplemented with 5μg/mL insulin
(Sigma-Aldrich I9278), 1μM dexamethasone (Sigma-Aldrich D1756), 0.5mM 3-isobutyl1-methylxanthine (IBMX, Sigma-Aldrich I5879), and 125μM indomethacin (SigmaAldrich I7378) was used for 2 days. After induction, differentiating white adipocytes were
cultured in a maintenance cocktail comprised of basal medium supplemented with
5μg/mL insulin for 12 days. For beige adipocyte differentiation, induction cocktail
comprised of basal medium supplemented with 5μg/mL insulin, 5μM dexamethasone,
0.5mM IBMX, 125μM indomethacin, 0.5μM rosiglitazone (Sigma-Aldrich R2408), and
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1nM (T3, Sigma-Aldrich T6397) and used for 2 days. After induction, differentiating
beige adipocytes were cultured in a maintenance cocktail comprised of basal medium
supplemented with 5μg/mL insulin, 1μM rosiglitazone, and 1nM T3 for 12 days. See
next subsections for experimental conditions after maturation. Medium for all cells was
changed every 2-3 days. The maximum passage number used for any mIWPA
experiments was passage 13.

2.6.2 Murine primary SVF differentiation
Primary mouse SVF cells were grown in a basal cell culture medium as
described in section 2.4.1. Cells were plated on cell culture plates coated with 0.1%
gelatin solution and grown to confluency in basal cell culture medium before
differentiation. For white adipocyte differentiation, an induction cocktail comprised of
basal medium without Normocin, supplemented with 5μg/mL insulin, 1μM
dexamethasone, 0.5mM IBMX, and 125μM indomethacin was used for 4 days. After
induction, differentiating white adipocytes were cultured in a maintenance cocktail
comprised of basal medium without Normocin supplemented with 5μg/mL insulin for 12
days. For beige adipocyte differentiation, induction cocktail comprised of basal medium
without Normocin, supplemented with 5μg/mL insulin, 5μM dexamethasone, 0.5mM
IBMX, 125μM indomethacin, 0.5μM rosiglitazone, and 1nM T3 and used for 4 days.
After induction, differentiating beige adipocytes were cultured in a maintenance cocktail
comprised of basal medium without Normocin supplemented with 5μg/mL insulin, 1μM
rosiglitazone, and 1nM T3 for 12 days. See next subsections for experimental
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conditions after maturation. Medium for all cells was changed every 2-3 days. The
maximum passage number used for any primary SVF experiments was passage 4.

2.6.3 Human primary SVF differentiation
Primary human SVF preadipocytes were grown in a basal cell culture medium as
described in section 2.4.2. Cells were plated on cell culture plates coated with 0.1%
gelatin solution and grown to confluency in basal cell culture medium before
differentiation. For white adipocyte differentiation, an induction cocktail comprised of
basal medium (either of the two basal mediums described in section 2.4.2)
supplemented with 5μg/mL insulin, 1μM dexamethasone, 0.5mM IBMX, and 125μM
indomethacin was used for 4 days. After induction, differentiating white adipocytes were
cultured in a maintenance cocktail comprised of basal medium supplemented with
5μg/mL insulin for 12 days. For beige adipocyte differentiation, induction cocktail
comprised of basal medium supplemented with 5μg/mL insulin, 5μM dexamethasone,
0.5mM IBMX, 125μM indomethacin, 0.5μM rosiglitazone, and 1nM T3 and used for 4
days. After induction, differentiating beige adipocytes were cultured in a maintenance
cocktail comprised of basal medium supplemented with 5μg/mL insulin, 1μM
rosiglitazone, and 1nM T3 for 12 days. See next subsections for experimental
conditions after maturation. Medium for all cells was changed every 2-3 days. The
maximum passage number used for any primary human SVF experiments was passage
6.
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2.7 Cancer cells lines and culture
2.7.1 E0771
Murine E0771 cells (CH3 BioSystems 940001) were grown in basal cell culture
medium consisting of RPMI1640+GlutaMAX (Thermo Fisher 61870-036), supplemented
with 10% FBS and 200U/mL penicillin, 0.2mg/mL streptomycin, and 25μg/mL
amphotericin B. This murine breast cancer cell line has a C57BL/6 background and is
ER+. The maximum passage number used for any experiments was passage 5.

2.7.2 4T1
Two populations of murine 4T1 cells were used in experiments. One population
was obtained at passage 3 from the laboratory of Dr. Harry Bear, and the other was
purchased from ATCC (ATCC CRL-2539). Both were grown in basal cell culture
medium consisting of RPMI1640+GlutaMAX supplemented with 10% FBS and 200
U/mL penicillin/streptomycin. This murine breast cancer cell line has a BALB/c
background and has a more metastatic phenotype than E0771 cells. The maximum
passage number used for any experiments was passage 7.

2.7.3 LLC
Murine Lewis lung carcinoma (LLC) cells were obtained at passage 8 from the
laboratory of Dr. David Gewirtz, and grown in basal cell culture medium consisting of
DMEM/F12+Glutamax supplemented with 10% FBS and 200 U/mL
penicillin/streptomycin. The maximum passage number used for any experiments was
passage 11.
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2.7.4 MCF-7
Human MCF-7 cells were obtained at passage 10 from the laboratory of Dr.
Kazuaki Takabe and grown in basal cell culture medium consisting of
RPMI1640+GlutaMAX supplemented with 10% FBS and 200 U/mL
penicillin/streptomycin. This cell line of human breast adenocarcinoma is ‘luminal’ type
A (ER+, PR+, HER2-). The maximum passage number used for any experiments was
passage 13.

2.7.5 MDA-MB-231
Human MDA-MB-231 cells were obtained at passage 12 from the laboratory of
Dr. Kazuaki Takabe, and grown in basal cell culture medium consisting of
RPMI1640+GlutaMAX supplemented with 10% FBS and 200 U/mL
penicillin/streptomycin. This cell line of human breast adenocarcinoma is ‘basal’ type
and triple negative (ER-, PR-, and HER2-). The maximum passage number used for
any experiments was passage 15.

2.8 Cancer conditioned medium and coculture experiments
For conditioned medium collection, cells were grown to ~70% confluency, and
then cell culture medium was changed. This conditioned medium was harvested 24
hours later and filtered through a 0.22µm pore size filter (Millipore SLGP033RS) for use
in experiments. For coculture experiments, cells were grown to ~70% confluency on
coculture inserts (Fisher Scientific 08-771-21) and then moved to the appropriate
adipocyte wells for experiments. Empty coculture wells were placed in all other
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adipocyte wells. The maximum passage number used for any experiments was
passage 11.

2.8.1 mIWPA experiments
mIWPA cells were grown and induced to either mature white or beige adipocytes
as described in section 2.6.1. On day 14, mature white preadipocytes were exposed to
white maintenance medium plus one of the following for 24 hours: 1) no treatment
(white control) or 2) cancer conditioned medium (E0771 or LLC) in a 1:1 ratio with white
maintenance medium cocktail. Mature beige adipocytes continued on beige
maintenance medium (beige control). Schematic of exposure periods visualized in
Figure 7.
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Figure 7. Murine immortalized SVF experiment schematic
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2.8.2 Primary murine SVF experiments
Primary murine SVF cells were isolated, grown, and induced to either mature
white or beige adipocytes as described in section 2.6.2. On day 16, mature white
preadipocytes were exposed to white maintenance medium plus one of the following for
24 hours: 1) no treatment (white control), 2) 10µM CL 316,243 hydrate (Sigma-Aldrich
S5976), 3) cancer conditioned medium (either E0771 or 4T1) in a 1:1 ratio with white
maintenance medium cocktail, or 4) coculture (with either E0771 or 4T1). Mature beige
adipocytes continued on beige maintenance medium (beige control). Schematic of
exposure periods visualized in Figure 8.
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Figure 8. Murine primary SVF experiment schematic
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2.8.3 Primary human SVF experiments
Primary human SVF cells were isolated, grown, and induced to either mature
white or beige adipocytes as described in section 2.6.3. On day 16, mature white
preadipocytes were exposed to white maintenance medium plus one of the following for
24 hours: 1) no treatment (white control) or 2) cancer conditioned medium (either MCF7 or MDA-MB-231) in a 1:1 ratio with white maintenance medium cocktail. Mature beige
adipocytes continued on beige maintenance medium (beige control). Schematic of
exposure periods visualized in Figure 9.
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Figure 9. Human primary SVF experiment schematic
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2.9 IL6 experiments
Mature adipocytes from primary murine SVF cells were prepared as described in
section 2.6.1. On day 16, mature white preadipocytes were exposed to white
maintenance medium plus one of the following for 3 days: 1) no treatment (white
control), 2) 10µM CL 316,243, 3) 40ng/mL mouse recombinant IL6 (R&D Systems 406ML/CF), 4) 40ng/mL mouse recombinant IL6 + 200ng/mL mouse recombinant IL6RA
(R&D Systems, 1830-SR/CF). Mature beige adipocytes continued on beige
maintenance medium (beige control). Schematic of experiment visualized in Figure 10.

78

Figure 10. IL6 experiment schematic
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2.10 Tumor lysate & CD11b+ cell experiment
In collaboration with the laboratory of Dr. Paula Bos, tumor lysate and isolated
CD11b+ cells were obtained from the following murine models of breast cancer: MMTVPyMT at an early stage (10 weeks old at time of harvest), MMTV-PyMT at a late stage
(24 weeks old at time of harvest), PyMT-derived cell line injected into bilateral inguinal
mammary pads of a C57BL/6J mouse (6-8 weeks old age at time of injection, 150,000
cells injected, harvested when tumors reach 2000mm 3), E0771 cell line injected into
bilateral inguinal mammary pads of a C57BL/6J mouse (6-8 weeks old age at time of
injection, 500,000 cells injected, harvested 10 days later). All mice were female.
For tumor lysate isolation, mice were euthanized via cervical dislocation. Tumors
were dissected from mice and immediately frozen on dry ice for 10 minutes. Tissue was
powdered using a mortar and pestle on dry ice. Cytokine lysis buffer consisting of (for
every 50mL total): 2.5mL of 50mM Tris pH 7.5 (Fisher), 7.5mL of 150mM NaCl (Fisher),
2.5mL of 1% NonidetP-40 (Fisher), 0.1mL of 1mM EDTA (Fisher), 37.4mL of H 2O, and
1x protease inhibitor cocktail (SIGMA cat#4693132001) was made. Frozen tissue
powder was incubated in cytokine lysis buffer at a ratio of 1-2µL buffer for every 1mg of
tissue for one hour in a cold room on a rotator. Solution was then sonicated three times
at an amplitude of 40µm, 10 seconds each time with 30 seconds rest on ice in between.
The tissue homogenate was then centrifuged three times at 14000rpm at 4°C for 10
minutes each. In between each centrifugation, supernatant was collected and moved to
a new tube for the next centrifugation, and pellet (cell debris, etc) was discarded. After
final centrifugation and transfer of supernatant (tumor lysate) to final tube, lysate protein
concentration was quantified using the Thermo Pierce BSA Protein Assay Kit (Thermo
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23225) using the microplate protocol. Various dilutions of lysate were used to ensure
that sample would be within the standard’s working range for quantification (examples
include 1:1, 1:10, 1:50 in cytokine lysis buffer). Absorbance was measured at 560nm
using a POLARstar OPTIMA plate reader. Program software was used to calculate
protein concentrations. Tumor lysate was frozen at -80°C until needed.
Isolation of CD11b+ cells was performed using Dynabeads magnetic separation
technology. Mice were euthanized via cervical dislocation. Tumors near inguinal fat
pads were removed from mice, careful to exclude lymph nodes, rinsed in ice-cold PBS,
and then minced in 1x LiberaseTL (Roche). Homogenate was incubated for 30 minutes
on a rotator in a 37°C incubator. 10mL of cell medium consisting of DMEM (Gibco),
10%FBS (WZ), and penicillin/streptomycin (Gibco) was added to homogenate, and then
filtered using 100µm pore size filters into 50mL tubes, then flushed with an extra 10mL
of cell culture medium. Everything from this point was performed under sterile
conditions in the lab’s cell culture room. Cells were centrifuged at 350g for 5 minutes at
4°C. Supernatant was removed and cells were resuspended in 8mL of 43% Percoll
(GE) + 2% FBS (VWR). Cells were centrifuged at 500g for 8 minutes at 4°C.
Supernatant was removed again and cells were washed with 2mL of MACS sorting
buffer (0.5% BSA, 2mM EDTA) before another centrifugation at 350g for 5 minutes at
4°C. Supernatant was removed and cells were resuspended in 300µL of MACs sorting
buffer and incubated in 200µL of Fc block (2.4g2) and 4µL of biotinylated CD11b
monoclonal antibody (eBioscience 13-0112-86) for 30 minutes in cold room on a rotator.
Magnetic bead master mix was created by diluting 100µL of Dynabeads (Biotin Binder,
Invitrogen 11047) in 2mL of MACs in a 15mL conical tube (multiples were created when
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needed). Tubes were placed in a magnet (DynaMagTM-15 Invitrogen 12301D) and
remaining liquid was removed, leaving only washed magnetic beads. These beads were
then resuspended in 100µL of MACs. 100µL of Magnetic bead master mix and 200µL of
MACs was added to each tube of cells after incubation in Fc blocker and antibody.
Tubes were placed in magnet for about 2 minutes, and liquid supernatant was
discarded (CD11b+ cells should be attached to beads which went to magnet).
Remaining cells conjugated to beads were resuspended in 500µL of MACs and 500µL
of release buffer (Dynabead component-same catalog number) and incubated for 10-20
minutes on a rotator in the cold room. After this, 1mL of MACs was added to each tube
and tubes were placed on magnet. Liquid supernatant was collected into a new tube
and beads were discarded. Suspended cells were centrifuged at 350g for 5 minutes at
4°C, supernatant removed, and then cells were resuspended in 1mL of cell culture
medium. Cells were counted using an automated cell counter (Life Technology
Countess II) with Trypan blue (1:1 with cells) for live-dead differentiation. Live cell count
was recorded, and cells were kept on ice until plated.
Primary C57BL/6J SVF cell lines were isolated as described in section 2.6.2.
Cells were plated on to gelatin-coated 12 well plates at passage 4 at a density of 3000
cells/cm2. Basal cell culture medium was changed every other day until cells reached
full confluency, at which point induction and maintenance mediums were used
(compositions described in section 2.6.2). After 4 days of induction followed by 15 days
of maintenance medium, some W and B wells were harvested for baseline mRNA,
protein, and lipid droplet visualization analyses (see sections 2.14, 2.15, and 2.16,
respectively). For the remaining wells, medium was changed to either continued white
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or beige maintenance medium for controls, or to continue white maintenance medium
plus one of the following experimental conditions (concentrations/amounts are for each
well exposed): 40ng/mL of mouse recombinant IL6; 40ng/mL recombinant mouse TNFa
(R&D Systems 410-MT-010/CF); 10uM CL 316,243 hydrate; 4µg of either MMTV early
tumor lysate, MMTV late tumor lysate, Pymt tumor lysate, E0771 tumor lysate; 0.6µL of
cytokine lysis buffer without protease inhibitor cocktail as a control for lysates; 28,000
Pymt CD11b+ cells; 15,000 E0771 CD11b+ cells (pan myeloid); 1mL of E0771 cancer
conditioned medium (see cancer conditioned medium experiments); 1mL RPMI-based
culture medium as a control for cancer conditioned medium. Cells were harvested after
3 days of exposure (Figure 11).
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Figure 11. Tumor lysate & CD11b+ cell experiment schematic
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2.11 4T1 allograft experiment
In collaboration with the laboratory of Dr. Daniel Conrad, nine BALB/c wild-type
(WT) (4 female, 5 male) and nine BALB/c Rag1-/- mice (4 female, 5 male) were used for
this 4T1 allograft experiment.
4T1 cells were prepared for injection via the following protocol: cells were
cultured in their basal culture medium in 150mm flasks until confluent. Once cells
reached confluency, flasks were washed with 1X PBS. Cells were scraped and
centrifuged at 1500rpm for 5 minutes at 21°C. Supernatant was removed and cells were
resuspended in 5mL 1X PBS and kept on ice to prevent clumping. 10µL of cell
suspension was mixed with 10µL of 2% trypan blue to count live cells. 1X PBS was
added to achieve concentration of 1x106 cells/mL.
Mice were inoculated with either 200,000 4T1 cells in 200µL PBS (‘4T1 group’) or
200µL PBS (vehicle control, ‘control group’) unilaterally in the right inguinal area using a
26 gauge needle at the following ages for the mice (
Figure 12): WT females 62 days (about 9 weeks); WT males 49 days (7 weeks);
Rag1-/- females 76 days (about 11 weeks); Rag1-/- males 57 days (about 8 weeks). Mice
were kept in cages (separated based on sex and genotype) at 23°C. Mice were
weighed at baseline and every other day. Injection site palpated every other day. Once
tumor became palpable, tumor size was measured with calipers every day.
4T1 group mice were euthanized 10 days after inoculation. Control group mice
were euthanized 14 days after inoculation. Rectal temperature was obtained using a
rectal temperature probe for all mice prior to euthanization. Mice were euthanized in
isoflurane. Tumor (if present) and adipose tissues (interscapular, axillary, inguinal, and
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gonadal) were harvested for gene expression and flow cytometry analyses (see
sections 2.14 and 2.12, respectively).
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Figure 12. 4T1 allograft experiment schematic
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2.12 Flow cytometry
Data for both cell-surface and intracellular flow cytometry were acquired on the
LSR Fortessa flow cytometer (BD Biosciences) in the VCU Flow Cytometry Core. Data
were analyzed using FCS Express 5 (De Novo Software).

2.12.1 Cell surface flow cytometry
Cell surface flow cytometry staining was performed as described previously [161]
for either whole tissue or cells grown in cell culture:
For cells grown in vitro, primary murine SVF were isolated, grown, and induced
to either mature white or beige adipocytes as described in section 2.6.1 until day 16.
Cells were gently washed twice with 1X PBS. Staining solution was added to each well
(for each well on 12-well plate: 250µL total volume consisting of respective targets
(Table 2) with Fc blocker diluted in 1X PBS) and left to incubate at 4ºC in the dark for 20
minutes. 100µL of live-dead stain (Biolegend Zombie Aqua Dye 77143 in DMSO) diluted
1:100 in 1X PBS was added to each well (still had staining solution it) and incubated for
15 minutes at room temperature in the dark. 350µL of 1X FACS with Azide was added
to each well for 5 minutes at room temperature. Cells were then gently scraped off of
the well and moved to a FACS tube. Suspension was pipetted up and down several
times to encourage single-cell suspension. 700µL of Fixation buffer (Biolegend 420801)
was added to each sample and left to incubate for 20 minutes at room temperature.
Tubes were then centrifuged at 250g for 10 minutes at room temperature. Sheets and
clumps of cells remained floating at the top, some cellular material floated in the middle,
and a small amount of cellular material precipitated to the bottom. The top and middle
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portions were discarded, and the bottom portion was resuspended in 300µL of FACS
with Azide, pipetting up and down several times to encourage single-cell suspension.
Samples were passed through a 100µm mesh filter before running on flow cytometry
instrument.
For whole tissue, tissue samples were placed in 12 well dishes with 1mL of
1mg/mL collagenase A and homogenized. For each sample, homogenized tissue and
collagenase was moved to a 2mL Eppendorf tube and placed on a rotator in a 37°C
incubator for about 45 minutes. Homogenized solution was filtered into 50mL tube with
a 70µM filter (Fisherbrand 22363548). Filtered cell solution was centrifuged at 1500rpm
for 5 minutes at room temperature. Supernatant was decanted and 100µL of 1X
mojosort was added. This mixture was then moved to a well on a 96 well plate and kept
on ice. Once all samples were loaded, the plate was centrifuged at 2000rpm for 4
minutes at room temperature, decanted, and washed with 200µL of 1X PBS per well.
This was repeated twice. 100µL of live-dead stain (Biolegend Zombie Aqua Dye 77143
lot B194251 in DMSO) diluted 1:100 in 1X PBS was added to each well and incubated
for 10 minutes at room temperature in the dark. Plate underwent two cycles of 100uL 1X
mojosort buffer wash per well, centrifuged, and decanted. 50µL of 2.4g2 [162] to block
Fc receptors (diluted in 1X mojosort) was added to each well and incubated for 10
minutes at room temperature. 50µL of antibody mix per well (25µL brilliant blue stain
buffer, 0.5µL of each antibody used (Table 2), and the remaining with 1X mojosort) was
added to each well and moved to refrigerator to incubate for 30 minutes. Plate was
centrifuged, decanted, and then samples washed with 200µL 1X mojosort per well
before another cycle of centrifugation and decanting. Cells were then fixed with 150µL
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of 1X fixing solution for 10 minutes at room temperature. Plate was centrifuged and
decanted. 200µL of 1X mojosort was added to each well and the solution in each well
was transferred to individual tubes for running flow cytometry.

2.12.2 Intracellular flow cytometry
For intracellular cytokine staining, cells (mIWPA, E0771, LLC, 4T1, mouse
peritoneal cavity cells) were cultured in 6 or 12 well plates for each cell type until ~70%
confluent. Murine peritoneal cavity cells were isolated by lavage the day preceding each
experiment by the Conrad laboratory. Cells were treated with one of the following
conditions in basal medium before harvest: 1) 1X Brefeldin A (BioLegend 420601) and
1X Monensin (BioLegend 420701) for 6 hours; 2) 1X Brefeldin A, 1X Monensin, 1X
phorbol 12-myristate-13-acetate (PMA; Sigma-Aldrich P1585) and 1X Ionomycin
(ThermoFisher I24222) for 3 hours; 3) no treatment.
Wells of same treatment group were pooled together and harvested with trypsin,
pelleted, and resuspended in 200µL of 1X mojosort to encourage single cell
suspensions. 100µL of cell suspension moved into two wells of a 96-well plate on ice.
The 96-well plate was contributed at 2000rpm for 3 minutes at room temperature,
decanted, washed with 200µL of 1X PBS per well, spun again, and decanted. 100µL of
live-dead stain was added per well (Biolegend Zombie Aqua in DMSO, diluted 1:200 in
1X PBS) and left to incubate in the dark at room temperature for 10 minutes. Wells were
washed with 100µL 1X FACS with Azide, spun at 2000rpm for 4 minutes at room
temperature, decanted, and washed again with 180µL 1X mojosort, spun, decanted.
100µL of 2.4g2 was added in 1X FACS (40µL 2.4g2 in 4mL FACS)) for 5 minutes at
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room temperature, then spun and decanted. 150µL of fixation buffer was added per well
and left to incubate in the dark at room temperature for 15 minutes. Plate was spun,
decanted. Wells were washed, spun, decanted with 170µL of 1X permeabilization buffer
(Biolegend 421002 diluted to 1X in H2O) twice. Intracellular stain mixture was made to
get 100µL per well: 98µL of 1X perm buffer, 1µL antibody (Table 2), and 1µL of Fc
blocker. 100µL of intracellular stain mixture was added and incubated for 40 minutes in
the dark at room temperature. Plate was then spun, decanted. Wells were washed twice
with permeabilization buffer, 170µL per well each time, spun, and decanted. Wells were
then washed with 170µL 1X FACS to seal the membrane, spun, decanted. 150µL of
fixation buffer was added to each well and incubated at room temperature in the dark for
15 minutes. Plate was spun and decanted. Wells were resuspended in 200µL FACS
and transferred to flow tubes. An additional 100µL FACS was added to each tube to get
300µL per tube. Tubes were covered in foil and placed in the refrigerator for storage
before flow cytometry was performed.
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Table 2. Flow cytometry antibodies

Isotype

Stain/
Dye

CD45

Rat
IgG2b, κ

APC/Fire
750

30-F11

103154

-

Biolegend

2µg/mL

Cell surface

Ly6G

Rat
IgG2a, κ

Brilliant
Violet

D7

108131

-

Biolegend

2µg/mL

Cell surface

FcεR

Rat
IgG2a, κ

FITC

1A8

127606

-

Biolegend

2µg/mL

Cell surface

CD3ε

Hamster
IgG

PE/Cy7

145-2C11

100320

-

Biolegend

2µg/mL

Cell surface

CD45R/B
220

Rat
IgG2a, κ

PE/Cy7

RA3-6B2

103222

-

Biolegend

2µg/mL

Cell surface

I-A/I-E

Rat
IgG2b, κ

Brilliant
Violet

M5/114

107632

-

Biolegend

2µg/mL

Cell surface

CD11c

Hamster
IgG

Brilliant
Violet 605

N418

117334

-

Biolegend

2µg/mL

Cell surface

Ly6C

Rat
IgG2c, κ

APC

HK1.4

17-5932-80

-

eBiosciences

2µg/mL

Cell surface

F4/80

Rat
IgG2a, κ

PE

BM8

123110

-

Biolegend

2µg/mL

Cell surface

CD11b

Rat
IgG2b, κ

BUV395

M1/70

563553

-

BD Horizon

2µg/mL

Cell surface

FcεR1α

Hamster
IgG

PE/Dazzl
e

MAR-1

134332

-

Biolegend

2µg/mL

Cell surface

Mouse IL6

Rat
IgG1, κ

PE

MP5-20F3

554401

7159590

BD
Biosciences

2µg/mL

Intracellular

-

Rat
IgG1, κ

PE

R3-34

554685

7026874

BD
Biosciences

2µg/mL

Intracellular
isotype
control

Mouse
GP130
(CD130)

Rat
IgG2b, κ

PE

4H1B35

149404

B248938

Biolegend

2µg/mL

Cell surface

-

Rat
IgG2b, κ

PE

RTK4530

400607

B255376

Biolegend

2µg/mL

Cell surface
isotype
control

Mouse
IL6RA
(CD126)

Rat
IgG2b, κ

APC

D7715A7

115812

B249718

Biolegend

2µg/mL

Cell surface

-

Rat
IgG2b, κ

APC

RTK4530

400611

B261320

Biolegend

2µg/mL

Cell surface
isotype
control

Target

Clone

Catalog
Number
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Lot
Number

Company

[]
Used

Use

2.13 RNA isolation and cDNA generation
Total RNA was isolated with TRIzol (Thermo Fisher 15596018) according to
manufacturer protocol for whole tissue or culture cells. Isolation was performed with
UltraPure Glycogen (Thermo Fisher 10814-010). RNA was quantified using the
NanoDrop 1000 Spectrophotometer (Thermo Fisher). cDNA was generated using the
BioRad iScript cDNA Synthesis Kit (BioRad 170-8891) with an input of 1µg of RNA on a
C1000 Thermal Cycler (BioRad). The cDNA was then diluted 1:3 in molecular grade
water.

2.14 Quantitative PCR (qPCR)
qPCR was performed on the QuantStudio 3 Real-Time PCR System (Thermo
Fisher) with 10µL per reaction on 96 well plates in technical duplicates or triplicates: 1X
PowerUp SYBR Green Master Mix (Applied Biosystems A25778), forward and reverse
primers (0.5µM for mouse, 1µM for human; refer to Table 3 and Table 4 respectively for
sequences and information), and 3µL of diluted cDNA. The Thermo Fisher Cloud
platform was used for analysis of efficiency-corrected Cq values using endogenous
control (Tbp for mouse, TBP for human), and fold-changes (2^ΔΔCq) were calculated
using Microsoft Excel.
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Table 3. Mouse primers used for qPCR

Gene

Cfd

Cidea

Efficiency

Full Name

97.247

complemen
t factor D
(adipsin)

99.083

cell deathinducing
DNA
fragmentati
on factor,
alpha
subunit-like
effector A
Delta like
noncanonical
Notch
ligand 1

NCBI
Gene
ID

NCBI
Reference
Sequence

Product
Length
(bp)

Variants
Targeted

Forward
Primer (5’-3’)

Reverse
Primer (5’-3’)

11537

NM_01345
9.3

100

V1, V2,
V3

AACCGGACA
ACCTGCAAT
CT

AGTCTCCCCT
GCAAGTGTCC

12683

NM_00770
2.2

197

Cidea
mRNA

TCCTCGGCT
GTCTCAATG

TGGCTGCTCT
TCTGTATCG

NM_01005
2.5

109

V1-V5;
X1-X2

AAGTGTGTA
ACTGCCCCT
GG

TGCAAGCCCG
AACGTCTATT

104

Fasn
mRNA

13386

Dlk1

97.176

Fasn

99.309

fatty acid
synthase

14104

NM_00798
8.3

Il6

93.237

Interleukin6

16193

NM_03116
8.2

Il6ra

97.549

16194

NM_01055
9.3

104

V1, V2

Il6st

99.644

16195

NM_01056
0.3

60

Il6st
mRNA

interleukin
6 receptor,
alpha
interleukin
6 signal
transducer

(aka
Pref-1)

79

V1, V2

TGCACCTCA
CAGGCATCA
AT
CCACTTCAC
AAGTCGGAG
GC
TGAATGATG
ACCCCAGGC
AC

GTCCCACTTG
ATGTGAGGGG
TTGCCATTGC
ACAACTCTTTT
CT
ACACCCATCC
GCTCTCTACT

TTACAACAC
CAAAGTTCG
CTCA

CTAAGCACAC
AGGCACGACT
A

GCAGTGCCT
ATCCAGAAA
GTCC
CGCTACACA
AAGGCTGCT
TC

GGAATGAAGT
CCAAGCCAGT
GAC

GCGTAGCAG
GAAGTCTGA
CCAA
CGCGAGGTT
TCCTTCCCTA
A

AGCGTCATCA
GGAGAAAGG
CGA

aka Gp130
Lep

91.876

leptin

16846

NM_00849
3.3

131 (128
variant
X1)

Lep
mRNA,
X1

Lipe

100.441

lipase,
hormone
sensitive

16890

NM_01071
9.5

150

V1,V2
X1,X2,X3

Lpl

90.259

lipoprotein
lipase

16956

NM_00850
9.2

113

Lpl mRNA

Mgll

108.576

monoglycer
ide lipase

23945

72

V1, V4

Oplah

98.557

Pparg

98.04

Pparg
c1a

99.095

5oxoprolinas
e
peroxisome
proliferative
activated
receptor,
gamma
peroxisome
proliferative
activated
receptor,

NM_00116
6251.1

AACTGGCGGT
CACACTGAG

AAAGTCACCC
CGATTCTCCG

75475

NM_15312
2.2

108

Predicted
isoforms

CTGCTGGTG
GGTTCTCCC

CCACGGTCGA
TGGCAAAATG

19016

NM_01114
6.3

73

V2, X8

GCATGGTGC
CTTCGCTGA

TGGCATCTCT
GTGTCAACCA
TG

19017

NM_00890
4.2

52

V1
mRNA,
V2 ncRNA

ATGTGCAGC
CAAGACTCT
GT

CAACCAGAGC
AGCACACTCT

94

Prdm
16

97.145

Ptk2b

87.917

Slc27
a1

99.235

Slc29
a1

96.822

Socs
3

110.721

Tbp

94.570

Tnfrsf
9

97.105

Ucp1

95.837

gamma,
coactivator
1 alpha
PR domain
containing
16
Proteintyrosine
kinase 2beta
long-chain
fatty acid
transport
protein 1
equilibrativ
e
nucleoside
transporter
1
Suppressor
of cytokine
signaling 3
TATA box
binding
protein
tumor
necrosis
factor
receptor
superfamily
, member 9
(aka
Cd137)
uncoupling
protein 1
(mitochond
rial, proton
carrier)

70673

NM_02750
4.3

87

V1-4, X17

CAGCACGGT
GAAGCCATT
C

GCGTGCATCC
GCTTGTG

19229

NM_00116
2366.1

81

V1-V3,
X1-X7

TGCAGACAG
AGATCCAGG
AGA

TATTCGCCCA
CTCAGGAGGA

26457

NM_01197
7.3

106

Plus other
predicted

GGGATCTCT
CTCTCCACC
CC

GAGCTTGCCT
GATCCAGCTT

63959

NM_00119
9113.1

120

V1-V5;
other
predicted

CACCAGCCT
CAGGACAGG
TAT

GTCCAGGCG
GTTTGTGAAA

12702

NM_00770
7.3

122

mRNA,
predicted
variant X1

21374

NM_01368
4.3

98

Tbp
mRNA

TAGACTTCA
CGGCTGCCA
AC
AGAACAACA
GCCTTCCAC
CT

21942

NM_01161
2.2

104

V1,V2,V3,
X1

CGTGCAGAA
CTCCTGTGA
TAAC

GTCCACCTAT
GCTGGAGAAG
G

22227

NM_00946
3.3

91

Ucp1
mRNA

CACCTTCCC
GCTGGACAC
T

CCCTAGGACA
CCTTTATACC
TAATGG

95

CGGGGAGCT
AGTCCCGAA
GCCGTAAGGC
ATCATTGGAC

Table 4. Human primers used for qPCR

Gene

Efficiency

EAR2

105.984

OPLA
H

103.185

PDK4

103.216

PPA
RGC
1A

93.971

PPA
RG

SLC2
7A1

94.305

99.693

SLC2
9A1

99.144

TBP

102.419

TME
M26

104.328

UCP1

101.358

Full Name
Nuclear
receptor
subfamily 2
group F
member 6
5oxoprolinas
e
[Pyruvate
dehydroge
nase
(acetyltransferring
)] kinase
isozyme 4,
mitochondri
al
Peroxisom
e
proliferatoractivated
receptor
gamma
coactivator
1-alpha
Peroxisom
e
proliferatoractivated
receptor
gamma
coactivator
1-alpha
Long-chain
fatty acid
transport
protein 1
Equilibrativ
e
nucleoside
transporter
1
TATA-boxbinding
protein
Transmem
brane
protein 26
Uncoupling
protein 1

NCBI
Gene
ID

NCBI
Reference
Sequence

Product
Length
(bp)

Variants
Targeted

Forward
Primer (5’-3’)

Reverse
Primer (5’-3’)

2063

NM_00523
4.3

81

EAR2
mRNA

TACACCTGC
CGGTCCAA

ACCCGGAAGC
ACTTCTTGAG

26873

NM_01757
0.4

106

OPLAH
mRNA

GAGCCGAGC
GCCAGTTTTT
C

GTCGATGGCA
AAGTGGAAGC

5166

NM_00261
2.3

65

PDK4
mRNA

CCAAGCCAC
ATTGGAAGC
AT

TCAAAGGCAT
CTTGGACCAC

10891

NM_01326
1.3

91

PPARGC
1A mRNA

TGACTGGCG
TCATTCAGG
AG

TGACTGGCGT
CATTCAGGAG

70

PPARG
mRNA,
and
predicted
variants

ACCCAGAAA
GCGATTCCT
TCA

GTGTCAACCA
TGGTCATTTC
TTGT

TGTACCACT
CGGCAGGAA
AC

GGACGACTGT
CAGCCCATAG

ATCGATCTG
GAGCCCGTG
GA

ATCGATCTGG
AGCCCGTGGA

5468

NM_01586
9.4

SLC27A1
mRNA,
and
predicted
variants
SLC29A1
mRNA,
and
predicted
variants

376497

NM_19858
0.2

66

2030

NM_00107
8177.1

100

6908

NM_00319
4.4

68

TBP
mRNA

219623

NM_17850
5.6

111

TMEM26
mRNA

7350

NM_02183
3.4

51

UCP1
mRNA

96

CGGCTGTTT
AACTTCGCTT
CC
TGACCTGGC
AGTACAGAA
CG
GGCTTTCTT
CAAGGGGTT
GGTA

CAAGAAACAG
TGATGCTGGG
TC
ACGCTGATTC
CGATGTTCCA
TTCCAGGATC
CAAGTCGCAA

2.15 Protein quantification & western blotting
If protein samples were stored in -80ºC freezer, they were thawed on ice prior to
isolation and quantification. Protein isolation was performed using RIPA lysis and
extraction buffer (Thermo Scientific 89901). RIPA buffer was supplemented with
protease inhibitor (Roche 4693116001) and phosphatase inhibitors (Roche
4906837001) (1 tablet each per 10mL of RIPA buffer). 1µL of 1X nuclease solution
(Pierce 88701, diluted in supplemented RIPA buffer) was added to each sample and
placed on rotator at room temperature for 10 minutes. Samples were then centrifuged at
4ºC at 13,000rcf for 10 minutes.
Protein quantification was performed using Pierce BCA Protein Assay Kit
(Thermo Scientific 23227) according to manufacturer’s ‘microplate’ protocol.
Absorbance was measured at 562nm using a VersaMax microplate reader (Molecular
Devices). And standard curve was generated using a four-parameter curve with
SoftMax Pro 5.3 software. This standard curve was then used to determine the protein
concentration of unknown samples.
Protein lysates were prepared for separation using 20µg of sample per well, with
1X NuPAGE LDS loading buffer (Invitrogen NP0007) and 1X NuPAGE reducing agent
(Invitrogen NP0009). These samples were then ‘boiled’ on a 70ºC heat block for 10
minutes. Samples were separated on NuPAGE 4-12% Bis-Tris Midi Gels (ThermoFisher
WG1401BOX) using an XCell4 Surelock Midi-Cell (Invitrogen) and 1X NuPAGE MOPS
SDS running buffer (Invitrogen NP0001, diluted in H 2O). 8µL of pre-stained protein
ladder (Fisher 26616) was loaded in first and/or last well. Gel transfer was performed
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using the iBlot Transfer Stack, PVDF, regular size (Invitrogen IB401001) ‘dry blot
transfer’ method.
Membranes were washed with distilled H2O and then 100% methanol.
Membranes were left to air-dry and were re-wetted in 100% methanol before being
transferred to box with 5% non-fat milk solution (BioRad 170-6404, diluted in 1X TBST).
Membranes were left for blocking on a rocker at room temperature for 1 hour.
Membranes were then washed once in TBST, cut as necessary for appropriate targets,
and moved into separate tubes for primary antibody incubation (primary antibodies in
Table 5 diluted in 1% BSA in 1X TBST) on a rotator in cold room overnight.
The next day, membranes were washed three times in 1X TBST on a shaker at
room temperature for 10 minutes each. Membranes were moved to black boxes for
secondary antibody incubation (secondary antibodies in Table 5 diluted in non-fat milk
solution saved from prior day) on a rocker at room temperature for one hour.
Membranes were then washed with 1X TBST three times on a shaker for 10 minutes
each.
Membranes were incubated in chemiluminescence substrates for 1-2 minutes
(Cell Signaling 7003, both diluted to 1X in distilled H2O) to detect western blot signal.
Images were captured either using film or the ChemiDoc MP Imaging System (BioRad).
Stat1/2/3/5 Control Cell Extracts (Cell Signaling 9133) were used for
phosphorylated STAT3 negative and positive controls.
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Table 5. Western blot antibodies

Target

Isotype

Stain
/ Dye

Clone

Catalog
Number

Lot
Number

Company

Concentration
Used

Use

PhosphoSTAT3
(Tyr705)

Rabbit
IgG

-

D3A7

9145 S

34

Cell Signaling

1:2000

Primary
antibody

PhosphoSTAT3
(Ser727)

Rabbit
IgG

-

-

9134 S

21

Cell Signaling

1:1000

Primary
antibody

STAT3

Mouse
IgG2a

-

124H6

9139 S

10

Cell Signaling

1:1000

Primary
antibody

TBP

Rabbit
IgG

-

D5C9H

44059 S

1

Cell Signaling

1:2000

Primary
antibody

UCP1

Rabbit
IgG

-

-

ab10983

GR31884
78-5

Abcam

1:1000

Primary
antibody

αTUBULIN

Mouse
IgM

-

-

sc-8035

-

Santa Cruz

1:1000

Primary
antibody

-

Rabbit
IgG

-

-

A6154

SLBG72
01V

Sigma-Aldrich

1:5000

Secondary
antibody

-

Mouse
IgG

-

-

A4416

SLBS101
0V

Sigma-Aldrich

1:5000

Secondary
antibody
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2.16 Oil Red O staining & imaging
Oil Red O (Sigma-Aldrich O0625) was used to stain adipocytes after
differentiation according to established Lonza protocol (#WEB-PR-PT-2501 OIL-3).
Wells were kept covered with water until visualized by bright-field microscopy using a
Zeiss AxioObserver A1 Microscope at the VCU Department of Anatomy and
Neurobiology Microscopy Facility.

2.17 Lipid droplet quantification
Lipid droplet size was quantified using MIPAR Image Analysis Software. A
customized recipe was developed to invert the color of the images obtained from Oil
Red O staining and then calculate the area of each lipid droplet via color detection.

2.18 Human subjects research
All human subjects research was performed in accordance with VCU IRB and
PRMC-approved protocols (HM20009089 and MCC-17-13470, respectively). Please
refer to Appendices for detailed documentation. Below is a summary for of the two aims
of this project:

2.18.1 Chart review
Aim: To identify patients with cancer and positive and negative brown adipose
tissue on PET imaging and obtain pertinent preliminary information including MRN, zip
code, age, gender, ethnicity, BMI, weight, primary cancer, diabetes status, fasting
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glucose data, thyroid function testing results, medication list, PET scan image and year,
and brown adipose tissue status.
Methods: Investigators will query medical records using Cerner and Montage
programs for patients who are at least 40 years of age and who have cancer and have
had a PET scan. The PET report will be studied to assess brown adipose tissue
presence. Information to be recorded includes: medical record number (MRN), zip code,
age, gender, ethnicity, BMI, weight, primary cancer, diabetes status, fasting glucose
data, thyroid function testing results, medication list, brown adipose tissue status (either
positive or negative depending on PET image report), and PET scan image and year.
For preliminary findings included in Chapter 6, Montage program was queried
using the following parameters:
1.

All these words: "Brown fat" | "Brown adipose tissue"

2.

Date range: 1/1/2007 to 1/31/2017

3.

Modalities: PET (PT) and PT/CT

2.18.2 Measuring energy expenditure using whole room indirect calorimeters
Aim: To characterize and measure the difference in energy metabolism profiles,
quality of life, and biochemical profiles of patients with cancer with and without evidence
of brown adipose tissue activation both at room temperature and following exposure to
warm temperature.
Methods: We will recruit patients with cancer and brown adipose tissue activation
to compare their energy expenditure with the energy expenditure of age-, sex-, BMI-,
and cancer type-matched patients with no brown adipose tissue activation at room
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temperature. We will then assess if exposure to warm temperature, a known
intervention to quench brown fat activation, is sufficient to decrease the energy
expenditure in cancer patients with evidence of BAT activation. The primary endpoint in
this Aim will be Energy Expenditure, measured using whole-room indirect calorimeters.
The indirect calorimeter technique allows for non-invasive real-time recording of energy
expenditure and respiratory quotient (a proxy for substrate utilization) by measuring
oxygen consumption and carbon dioxide production. Other data that will be collected for
secondary endpoints include: a quality of life questionnaire, thermal comfort
questionnaires, infrared photography, blood collection, and urine collection.
There will be three visits in total for participants that complete this study. Visit 1
will be a Screening visit, where informed consent will be obtained, inclusion/exclusion
criteria will be confirmed, medical history will be obtained, physical examination will be
performed, weight and vital signs will be recorded, bio-impedance analysis will be
conducted, and a quality of life questionnaire will be filled out by the participant. At both
visits 2 and 3, participants will have their resting energy expenditure measured by
resting in the indirect calorimeters for 4 hours per visit. Urine and blood will be collected
before and after each session in the calorimeter. Thermal comfort questionnaires will be
completed before and after each session in the calorimeter. A general overview of these
three visits is visualized in Figure 13.
Detailed methodology regarding calculation of energy expenditure recording is
detailed in our laboratory’s recently published article, DOI
10.1371/journal.pone.0193467.

102

Figure 13. Human subjects research intervention study design
For additional details, refer to Appendices.
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2.19 Paraganglioma clinical and laboratory research
2.19.1 Clinical results
Imaging and lab results and clinical notes were obtained without any personal
identifiers from the VCUHS Cerner medical system.
All anti-GAD65 antibody assays were performed by Lab Corp using an FDAcleared enzyme-linked immunosorbent assay (ELISA) purchased from Kronus
(KR7710).

2.19.2 Specimen collection
Slides were retrospectively identified archival tissues processed for routine
surgical pathology specimen processing in the VCUHS CLIA-compliant clinical lab.
Tissues were formalin-fixed and paraffin-embedded. Tissue blocks were cut at 4
micrometers for slide preparation and were deidentified.

2.19.3 Immunohistochemistry and imaging
Hematoxylin and eosin (H&E) staining was performed by the Department of
Pathology using routine processing procedures. Human GAD65 protein expression
(Santa Cruz, sc-377145) was detected using the SuperPicTure Polymer Detection Kit
(Invitrogen 87-8963) and slight protocol modifications. Expression of FH and SDHB was
assessed (FH: Santa Cruz sc-100743, SDHB: Abcam ab14714) under routine CLIAcertified clinical protocols as reported previously [163]. Slides were digitally scanned
using the NanoZoomer 2.0-HT Whole Slide Imager Digital Pathology Slide Scanner
(Meyer Instruments) by the Department of Pathology.
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2.20 Statistical analyses
GraphPad Prism was used for visualization of data and statistical analyses.
Appropriate tests were used to correct for multiple analyses with nonparametric
assumptions; specific tests used are described in each figure legend. For all analyses
unless otherwise noted, error bars = standard deviation, and p-values are represented
as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; #p < 0.05.
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Chapter 3: Local Browning of White Adipose Tissue Occurs in Breast Cancer

3.1 Rationale
Browning of WAT has been demonstrated in several murine cancer models and
human cancer samples [103, 112, 113]; however, WAT browning in breast cancer has
not been established. Breast cancer represents a unique and advantageous model for
investigating WAT browning as it is directly contiguous with surrounding breast WAT
and is removed from confounding variables such as nausea and malabsorption in
gastrointestinal malignancies. In this chapter, we sought out to determine whether WAT
browning occurs in breast cancer in both murine breast cancer models and in human
breast cancer samples.

3.2 Results
3.2.1 WAT browning occurs locally in the C57BL/6J MMTV-PyVT murine model of
spontaneous mammary tumor
We first addressed whether WAT browning could be observed in the C57BL/6J
MMTV-PyVT murine model of spontaneous breast cancer. Compared to their respective
ovarian WAT (Figure 14A), adipocytes surrounding mammary tumors in both axillary
and inguinal mammary fat pads demonstrate an increased staining intensity for UCP1
protein (Figure 14B), but not as much as their respective interscapular BAT (Figure
14A). The lipid droplets in the adipocytes closest to the tumor also appear smaller than
lipid droplets further away.
Results from blinded qualitative scoring demonstrate that UCP1 staining intensity
of adipose tissue at the tumor-adipose interface is significantly increased (Figure 15A).
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Staining intensity of adipose tissue further from the tumor was less than at the tumoradipose interface in both axillary and inguinal fat pads (Figure 15B). Interestingly,
axillary adipose tissues had significantly higher staining intensity further from the tumor
compared to inguinal adipose tissues (Figure 15B). The staining intensity gradient,
identified as the intensity at the interface minus the intensity further from the tumor, was
higher in the inguinal adipose tissues compared to axillary, but not significantly (Figure
15C).
MATLAB analyses on the images with tumor-adipose tissue interface were
performed to quantify the number of brown pixels, as a measure of UCP1 staining
intensity, across each image. Similar to the results in Figure 15, UCP1 protein
expression is most robust at the tumor-adipose tissue interface, and UCP1 protein
expression sharply declines moving further from the tumor (representative analysis in
Figure 16, with all analyses in Figure 17).
We then looked at gene expression levels of several key adipocyte markers in
these adipose tissue depots. Compared to ovarian WAT controls, BAT expressed over
256-fold more Ucp1 mRNA, while axillary WAT expressed roughly 2-fold more Ucp1
mRNA and inguinal WAT expressed roughly 8-fold more Ucp1 mRNA (Figure 18A). For
other markers related to thermogenic adipose tissue, interscapular BAT, compared to
ovarian WAT control, expressed significantly more Cidea (cell death-inducing DNA
fragmentation factor, alpha subunit-like effector A), increased (though not significantly)
Oplah (5-oxoprolinase), Ppargc1a (peroxisome proliferative activated receptor, gamma,
coactivator 1 alpha), and Slc29a1 (equilibrative nucleoside transporter 1), and no
change or less Pparg (peroxisome proliferative activated receptor, gamma) and Slc27a1
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(long-chain fatty acid transport protein 1) (Figure 18B). Expression of these genes was
more variable for the axillary and inguinal WAT with tumor; although there were no
statistically significant increases in gene expression, many of the WAT depots had
increased expression of thermogenic adipose tissue genes compared to ovarian WAT
control. For example, the right inguinal WAT depots expressed an average 3-fold more
Cidea and Slc29a1, and axillary WAT depots demonstrate an average 20-fold increase
in expression of Oplah, and 3-fold increase in expression of Slc29a1 (Figure 18B).
Lastly, both Lipe (hormone sensitive lipase) and Lpl (lipoprotein lipase) expression
levels were significantly decreased in WAT with tumor compared to ovarian WAT
control (Figure 18C).
We plotted individual values along with the average expression value for each
adipose tissue and gene tested, which demonstrate a large range of variability in
expression values for each adipose tissue depot. (Figure 19 panels B, D, and E).
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Figure 14. Immunohistochemistry shows increased UCP1 protein expression in adipocytes
adjacent to spontaneous mammary tumors
Four-month old female C57BL/6J MMTV-PyVT mouse tissue was harvested and stained for UCP1 protein
in (A) ovarian WAT (negative controls), interscapular BAT (positive controls), and (B) axillary and inguinal
mammary fat pads with tumor. Each row corresponds to one of three individual mice. Scale bars =
200µm. UCP1 = uncoupling protein 1, WAT = white adipose tissue, BAT = brown adipose tissue.
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Figure 15. Qualitative scoring of UCP1 staining intensity in adipocytes adjacent to spontaneous
mammary tumors
Scoring was performed in adipocytes at (A) the tumor-adipocyte interface and (B) further from tumor, as
well as staining intensity gradient (C). Statistical tests: (A), (B), and (C) one sample t-tests for each WAT
depot compared to null hypothesis of no staining; unpaired t-tests to compare staining intensity between
axillary and inguinal WAT depot. UCP1 = uncoupling protein 1.
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Figure 16. Representative MATLAB analysis of immunohistochemistry for UCP1 in adipocytes
adjacent to spontaneous mammary tumors
Results indicate a sharp decline in UCP1 staining intensity with increasing distance from the tumor. Scale
bars = 200µm. UCP1 = uncoupling protein 1, WAT = white adipose tissue, BAT = brown adipose tissue.
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Figure 17. MATLAB analyses of UCP1 immunohistochemistry in adipocytes adjacent to
spontaneous mammary tumors
Indicating a sharp decline in UCP1 staining intensity with increasing distance from the tumor. Scale bars
= 200µm. UCP1 = uncoupling protein 1.
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Figure 18. Adipose tissue depots contiguous to spontaneous mammary tumors have altered
expression of several adipocyte-related genes
Four-month old female C57BL/6J MMTV-PyVT mouse tissue was harvested for qPCR in ovarian WAT
(‘Ovarian’ in image legend; negative controls), interscapular BAT (‘BAT’ in image legend; positive
controls), left axillary WAT (‘Axil L’ in image legend), and left and right inguinal WAT (‘Ing L’ and ‘Ing R’ in
image legend, respectively). Quantitative PCR for (A) Ucp1, (B) markers of thermogenic adipose tissue,
and (C) other markers of white adipocytes and WAT lipolysis. Please note y-axis scale is log2. n = 2-4
mice. Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B) and (C) Two-way
ANOVA and Dunnett’s multiple comparisons tests.
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Figure 19. Variability of gene expression changes in white adipose tissue depots contiguous to
spontaneous mammary tumors
WAT (‘Ovarian’ in image legend; negative controls), interscapular BAT (‘BAT’ in image legend; positive
controls), left axillary WAT (‘Axil L’ in image legend), and left and right inguinal WAT (‘Ing L’ and ‘Ing R’ in
image legend, respectively). (A), (C), and (E) are the same from Figure 15, (B), (D), and (F) show same
averages but with individual data points plotted. Please note y-axis scale is log2. n = 2-4 mice. Statistical
tests: (A) and (B) Kruskal-Wallis and Dunn’s multiple comparisons tests, (C), (D), (E), and (F) Two-way
ANOVA and Dunnett’s multiple comparisons tests.
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3.2.2. WAT browning occurs with time specificity in the FVB MMTV-PyMT murine model
of spontaneous mammary tumor
We next asked whether WAT browning could be observed in another murine
mouse model of spontaneous breast cancer, FVB MMTV-PyMT, at the protein level.
Western blot for UCP1 was performed at two timepoints, 4 weeks and 13 weeks, for
both wild type mice and mice with spontaneous mammary tumor development (referred
to as ‘PyMT mice’). Image of western blot is included in Figure 20A. We quantified the
blot intensity for each group using Image J software (Figure 20B,C). Compared to wildtype (WT) age-matched controls, PyMT mice demonstrate increased UCP1 protein
expression in inguinal adipose tissue at 4 weeks of age; interestingly, this trend is
reversed at 13 weeks (Figure 20B). In interscapular BAT, UCP1 expression is increased
in PyMT mice at 13 weeks, but not at 4 weeks (Figure 20C).
Gene expression analysis on the adipose tissue pads in PyMT mice
demonstrates an approximate 2-fold decrease in Ucp1 mRNA expression at 13 weeks
compared to 4 weeks in both inguinal WAT (Figure 21A) and interscapular BAT (Figure
21B). Figure 21C demonstrates that at both timepoints, interscapular BAT expresses at
least 50-fold more Ucp1.
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Figure 20. Adipose tissue depots in mice with spontaneous mammary tumors have timedependent changes in UCP1 protein expression
Four and thirteen week-old female FVB MMTV-PyMT with age-matched wild-type (WT) tissue was
harvested for protein analysis in interscapular BAT (‘Interscapular BAT’ or ‘BAT’ in image legend; positive
controls), and inguinal WAT (‘Inguinal WAT’ or ‘Ing’ in image legend, respectively). (A) Western blot of
UCP1 and alpha tubulin. Quantification of western blot for (B) inguinal WAT and (C) interscapular BAT.
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Figure 21. Adipose tissue depots in mice with spontaneous mammary tumors have timedependent changes in Ucp1 mRNA expression
Four and thirteen week-old female FVB MMTV-PyMT was harvested for gene expression analysis in
interscapular BAT (‘Interscapular BAT’ or ‘BAT’ in image legend; positive controls), and inguinal WAT
(‘Inguinal WAT’ or ‘Ing’ in image legend, respectively). Quantitative qPCR for (A) Ucp1 in inguinal WAT
and (B) Ucp1 in interscapular BAT with results normalized to respective 4-week expression levels. (C)
Ucp1 mRNA expression for both adipose tissue depots, normalized to 4-week inguinal WAT.
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3.2.3. Adipose tissue adjacent to human breast cancer exhibits variable WAT browning
Lastly, we explored whether white adipose tissue adjacent to human samples of
breast cancer exhibits browning. We first obtained samples of benign breast WAT from
elective breast reduction surgeries to serve as our negative controls, and stained them
for UCP1. Breast WAT exhibits no to minimal UCP1 protein expression, and lipid droplet
sizes are larger – both features we expect from benign WAT (Figure 22).
We then stained human breast cancer samples with adjacent adipose tissue for
UCP1. These breast cancer samples were previously identified by the TDAAC and/or
Department of Pathology as either triple negative, estrogen receptor positive, or HER2
expressing. For all breast cancer types, adipose tissue at the tumor-adipocyte interface
express more UCP1 than benign breast WAT, and in many samples, have lipid droplets
that are smaller in diameter compared to benign breast WAT (representative images,
one from each cancer type in Figure 23). While expression of UCP1 appears to be
greater than benign breast WAT in all samples, the intensity of stain appears to vary
significantly (Figure 24, Figure 25, Figure 26).
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Figure 22. Benign breast white adipose tissue from human female subjects do not express UCP1
protein
Breast WAT from four different female subjects undergoing elective breast reduction surgery was stained
for UCP1 protein. Each row corresponds to one of four individual human subjects. Scale bars for 4X
magnification = 200µm; 10X magnification = 100µm.
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Figure 23. Immunohistochemistry shows increased UCP1 protein expression and decreased lipid
droplet size in adipocytes adjacent to human breast carcinomas
Representative IHC images for UCP from the following: Benign breast tissue (1 st row), triple negative
breast cancer (2nd row), HER2+ breast cancer (3rd row), estrogen receptor breast cancer (ER+ BC, 4th
row). Scale bars for 1.25X magnification = 800µm; 4X magnification = 200µm; 10X magnification =
100µm.
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Figure 24. Immunohistochemistry shows variability in UCP1 expression in adipocytes adjacent to
triple negative human breast carcinomas.
Each image represents a unique patient sample. All images at 10X magnification, with scale bars =
100µm.
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Figure 25. Immunohistochemistry shows variability in UCP1 expression in adipocytes adjacent to
HER2+ human breast carcinomas.
Each image represents a unique patient sample. All images at 10X magnification, with scale bars =
100µm.
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Figure 26. Immunohistochemistry shows variability in UCP1 expression in adipocytes adjacent to
estrogen receptor-positive (ER+) human breast carcinomas.
Each image represents a unique patient sample. All images at 10X magnification, with scale bars =
100µm.
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3.3 Discussion
We first asked whether WAT browning could be observed in murine models of
breast cancer. In the C57BL/6J MMTV-PyVT model, we show that adipocytes closest to
the tumor-adipocyte interface in vivo have increased UCP1 protein expression, the
hallmark of thermogenic adipose tissue function, via immunohistochemistry (Figure 14).
The increase in UCP1 protein expression is most robust at the tumor-adipose tissue
interface, and UCP1 protein expression sharply declines moving further from the tumor,
demonstrated qualitatively by higher intensity scoring at the tumor-adipocyte interface
(Figure 15) and quantitatively by a trend that fits the inverse power law upon curve
fitting (Figure 16, Figure 17). This suggests that the strength of browning is inversely
related to the center of its driver, the tumor cells, which has recently been noted in a
xenograft model of breast cancer as well [117]. We also observe smaller lipid droplets in
these adipocytes, which has been observed and described as a characteristic of
‘cancer-associated adipocytes (CAA)’ at the tumor forefront [116]. Together, the
decreased lipid size and increased UCP1 expression in adipocytes closest to the tumor
in our IHC images confirm the phenotypic changes consistent with a maladaptive
transdifferentiation from white to beige adipose tissue in response to the tumor
microenvironment. Furthermore, the localized nature of this browning suggests a
paracrine signaling interaction between the tumor and adjacent adipocytes.
mRNA expression levels of key adipocyte gene markers further support
adipocyte plasticity in these WAT depots with tumor (Figure 18). Ucp1 mRNA
expression was increased in two of the three WAT fat pads with spontaneous mammary
tumor, with up to an 8-fold increase in expression. Other markers related to thermogenic

124

adipose tissue, such as Cidea, Oplah, and Slc29a1, were increased in the axillary
and/or inguinal WAT with tumor development. Interestingly, WAT in the fat pads with
tumor expressed significantly less Lipe and Lpl, two markers of WAT lipolysis. This
supports the hypothesis that the smaller lipid droplets observed at the tumor-adipocyte
interface in our IHC images are the results of WAT browning as opposed to WAT
lipolysis.
It is important to highlight the variability in the mRNA expression data, most
notably in the thermogenic adipose tissue-related genes (Figure 19). This variability is
not surprising considering that the tissue analyzed was comprised of white adipose
tissue both proximal and distal to the spontaneous mammary tumors. It is likely that
WAT at the tumor-adipocyte interface was variably excised, as it was dissected via
manual inspection. We do not have the capability to perform laser capture
microdissection on our samples, which would be the best way to assess this, especially
considering the very localized (~200um) browning effect noted on IHC.
In another murine model of spontaneous breast cancer, the FVB MMTV-PyMT
model, we demonstrate additional evidence to support WAT browning in breast cancer.
Interestingly, both WAT and BAT depots in these mice with early (4 week) and later (13
week) stage tumors appear to exhibit time-dependent changes in UCP1 protein
expression (Figure 20). Pooled samples of human breast cancer xenografts grown in
mice have been shown to express varying amounts of UCP1 protein dependent on the
length of xenograft growth, with UCP1 present at 1 week post-implantation, peaking at
5-7 weeks, and decreasing to less than the 1-week level at 15 weeks [117]. While these
changes may have contributions from cells within the entire tumor microenvironment,
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our results suggest temporal regulation of adipocyte plasticity in breast cancer. Ucp1
mRNA expression levels in these tumors suggest a decrease in transcript expression at
later timepoints in both inguinal WAT and interscapular BAT (Figure 21); however, these
results were obtained by comparing mice with tumor, without the use of age-matched
controls as in our western data. We also recognize the same limitations to these results
as explained for the C57BL/6J MMTV-PyVT mRNA results earlier in this section.
Additional studies with a larger samples sample size (as ours only had 2 mice per
group) would be useful to confirm this time-dependence, and eventually probe into the
mechanisms behind it.
Lastly, as we have seen WAT browning in two different murine models of
spontaneous mammary tumor, we asked whether WAT browning occurs in human
samples of breast cancer. We first demonstrate that benign breast WAT has no UCP1
expression at baseline using samples from 4 women of different ages (Figure 22), and
then show via IHC that UCP1 protein expression is increased in white adipocytes
surrounding human breast carcinoma samples (Figure 23). This supports the global
concept of WAT browning in cancer, as IHC studies performed by Petruzzelli and
colleagues demonstrated that several other human cancers (melanoma, colon,
pancreatic, and lung cancers) were associated with increased UCP1 in WAT [112].
In human breast cancer samples, similar to what we observed in our mouse IHC,
there appears to be a gradient of UCP1 expression, highest at the tumor-adipocyte
interface and decreasing moving distally from the tumor (Figure 23). Interestingly, it
appears that some of the tumor cells stain positively for UCP1 in several of the samples.
In the literature, there are several reports of UCP1 expression in cancer, including
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breast cancer xenografts and human samples of non-small cell lung cancer [117, 164],
so this observation is not surprising.
We further demonstrate that this increase in UCP1 expression in WAT in cancer
is seen in a variety of subtypes of breast carcinoma, including triple negative (Figure
24), HER2 expressing (Figure 25), and ER+ (Figure 26) breast cancers. Future
analyses using additional samples with a larger volume/area of WAT adjacent to tumors
will be helpful to determine whether differences exist between receptor statuses.
Correlating stage of tumor at time of resection with UCP1 staining intensity would
provide additional insight into the time-dependency we noted in our murine studies on
the human level.
While increased UCP1 staining intensity is observed in all breast cancer
subtypes we analyzed, there is certainly variability in staining intensity between
individual samples (Figure 24, Figure 25, Figure 26). It is well established that inter- and
intra-organism tumor heterogeneity exists in breast cancer [165, 166]. Since we
hypothesize that the tumor and tumor microenvironment are responsible for these
adipocyte changes, it is therefore not surprising that the variability between tumor and
host responses would result in variable adipocyte changes.

3.4 Conclusion
Taken together, our results demonstrate the presence of WAT browning
(increased UCP1 expression and decreased lipid droplet size) in adipose tissue
surrounding tumors in both murine and human breast cancers. This illustrates the
importance and translational potential of our work. Furthermore, our results suggest a
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local, paracrine (cell-cell) interaction between adipocytes and tumor and tumor
microenvironment as the driver of the adipocyte changes. These are the interactions
that we explore in the next two chapters.
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Chapter 4: Cancer-Adipocyte Interactions Induce Changes to White Adipocytes In Vitro

4.1 Rationale
Based on the WAT browning observed in vivo (Chapter 3), we established a cell
culture system which would allow us to methodically and systematically study the
effects of individual components of the tumor microenvironment on adipocytes in vitro.
Furthermore, as the WAT browning demonstrated in Chapter 3 is extremely localized in
nature, and other studies have implicated tumor-secreted factors in WAT browning and
remodeling [113], we asked whether local factors secreted by breast cancer cells (and
other cancer cells) are the driver of these local WAT changes.

4.2 Results
4.2.1 Immortalized murine SVF cells are capable of undergoing differentiation to mature
white and beige adipocytes
We first tested the differentiation capacity of our lab’s immortalized male mouse
inguinal stromal vascular fraction cells (referred to as mouse immortalized white
preadipocytes, or mIWPAs). Immature stromal vascular fraction cells are able to
successfully undergo differentiation to both mature white and beige adipocytes with high
percentage of differentiation (Figure 27A). Expression of Dlk1 (Delta like non-canonical
Notch ligand 1), a marker of immature/undifferentiated adipocytes, is increased by
about 5-fold in undifferentiated preadipocytes compared to differentiated white and
beige adipocytes (Figure 27B). Expression of other gene markers associated with
mature adipocytes was decreased in the preadipocytes, most notable being Cidea.
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Lastly, Ucp1 was significantly increased in the mature beige adipocytes, demonstrating
that our in vitro immortalized cell culture model expresses appropriate differences in
thermogenic gene expression.
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Figure 27. Immortalized murine SVF are capable of differentiation to mature white and beige
adipocytes
Inguinal SVF isolated from inguinal WAT from a young male C57BL/6J mouse were immortalized, then
cultured and differentiated to either white or beige adipocytes as described in methods. (A)
Representative Oil Red O staining after completed induction and maintenance protocol. Scale bars =
100µm. (B) Quantitative PCR for various adipocyte-related markers. Please note y-axis scale is log2. n =
4 for all groups. Error bars = standard deviation. Statistical tests: (B) 2-way ANOVA and Dunn’s multiple
comparisons tests.
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4.2.2 Cancer conditioned medium from E0771 and LLC cells do not induce WAT
browning in our immortalized cell culture model
We next asked if white preadipocyte exposure to cancer-conditioned medium
would induce maturation of beige adipocytes. As described in methods section 2.8.1
(Figure 7), immortalized preadipocytes were exposed to cancer conditioned medium at
various stages of differentiation: either the induction phase, the maintenance phase,
both, or pretreatment and both. When preadipocytes are exposed to E0771 cancer
conditioned medium during the induction phase and the cancer conditioned medium is
removed for the duration of maintenance, there are no changes in gene expression
profiles (Figure 28A). When preadipocytes undergo normal induction and then are
exposed to cancer conditioned medium throughout the maintenance period, there is a
significant decrease in mRNA expression of Ucp1, and decreases (though not
statistically significant after correcting for multiple comparisons) in Cidea and Ppargc1a
(peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) (Figure 28B).
When preadipocytes are exposed to cancer conditioned medium throughout both
induction and maintenance phases of differentiation, statistically significant decreases in
Cidea, Ppargc1a, and Ucp1 are observed (Figure 28C). No changes are observed with
pre-treatment before and during differentiation (Figure 28D). For all treatment groups,
no changes in lipolysis-related genes Lipe or Lpl occurred.
We also asked if the time during maintenance was important. We demonstrate
again that exposure to cancer conditioned medium before induction, or throughout
induction, do not increase Ucp1 expression (Figure 29A,B). Significant decreases in
Ucp1 mRNA expression were detected in mature adipocytes after exposure to cancer
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conditioned medium at various timepoints throughout the maintenance period of
differentiation (Figure 29C-F). Lastly, we demonstrate that exposure to cancer
conditioned medium during both induction and maintenance results in the most dramatic
and significant decrease in Ucp1 and Cidea expression (Figure 29G).
While these results highlight the changes from cancer conditioned medium that
can be observed in differentiating adipocytes, we next asked whether transdifferentation
could occur – whether mature white adipocytes could transdifferentiate into beige
adipocytes – when exposed to cancer conditioned medium. This question is more
physiologically relevant as there is only a small percentage of adipocyte turnover
(preadipocyte differentiation into mature white adipocytes) in vivo [25]. We exposed fully
mature white adipocytes to E0771 cancer conditioned medium exposure for 7 or 14
consecutive days. Interestingly, our results suggest that similar to differentiating
adipocytes, mature white adipocyte exposure to cancer conditioned medium results in a
significant decrease in Ucp1 mRNA expression (Figure 30).
We next asked whether we would observe a similar decrease in Ucp1 expression
using cancer conditioned medium from another mouse cancer cell line. Using cancer
conditioned medium from Lewis Lung Carcinoma (LLC) cells, we demonstrate that the
effect of decreased Ucp1 is consistent across exposure to cancer conditioned medium
from these two distinct cell lines (Figure 31B). Lastly, we asked whether 24 hours of
exposure could induce these changes. Our results suggest that 24 hours of exposure is
sufficient to cause a decrease in Ucp1 mRNA expression in our in vitro model with both
cell lines (Figure 31C).
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Figure 28. Mature adipocyte mRNA expression is altered after exposure to cancer conditioned
medium during phases of differentiation; part 1
Immortalized SVF were exposed to either E0771 conditioned medium (gray bars) or control white medium
(white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and adipocyte gene
markers in mature adipocytes after (A) cancer conditioned medium during only the induction phase (‘I
only’) of differentiation, (B) cancer conditioned medium during only the maintenance phase (‘M only’) of
differentiation, (C) cancer conditioned medium during both induction and maintenance phases (‘I+M’) of
differentiation, and (D) cancer conditioned medium before differentiation and during both induction and
maintenance phases (‘Pretreat+I+M’) of differentiation. Please note y-axis scale is log2. n = 3. Statistical
tests: (A), (B), (C), and (D) Two-way ANOVA and Dunnett’s multiple comparisons tests.
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Figure 29. Mature adipocyte mRNA expression is altered after exposure to cancer conditioned
medium during phases of differentiation; part 2
Immortalized SVF were exposed to either E0771 conditioned medium (gray bars) or control white medium
(white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and adipocyte gene
markers in mature adipocytes after exposure to (A) cancer conditioned medium before differentiation
(‘pretreated preadipocytes’), (B) cancer conditioned medium during only the induction phase of
differentiation (‘I only (D2)’), (C) cancer conditioned medium during only the first three days of the
maintenance phase (‘M only (D5)’), (D) cancer conditioned medium during only the first six days of the
maintenance phase (‘M only (D8)’), (E) cancer conditioned medium during only the first nine days of the
maintenance phase (‘M only (D11)’), (F) cancer conditioned medium during only the entirety of the
maintenance phase (‘D14’), and (G) cancer conditioned medium during both induction and maintenance
phases of differentiation (‘I+M’). Please note y-axis scale is log2. n = 3. Statistical tests: (A), (B), (C), and
(D) Two-way ANOVA and Dunnett’s multiple comparisons tests.
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Figure 30. Mature adipocyte mRNA expression is altered after exposure to cancer conditioned
medium after maturation
Immortalized SVF were exposed to either E0771 conditioned medium (gray bars) or control white medium
(white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and adipocyte gene
markers in mature adipocytes after mature, fully differentiated white adipocytes were exposed to cancer
conditioned medium for (A) 7 days or (B) 14 days. Please note y-axis scale is log2. n = 3. Statistical tests:
(A), (B) Two-way ANOVA and Dunnett’s multiple comparisons tests.

136

Figure 31. Mature adipocyte mRNA expression is altered after exposure to cancer conditioned
medium both during and after maturation
(A) Quantitative PCR for Ucp1 in immortalized SVF (‘preadipocytes’ in image) before differentiation and in
mature white (‘White’ in image) and beige (‘Beige’ in image) adipocytes after differentiation. (B) and (C)
Quantitative PCR for Ucp1 in immortalized SVF exposed to cancer conditioned medium either (B) during
differentiation or (C) after differentiation was completed as described in methods. For (B) and (C), white
control is indicated as ‘W,’ ‘E0771’ represents E0771 conditioned medium, and ‘LLC’ represents LLC
conditioned medium. Please note y-axis scale is log2. n = 3-5. Statistical tests: (A), (B), (C) Kruskal-Wallis
and Dunn’s multiple comparisons tests.
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4.2.3 Primary murine stromal vascular fraction cells allow for in vitro differentiation to
white and beige adipocytes.
Next, we established a primary cell culture system that would confer additional
advantages to our methodical experiments to study the effects of breast cancer (and
other cancers) on adipocytes in vitro. Primary SVF cells (also referred to as
preadipocytes) are capable of undergoing differentiation to both mature white and beige
adipocytes (Figure 32). Oil Red O staining demonstrates successful differentiation in
both white and beige groups, with larger lipid droplets in the white differentiation group
(Figure 32 and Figure 33A). Expression of white adipocyte-associated genes Cfd
(complement factor D, also known as adipsin) and Lep (leptin) were significantly
decreased in both preadipocytes (not expressed for leptin) and beige adipocytes
relative to white adipocytes, and expression of Fasn (fatty-acid synthase) was
significantly decreased in preadipocytes (Figure 33C). Lastly, expression of
thermogenic adipocyte genes Cidea, Ppargc1a, Tnfrsf9 (tumor necrosis factor receptor
superfamily, member 9), and Ucp1 were significantly increased in differentiated beige
adipocytes (Figure 33D).
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Figure 32. Primary murine inguinal SVF can differentiate into mature white and beige adipocytes
Oil Red O brightfield images from primary culture female inguinal white (left column) or beige (right
column) adipocytes after full induction and maintenance periods (day 16). A,B,C,D represent 4 different
female primary culture lines. Scale bars = 100µm.

139

Figure 33. Primary murine SVF are capable of differentiation to mature white and beige adipocytes
Inguinal SVF isolated from young female C57BL/6J mice were differentiated to either white or beige
adipocytes as described in methods. (A) Representative Oil Red O staining confirming that our protocol is
highly selective for culture of preadipocytes capable of undergoing successful differentiation. Scale bars
= 100µm. Quantitative PCR for (B) Dlk1, (C) markers of white adipocytes, (D) markers of beige
adipocytes. Please note y-axis scale is log2. n = 5 primary SVF cell lines. Error bars = standard deviation.
Statistical tests: (B) Kruskal-Wallis and Dunn’s multiple comparisons tests, (C) and (D) Two-way ANOVA
and Dunnett’s multiple comparisons tests. SVF = stromal vascular fraction, n.d. = not detected.
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4.2.4 Cancer conditioned medium and coculture alter white adipocyte gene expression,
but do not increase thermogenic gene expression in murine primary differentiated white
adipocytes
To further investigate the localized WAT browning observed in vivo in Chapter 3,
we exposed differentiated, mature white adipocytes from primary mouse SVF to the
conditioned medium from E0771 murine breast cancer cells (Figure 34), or cocultured
them with E0771 cells (Figure 36). Ucp1 mRNA expression in white adipocytes exposed
to E0771 cancer-conditioned medium was decreased, although not significantly, relative
to control white adipocytes, and was significantly decreased when compared to both
control beige adipocytes and white adipocytes exposed to the β3 adrenergic agonist CL
316,243 (Figure 34A). Western blot of UCP1 confirms these mRNA expression results
on the protein level (Figure 35).
Cancer-conditioned medium exposure did not result in increased expression of
any of the thermogenic genes tested, except a trend towards higher Tnfrsf9 (Figure
34B). Interestingly, a significant decrease in the white adipocyte-associated genes Fasn
and Lep was observed in the cancer-conditioned medium treated adipocytes (Figure
34C). We also tested for genes associated with lipolysis, and found that white
adipocytes exposed to E0771 cancer-conditioned medium had no changes in
expression of Lpl or Mgll (monoglyceride lipase), but expressed less Lipe compared to
control white adipocytes (Figure 34D).
When differentiated white adipocytes were cocultured with E0771 cells, the same
pattern of Ucp1 expression was observed: a decrease (although not statistically
significant) in Ucp1 expression compared to control white adipocytes, but significantly
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lower Ucp1 expression compared to white adipocytes treated with CL 316,243 (Figure
36A). While there were no changes in gene expression of the thermogenic genes Cidea
or Ppargc1a, white adipocytes cocultured with E0771 cells expressed significantly more
Tnfrsf9 (Figure 36B). Similar to the cancer-conditioned medium results (Figure 34),
white adipocytes cocultured with E0771 cells expressed significantly less Fasn and Lep
mRNA compared to white control adipocytes, with no change in Cfd expression (Figure
36C). Lastly, expression of Mgll was significantly increased in white adipocytes
cocultured with E0771 cells, while expression of Lipe and Lpl was decreased but not
significantly (Figure 36D).
Lastly, we asked if these results could be replicated using a different murine
mouse model for SVF and breast cancer (BALB/c mice and the 4T1 breast cancer cell
line). We show, similar to Figure 34 and Figure 35, that exposure of mature white
adipocytes from BALB/c mice to 4T1 cancer conditioned medium decreases Ucp1
mRNA expression (Figure 37A) and UCP1 protein expression (Figure 38). 4T1 cancer
conditioned medium exposure resulted in only a 2-fold increase in Tnfrsf9, which was
not statistically significant (Figure 37B). Of the white adipocyte-associated genes tested,
only Lep expression was significantly decreased with 4T1 exposure (Figure 37C).
Lastly, although none of the lipolysis-related genes were significantly different after 4T1
cancer conditioned medium exposure, there were slight trends of decreasing Lpl
expression and increasing Mgll expression (Figure 37D).
Coculture of BALB/c -derived mature white adipocytes with 4T1 cells resulted in
relatively similar gene expression patterns (Figure 39): no change in Ucp1 expression
(Figure 39A), non-statistically-significant 4-fold increases in Tnfrsf9 expression (Figure
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39B) and 2-fold decreases in Lep expression (Figure 39C), and no changes in lipolysisrelated gene expression (Figure 39D).
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Figure 34. E0771 cancer-conditioned medium alters white adipocyte mRNA expression, but does
not induce white adipocyte browning in vitro
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or E0771 cancerconditioned medium (noted as ‘CC’ in images) and compared to controls as described in methods.
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes,
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 7 primary C57BL/6J SVF cell lines.
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way
ANOVA and Dunnett’s multiple comparisons tests.
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Figure 35. Representative western blot of UCP1 and TBP demonstrating that E0771 cancerconditioned medium does not induce white adipocyte browning in vitro
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or E0771 cancerconditioned medium (noted as ‘CC’ in images) and compared to white ‘W’ and beige ‘B’ controls. Western
blot performed in two of the seven primary C57BL/6J SVF cell lines used.
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Figure 36. E0771 coculture alters white adipocyte mRNA expression, but does not induce white
adipocyte browning in vitro.
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or cocultured with
E0771 cells (noted as ‘Coculture’ in images) and compared to controls as described in methods.
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes,
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 7 primary C57BL/6J SVF cell lines.
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way
ANOVA and Dunnett’s multiple comparisons tests.
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Figure 37. 4T1 cancer conditioned medium alters white adipocyte mRNA expression, but does not
induce white adipocyte browning in vitro
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or 4T1 cancerconditioned medium (noted as ‘CC’ in images) and compared to controls as described in methods.
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes,
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 3 primary BALB/cJ SVF cell lines.
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way
ANOVA and Dunnett’s multiple comparisons tests.
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Figure 38. Western blot of UCP1 and TBP demonstrating that 4T1 cancer-conditioned medium
does not induce white adipocyte browning in vitro
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or 4T1 cancerconditioned medium (noted as ‘CC’ in images) and compared to white ‘W’ and beige ‘B’ controls. Western
blot performed in all three of the BALB/cJ SVF cell lines used.
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Figure 39. 4T1 coculture alters white adipocyte mRNA expression, but does not induce white
adipocyte browning in vitro.
Differentiated white adipocytes were treated with CL 316,243 (noted as ‘CL’ in images) or cocultured with
4T1 cells (noted as ‘Coculture’ in images) and compared to controls as described in methods.
Quantitative PCR for (A) Ucp1, (B) other markers of beige adipocytes, (C) markers of white adipocytes,
and (D) markers of lipolysis. Please note y-axis scale is log2. n = 3 primary BALB/cJ SVF cell lines.
Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple comparisons tests, (B), (C), and (D) Two-way
ANOVA and Dunnett’s multiple comparisons tests.
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4.2.5 Human breast-derived stromal vascular fraction cells allow for in vitro
differentiation to white and beige adipocytes
We wanted to determine whether changes that occurred in murine cell culture
experiments could be replicated with human cell culture. Based on the results in mouse
cell lines, we decided to use human SVF. We tested differentiation requirements in
female human breast SVF and found that they require additional supplementation in
their cell culture medium in order to successfully differentiate, as demonstrated by
differences in Oil Red O staining (Figure 40).
We demonstrate that our human SVF cell culture system, similar to in mice, is
capable of differentiating into mature white and beige adipocytes with adequate
differentiation and larger lipid droplet accumulation in mature white adipocytes (Figure
41A). Additionally, UCP1 mRNA expression is significantly increased in our beige
adipocytes compared to white, and was not detected at all in the undifferentiated
SVF/preadipocytes (Figure 41B). These results demonstrate a viable human in vitro
model for studying the effects of tumor and tumor microenvironment on adipocyte
plasticity.
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Figure 40. Human breast SVF requires additional medium supplementation to allow for robust
differentiation to mature white and beige adipocytes.
Isolated white preadipocytes from female normal breast tissue obtained during breast reduction surgery
were differentiated to mature white and beige adipocytes with or without supplementation with the ATCC
Low Serum Fibroblast Growth Kit as described in methods. Representative Oil Red O images
demonstrate (A) poor differentiation percentage in cells without supplementation, (B) robust differentiation
in cells with supplementation. Scale bars = 100µm. hbbWPA = human benign breast white preadipocytes.
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Figure 41. Primary human SVF are capable of differentiation to mature white and beige
adipocytes.
SVF cells isolated from human female normal WAT were differentiated to either white or beige adipocytes
as described in methods. (A) Representative Oil Red O staining confirming that our protocol is highly
selective for culture of preadipocytes capable of undergoing successful differentiation. Scale bars =
50µm. (B) Quantitative PCR for thermogenic adipose tissue-related genes. N = 2. Statistical tests for (B)
Two-way ANOVA and Dunnett’s multiple comparisons tests. SVF = stromal vascular fraction, n.d. = not
detected.
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4.2.6 Cancer conditioned medium induces changes to white adipocyte gene expression
in human primary differentiated white adipocytes
The first question using our human SVF cell culture system, similar to that in our
murine SVF cell culture system, was whether exposure to breast cancer conditioned
medium at various points in the differentiation process would result in WAT browning.
As described in methods section 2.8.3 (Figure 9), human SVF cells were exposed to
MCF-7 and MDA-MB-231 cancer conditioned medium at various stages of
differentiation: either the entire induction phase, partial or entire maintenance phase, or
both induction & maintenance periods. Compared to mature white adipocytes, exposure
to MCF-7 or MDA-MB-231 cancer conditioned medium during only the induction phase
of differentiation resulted in no changes in Ucp1, but significantly decreased TMEM26
(transmembrane protein 26) expression (Figure 42A). Expression of several other
thermogenic adipose tissue-related genes such as EAR2 (nuclear receptor subfamily 2
group F member 6), OPLAH, and PPARGC1A were decreased, while PDK4
(mitochondrial pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 4)
expression was approximately 2-fold higher in both cancer conditioned medium treated
groups, but no changes were significant (Figure 42A). Exposure to MCF-7 or MDA-MB231 cancer conditioned medium during only the first half of the maintenance phase of
differentiation resulted in significant decreases in many of the genes tested, although
there was no change in UCP1 expression (Figure 42B). When differentiating white
adipocytes were exposed to MCF-7 or MDA-MB-231 cancer conditioned medium
throughout the entirety of the maintenance phase of differentiation, there were still
trends towards decreased expression of many of the thermogenic adipose tissue-
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related genes; however, for UCP1 expression, there was a 2.2-fold increase (not
statistically significant) in the group treated with MCF-7 conditioned medium, and a
statistically significant 3.8-fold increase in the group treated with MDA-MB-231
conditioned medium (Figure 42C). When exposure to cancer conditioned medium
spanned the entirely of the induction and maintenance phases, the MDA-MB-231
conditioned medium treatment group expressed significantly more UCP1, roughly 6.4fold more than mature white adipocyte controls (Figure 42D).
We also analyzed the Oil Red O images and quantified lipid droplet sizes.
Control beige adipocytes have significantly smaller lipid droplets than mature white
adipocytes (Figure 43A). Regardless of the timing or duration of cancer conditioned
medium exposure, maturing white adipocytes exposed to either MCF-7 or MDA-MB-231
cancer conditioned medium had significantly smaller lipid droplets when compared to
white adipocyte controls (Figure 43B-E).
Lastly, we tested the effects of these cancer conditioned mediums on mature
white adipocytes in an SVF cell line derived from a different human patient during
differentiation and after maturation for 24 hours. Interestingly, although this SVF cell line
had appropriate UCP1 expression levels in undifferentiated, mature white, and mature
beige adipocytes (Figure 44A), exposure to MCF-7 and MDA-MB-231 cancer
conditioned medium throughout differentiation resulted in a significant decrease in
UCP1 expression (Figure 44B). Exposure to mature white adipocytes to cancer
conditioned medium for 24 hours resulted in slightly different results, with a roughly 2fold increase in UCP1 expression in the MCF-7 conditioned medium group, and 8-fold
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decrease in UCP1 expression in the MDA-MB-231 conditioned medium group (Figure
44C).
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Figure 42. Mature human adipocyte mRNA expression is differentially altered after exposure to
MCF-7 and MDA-MB-231 cancer conditioned mediums during phases of differentiation
Primary SVF derived from normal WAT from a 27 year old woman were exposed to either MCF-7
conditioned medium (dark gray bars), MDA-MB-231 conditioned medium (light gray bars), or control white
medium (white bars) as described in methods. Quantitative PCR for a variety of adipogenesis and
adipocyte gene markers in mature adipocytes after exposure to (A) cancer conditioned medium during
only the induction phase of differentiation (‘I only (D5)’), (B) cancer conditioned medium during only the
first half of the maintenance phase (‘M only (D10)’), (C) cancer conditioned medium during only the
entirety of the maintenance phase (‘M only (D15)’), and (D) cancer conditioned medium during both
induction and maintenance phases of differentiation (‘I&M’). Please note y-axis scale is log2. n = 2-3.
Statistical tests: (A), (B), (C), and (D) Two-way ANOVA and Dunnett’s multiple comparisons tests.
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Figure 43. Lipid droplet size significantly decreases in mature human adipcoytes after exposure to
MCF-7 and MDA-MB-231 cancer conditioned mediums during differentiation
Primary SVF derived from benign breast WAT from a 27 year old woman were differentiated to mature
white or beige adipocytes. Lipid droplet sizes in (A) white (gray dots) versus beige (black dots) control
adipocytes, (B) cancer conditioned medium during only the induction phase of differentiation, (C) cancer
conditioned medium during only the first half of the maintenance phase, (D) cancer conditioned medium
during only the entirety of the maintenance phase, and (E) cancer conditioned medium during both
induction and maintenance phases of differentiation. For (B), (C), (D), and (E), MCF-7 conditioned
medium (blue dots), MDA-MB-231 conditioned medium (magenta dots), or control white medium (gray
dots) N=2 wells per group, with over 300 lipid droplets analyzed per condition. Statistical tests: (A)
Unpaired t-test without assuming same standard deviation between groups; (B), (C), (D), (E) One-way
ANOVA and Dunnett’s multiple comparisons tests.
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Figure 44. Mature adipocyte mRNA expression is differentially altered after exposure to MCF-7 and
MDA-MB-231 cancer conditioned mediums both during and after maturation
(A) Quantitative PCR for Ucp1 in primary human SVF derived from normal WAT from a 51 year old
woman (‘preadipocytes’ in image) before differentiation and in mature white (‘White’ in image) and beige
(‘Beige’ in image) adipocytes after differentiation. (B) and (C) Quantitative PCR for UCP1 in primary
human SVF exposed to cancer conditioned medium either (B) during differentiation or (C) after
differentiation was completed as described in methods. For (B) and (C), white control is indicated as ‘W,’
‘MCF7’ represents MCF-7 conditioned medium, and ‘MDAMB231’ represents MDA-MB-231 conditioned
medium. Please note y-axis scale is log2. n = 2-3. Statistical tests: (A), (B), (C) Kruskal-Wallis and Dunn’s
multiple comparisons tests.
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4.3 Discussion
We utilized our lab’s immortalized white SVF, derived from the inguinal WAT of a
male C57BL/6J mouse, to produce an in vitro model of adipocyte differentiation that
could be used to investigate the role of the cancer cell secretome in adipocyte plasticity
both during and after adipocyte differentiation. E0771, an estrogen-receptor positive
murine breast cancer cell line, is commonly used in many in vitro and in vivo C57BL/6
breast cancer studies [167-170]. Use of an established breast cancer cell line, as
opposed to the use of whole tumor lysate, provides a strategic advantage in the
mechanistic study of WAT browning in vitro because it is cultured without other cells
within the tumor microenvironment, which could confound results, and eliminates the
problems of inter- and intra-organism tumor heterogeneity [165, 166]. However, these
are not perfect replacements for cancer cells isolated from tumors grown in vivo, and
this should be kept in mind when interpreting our experimental results.
Our results using cancer conditioned medium from E0771 cells suggest that
exposure to cancer conditioned medium during the initial induction phase of
differentiation does not impact mature adipocyte gene expression; instead, exposure
during the induction and maintenance phase or during the maintenance phase alone
appears to have the most significant effects (Figure 28, Figure 29). This time-specificity
is not surprising, as other studies have influenced adipogenesis at time-specific periods
of differentiation. In 3T3-L1 ‘white preadipocytes,’ mature adipocytes can initiate
induction of differentiation of nearby preadipocytes, suggesting a role of endogenous
paracrine signaling in the induction phase [171]. Also in 3T3-L1 preadipocytes,
adipogenesis can be thwarted by retinoic acid-mediated decreases in PPARgamma and
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C/EBPalpha, but only when exposed during the induction phase [172, 173]. Even in
differentiation of brown adipocytes, STAT3 is required during the induction phase, but
not the maintenance phase [174]. Other factors, such as Lipin 1 (an enzyme involved in
lipid biosynthesis) and Microprocessor complex subunit DGCR8 (a protein critical for
miRNA biogenesis), have been shown to be necessary for both differentiation and
maintenance of white and/or brown adipocytes [175, 176]. Our results suggest that
exposure during the initiation period must be maintained throughout maintenance, or
even introduced just during the maintenance phase alone, in order to alter adipocyte
mRNA expression in the context of cancer
We were surprised to observe that cancer conditioned medium exposure results
in a decrease in mRNA expression of several thermogenic gene markers – Ucp1,
Cidea, and Ppargc1a – opposite our initial hypothesis. This suggests, contrary to other
studies, that the cancer cell secretome is not a direct driver of WAT browning in vitro.
Additionally, no changes in lipolysis-related gene expression via Lipe or Lpl were
identified in any of the treatment groups, further negating our hypothesized direct role of
cancer conditioned medium on adipocyte changes in this model.
While these results give valuable insight into the effects of cancer conditioned
medium on differentiating white preadipocytes, adipocyte turnover in vivo is quite low,
with an annual turnover rate measured at approximately 10% in adults [25]. This means
that the majority of cells impacted by any perturbations to surrounding environment are
mature, rather than differentiating, adipocytes. We therefore tested whether E0771
cancer conditioned medium would induce transdifferentiation of white to beige
adipocytes. We demonstrate that exposure of mature, fully differentiated, white
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adipocytes to the conditioned medium of E0771 cells does not induce WAT browning,
but instead results in a decrease in Ucp1 expression. Again, these results were
opposite our initial hypothesis. Furthermore, this decrease in Ucp1 expression occurred
regardless of whether the exposure lasted for one week, two weeks, or even just 24
hours (Figures 27, 28).
This prompted the use of 24 hour exposure periods for subsequent experiments
discussed later in this discussion, as this shorter timeframe provides several
advantages: it allows us to study more acute signaling changes which may initiate the
long term changes; it decreases the need for multiple medium changes which
introduces inherent variability (although we do our best to ensure consistency between
each harvest of cancer conditioned medium); it decreases risk of adipocyte detachment
before harvesting (based on our lab’s observations, the risk for detachment increases
the longer the mature adipocytes remain in culture, even with the use of gelatin-coated
cell culture plates).
Lastly, we demonstrate that decreased Ucp1 expression is not a response limited
to the E0771 cell line. A similar, and to an extent more robust, decrease in Ucp1 mRNA
expression occurred after exposure to LLC conditioned medium (Figure 31). LLC cancer
conditioned medium has been shown to induce muscle catabolism contributing to CAC
[177], but more importantly has been implicated in PTHrP-mediated WAT browning in
LLC tumor-driven cachexia in mice [178]. While we did not test our conditioned medium
for the presence of PTHrP, we used a filter with pore sizes that would allow passage of
PTHrP into the filtered medium used for adipocyte treatment, so our results suggest that
any PTHrP-mediated changes are not direct in nature. Obtaining the same results – a
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decrease in Ucp1 mRNA expression – with two completely different cancer cell lines
adds significant confidence to our conclusion that the cancer cell secretome is not the
driver of WAT browning in this cell culture model.
However, several key limitations to this model exist. These SVF cells, similar to
the commercially-available 3T3-L1 preadipocyte cell line [179], are derived from males,
not female mice. It is well-established that metabolic differences exist between sexes in
both mice and humans [180-182]. Use of a female SVF cell line would be advantageous
for breast cancer studies. These male SVF cells were immortalized with SV40 Large T
antigen, which inherently alters the genetic composition of these cells [160]. Although
we demonstrate that these cells are capable of differentiating into white and beige
adipocytes based on mRNA expression data (Figure 27) and have used these cells for
other adipogenesis-related studies [183], we cannot be certain that the decrease in
Ucp1 expression is confounded by the immortalized nature of these cells. While cell
lines offer several advantages, they are not always true replacements of primary cells
[184]; studies comparing other primary versus immortalized cells have identified
differential protein expression patterns that may lead to different experimental results
[185]. Lastly, these studies were performed with experimental replicates using the same
male immortalized SVF cell line, as opposed to SVF cells derived from different
individual mice. With these three limitations in mind, we sought to establish a more
robust and reliable cell culture system to test whether cancer conditioned medium could
cause WAT browning.
We have established a viable cell culture system using primary inguinal SVF
from female mice (Figure 32, Figure 33). The mRNA expression profiles of the
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preadipocytes, differentiated white adipocytes, and differentiated beige adipocytes are
appropriate for each respective cell type when compared to those of other models and
whole tissue lysates [186]. Qualitatively, there appears to be a more noticeable
difference between the lipid droplet sizes in mature white versus beige adipocytes in
these primary cell lines (Figure 33A) when compared to the immortalized cell line
(Figure 27A), suggesting that the immortalized preadipocyte cell line may in fact
produce a difference in baseline differentiation. Quantitatively, there were more
significant differences in mRNA expression values between preadipocytes, white
adipocytes, and beige adipose when using these primary SVF (Figure 33 versus the
immortalized SVF Figure 27). These significant differences are even more robust since
they come from the consolidation of data from adipocytes differentiated from SVF
derived from five different, individual female mice.
The exposure of white differentiated adipocytes from primary SVF to CL 316,243,
a β3 adrenergic agonist used as a positive control, results in an appropriate increase in
Ucp1 mRNA expression (for example, Figure 34A). This unique feature of the primary
preadipocytes provides a model of white to beige adipocyte transdifferentiation.
Together, these data demonstrate that the differentiation of primary inguinal SVF cells
from female mice provides a robust cell culture system, which is uniquely suited for
studying the local effects of breast cancer and other components within the tumor
microenvironment on white adipocyte browning.
We utilized this primary SVF in vitro cell culture system to explore whether the
E0771 cell secretome or E0771 coculture with white adipocytes would induce WAT
browning. To our surprise, Ucp1 mRNA expression in white adipocytes exposed to
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E0771 cancer conditioned medium or E0771 coculture was decreased relative to control
white adipocytes (Figure 34 and Figure 36, respectively). Although not statistically
significant, the trend of lower Ucp1 expression in white adipocytes exposed to either the
E0771 secretome or E0771 coculture was consistent with expression trends
demonstrated in the immortalized preadipocyte cell culture system.
Ucp1 mRNA was used as the primary target in our studies, as UCP1 is the
hallmark of thermogenic activity, and total Ucp1 mRNA correlates well with total UCP1
protein in mouse models of cold-induced adipocyte browning [187]. Furthermore,
western blotting of UCP1 in our experiments confirmed our Ucp1 mRNA expression
results on the protein level (Figure 35). This provided additional justification for the use
of Ucp1 mRNA expression. However, in the future, it would be helpful to gather
additional data related to the activity of the increased UCP1 protein, for example, by
measuring oxygen consumption rate and extracellular acidification rate using the
Seahorse Analyzers (Agilent). This will require technical troubleshooting, as our initial
attempts at using this technology were unsuccessful due to adipocyte detachment from
cell culture plates even with the use of gelatin-coating.
While there were no changes in gene expression of the thermogenesis
associated genes Cidea or Ppargc1a, white adipocytes cocultured with E0771 cells
expressed significantly more Tnfrsf9 (Figure 36B). White adipocytes exposed to
conditioned medium had increased, although not statistically significant, Tnfrsf9 (Figure
34B). Tnfrsf9 has been found to be elevated in breast cancer xenografts [117], but
within adipocytes, its expression changes often parallel Ucp1 and Ppargc1a [188],
which we did not observe in our results. TNFRSF9 (also known as CD137) promotes
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the activation of a variety of immune cells [189], and can enhance natural killer cellmediated destruction of breast cancer cells [190]. It is therefore possible that cross-talk
between white adipocytes and the E0771 cell line induces an immuneeliciting/enhancing response by the adipocytes.
Lep and Fasn mRNA levels were significantly decreased in both treatment
conditions compared to control differentiated white adipocytes, with no change in Cfd
expression (Figure 34C and Figure 36C). In WAT, leptin expression is associated with
lipid droplet size, so it was initially surprising that its expression is decreased in our
experimental system with plentiful nutrients in the cell culture medium, but also seemed
logical as this suggests lipolysis within the cells. Additionally, leptin is overexpressed in
breast tumors [191] and contributes to tumorigenesis by playing a role in mesenchymalepithelial transition and in regulating angiogenesis [192]. Additionally, leptin has been
shown to induce Notch signaling leading to increased breast cancer aggressiveness
[169]. Therefore, we speculate that the observed decrease in Lep expression by mature
white adipocytes represents a protective response after exposure to E0771 conditioned
medium or coculture. Multiple studies have shown that overexpression of fatty acid
synthase, a key enzyme for de novo fatty acid synthesis, in breast cancer cells confers
a more aggressive phenotype and allows for tumor growth and migration [193], so its
decreased expression in adipocytes after treatment is consistent with a protective
response. Additionally, transcription of Fasn is regulated, at least in part, by leptin [194],
whose mRNA expression we show here as also being downregulated.
We also tested for genes associated with lipolysis, and found that white
adipocytes exposed to E0771 cancer conditioned medium had no changes in
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expression of Lpl (lipoprotein lipase) or Mgll (monoglyceride lipase), but expressed less
Lipe (hormone sensitive lipase) compared to control white adipocytes (Figure 34D).
However, expression of Mgll was significantly increased in white adipocytes cocultured
with E0771 cells, while expression of Lipe and Lpl was decreased but not significantly
(Figure 36D). Increased monoglyceride lipase, an enzyme involved in lipolysis to
generate fatty acids, is implicated in progression of several cancer cell types, including
aggressive breast cancer [195]. Our results suggest that E0771-adipcyte cross talk, not
simply E0771 cell secretome components, may induce Mgll expression to provide
substrates for E0771 cancer cell utilization. Further experiments are needed to target
the cancer-adipocyte cross talk-related drivers of this process, and to determine if this
process results in paracrine or endocrine signaling contributing globally to CAC.
In our last set of murine cell culture experiments in this chapter, we established
primary SVF cell lines derived from BALB/c mice and used the 4T1 breast cancer cell
line to test the reproducibility of our C57BL/6J-E0771 results in a different mouse strain.
The 4T1 breast cancer cell line is an animal model for stage IV breast cancer, has a
more metastatic phenotype than classic E0771 cells [196], and is commonly used for in
vitro and in vivo BALB/c breast cancer studies [197] and allograft studies [198, 199].
4T1 conditioned medium exposure or coculture with BALB/c-derived mature
adipocytes demonstrated very similar results to our E0771 experiments. Ucp1 mRNA
expression in white adipocytes exposed to 4T1 cancer conditioned medium or 4T1
coculture was decreased relative to control white adipocytes, although not statistically
significant (Figure 37A and Figure 39A, respectively). Western blotting of UCP1 in
these experiments confirmed, again, our Ucp1 mRNA expression results on the protein
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level (Figure 38). There were no statistically significant changes in thermogenic
adipocyte-related gene expression, although there was a trend towards increased
Tnfrsf9. As described above, it is still possible that an immune-eliciting/enhancing
response by the adipocytes occurs in the presence of breast cancer. The only white
adipocyte gene marker that was changed in these 4T1 experiments was a decrease in
Lep expression after exposure to 4T1 cancer conditioned medium (Figure 37C). This is
slightly different from the E0771 results, which demonstrated a decrease in Lep and
Fasn in both treatment groups, but still suggests that an increase Lep expression by
mature white adipocytes represents a protective response in the presence of breast
cancer. No changes in any of the lipolysis-related genes occurs in the 4T1 experiments,
which suggests that differences between the E0771 and 4T1 cancer cell lines and/or
C57BL/6- and BALB/c-derived adipocytes may influence this aspect of adipocyte
plasticity.
We then utilized human cell culture methods to test whether breast cancer
directly induces WAT browning in vitro. First, we established the necessary cell culture
conditions to induce white and beige differentiation from female human benign breast
SVF cells, and found that human SVF cells need a low serum supplementation in order
to maximize health and differentiation capacity (Figure 40). The medium
supplementation has 2% FBS as opposed to 10% in the medium for murine cell culture,
and includes additional supplementation of L-glutamine, ascorbic acid, recombinant
human insulin, recombinant human FGF basic (fibroblast growth factor basic, also
known as FGF2), and hydrocortisone hemisuccinate. Many cells are cultured in low or
serum-free medium either at baseline or for particular experimental designs [200], and
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decreased serum here may be helpful here by increasing sensitivity of differentiating
cells to induction and/or maintenance medium. While L-glutamine and ascorbic acid are
both included in the DMEM medium used in our lab for most cell culture, they are
supplemented at much higher concentrations here, with approximately 3 times more Lglutamine and 8 times more ascorbic acid. Ascorbic acid is a water soluble molecule,
and additional amounts may be helpful as it acts as an antioxidant, electron donor for
several enzymes, and helps to protect against peroxidation of unsaturated fatty acids
[201]. Insulin is included in all induction and maintenance mediums, but is not in predifferentiation medium for mice; we suspect human SVF may require the additional
signaling that insulin provides to stimulate healthy cell proliferation before differentiation.
Hydrocortisone hemisuccinate is a water-soluble immunosuppressant, and we suspect
that it aids in human cell culture by dampening any autocrine or paracrine signaling that
may strain the cell before or during differentiation. Lastly, FGF2 activates tyrosine
kinase activity in vivo [202], and in murine adipogenesis studies using 3T3-L1 cells, the
nonreceptor tyrosine kinase c-Abl (Abelson murine leukemia viral oncogene) is critical
for initiation of differentiation [203]; we therefore expect that the addition of FGF2 aids in
priming our SVF for differentiation and in promoting differentiation once it begins. Once
optimized, our conditions yielded differentiation to mature white and beige adipocytes
with appropriate differences in lipid accumulation and UCP1 expression (Figure 41). We
then used this model to test the effects of two human breast cancer cell lines with
different receptor expression and aggressiveness on white adipocyte plasticity: MCF-7
(estrogen receptor positive) and MDA-MB-231 (triple negative, more aggressive
phenotype) [196].
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Using SVF derived from benign white breast adipose tissue from a 27 year old
woman with a history of diabetes mellitus, we show, similar to that in mice (Figure 28),
that most significant changes occur when differentiating cells are exposed to cancer
conditioned medium during periods of maintenance or throughout induction and
maintenance phases (Figure 42). UCP1 mRNA was significantly increased in maturing
adipocytes exposed to conditioned medium from MDA-MB-231 cells. In these
adipocytes treated with MDA-MB-231 conditioned medium, SLC27A1 was significantly
increased, while PPARG and PPARGC1A were significantly decreased. While not
significant, maturing adipocytes exposed to MDA-MB-231 conditioned medium
expressed about 4-fold less EAR2, and 2-fold less OPLAH and PDK4 (Figure 42).
Interestingly, these changes were not observed in maturing adipocytes exposed to
conditioned medium from MCF-7 cells; instead, these adipocytes expressed similar or
less mRNA (though not significant) for all of these genes compared to controls.
SLC27A1 encodes SLC27A1, more commonly known as fatty acid transport
protein 1 (FATP1), helps to control fatty acid uptake into cells [204]. Its expression has
been shown to be inversely related to BMI and adipocyte size, and increases as human
subjects lose weight [205]. Although its closely related family member SLC27A4
(FATP4) has just recently been shown to be increased in human breast cancer tissues
and increases free fatty acid uptake in the MDA-MB-231 cell line, in the same study,
higher SLC27A1 expression was correlated with increased survival [206]. Therefore, its
increased expression by mature adipocytes that were exposed to MDA-MB-231 cells
likely manifests as a protective response by the adipocytes, perhaps to change
substrate utilization to the demise of the tumor cells.
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PPARG in mice has been shown to be necessary for brown adipose tissue
function and intact beta-3 adrenergic signaling [207], as it is a transcriptional regulator
on the UCP1 promoter region. In breast cancer cells, PPARG is overexpressed and can
induce cell differentiation, although it is contested whether this exerts a positive or
negative effect on cancer progression [208]. A 2005 study found a correlation between
PPARG expression and estrogen receptor beta expression and that it is a favorable
prognostic factor for disease free survival [209]. Our results demonstrate significantly
decreased PPARG expression in the adipocytes treated with MDA-MB-231, while we
observed a mild decrease – though not significant – in expression after treatment with
MCF-7 conditioned medium. Since the MCF-7 cell line is estrogen receptor positive, and
MDA-MB-231 is not, this could perhaps explain the difference in the degree of
decreased PPARG expression. Breast cancer secreted microRNAs, such as miR-155,
downregulate PPARG expression and lead to metabolism reprogramming in mature
adipocytes contributing to cancer associated cachexia [210]. While we did not test for
the presence of specific factors such as miR-155, it is possible that they are
differentially expressed in different breast cancer cell lines and may contribute to the
observed decrease in PPARG expression.
Although UCP1 was significantly increased in the MDA-MB-231 conditioned
medium treatment group, PPARGC1A was significantly decreased. This was initially
surprising, as PPARGC1A substantially increases PPARG activity on the UCP1
promoter and is known to be involved in WAT browning in non-cancer-related studies
[211, 212]; however, it is not essential. The decreased PPARGC1A may therefore be a
response to the increased UCP1 expression, providing negative feedback to quench the
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maladaptive increase in UCP1. Other genes that are associated with classical brown
adipose tissue such as OPLAH [117] and WAT browning such as PDK4 and EAR2
[213, 214] were decreased, though not significantly, after exposure to MDA-MB-231
cells during differentiation. This further suggests that although UCP1 is increased in
these cells, other cell signaling processes are acting to downregulate that effect to
return to ‘homeostasis.’
When comparing lipid droplet sizes in these adipocytes, our results demonstrate
that cancer conditioned medium from either human breast cancer cell line results in
significantly decreased lipid droplet size in mature adipocytes, regardless of when the
exposure occurred during differentiation. Interestingly, when exposure occurred during
maintenance or during induction and maintenance, cells exposed to cancer conditioned
medium from MDA-MB-231 cells had a more significant decrease in lipid droplet size
than the MCF-7 conditioned medium-treated group. These results further support our
mRNA expression data, which suggest a differential response in adipocyte
differentiation to MDA-MB-231 versus MCF-7 secretomes. This further supports the
mRNA expression data for genes such as SLC27A1, which was significantly increased
and is known to increase with decreasing adipocyte size [205]. While we had different
thermogenic adipose tissue-related gene expression changes, the decreased lipid
droplet sizes in both exposure groups correlate with the ‘cancer associated adipocyte’
phenotype that has been recently described in breast cancer [116]. An increased
amount of lipid droplets has been shown to be associated with increased
aggressiveness of cancer using MCF-7 and MDA-MB-231 cells [215], but it is unclear
whether the lipid accumulation is a result of cancer-specific process or of local WAT
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changes and process. It would be interesting to test for genes related to lipid
metabolism and lipolysis to better understand the functional meaning of the changes
that we and other have noted in both adipocyte and breast cancer cells. Additionally,
cancer-associated adipose tissue has been shown to produce a protein secretome with
inflammatory characteristics [216], which we did not explore in our studies. It would be
interesting to test for these changes as well to better understand the complicated role of
inflammation and how it relates to breast cancer tumorigenesis and adipocyte-specific
changes in breast cancer.
Lastly, we tested the effects of these two human breast cancer cell lines’
conditioned mediums on mature white adipocytes in an SVF cell line derived from a
different human patient (this time, a 51 year old woman with no history of diabetes
mellitus) during differentiation and after maturation for 24 hours. Interestingly, our
results suggest that 24 hours of MCF-7 conditioned medium exposure is able to
increase UCP1 mRNA expression by about 4-fold, while MDA-MB-231 conditioned
medium decreased UCP1 mRNA expression by more than 8-fold (Figure 44C). When
replicating the conditions using the first SVF cell line, exposure of this different SVF cell
line to conditioned medium during induction and maintenance phases of differentiation
resulted in significant decreases in UCP1 mRNA expression compared to control
(Figure 44B). These results are in contrast to the results using the first SVF cell line,
which suggested that MDA-MB-231 conditioned medium caused an increase in UCP1
expression (Figure 42).
These conflicting results make it challenging to establish conclusive conclusions
regarding the direct effects of MCF-7 and MDA-MB-231 secreted factors on white
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adipocyte plasticity. It is entirely possible that the difference between UCP1 expression
in the first SVF cell line (Figure 42) and the second (Figure 44) are due to differences in
the women in which these cells were isolated from. It is well established that phenotypic
properties of tissue donors are at least partially retained when their cells are cultured in
vitro [217]. Therefore, the age difference (27 versus 51 years of age, respectively),
difference in diabetes status (positive versus negative, respectively), or difference in
other factors unknown to us such as body weight, between the two women whose
normal breast WAT was used for SVF isolation may be responsible for the differences
we have observed in our experiments. This suggests that individual characteristics may
render their differentiating and mature white adipocytes more or less resilient to cancermediated adipocyte changes. Additional experiments using a larger sample of humanderived SVF cells lines would be needed for further exploration.
Furthermore, there is clearly a differential response within an individual SVF cell
strain to different breast cancer cell lines. There are a host of differences including and
beyond those in the estrogen, progesterone, and HER2 receptor statuses between the
MCF-7 and MDA-MB-231 cell lines. Differences in angiogenic factors in the secretomes
of MCF-7 and MDA-MB-231 cells were found in a 2016 xenograft study [218]. Estrogen
increases oxidative stress in ER-positive cell lines such as MCF-7 cells to a significantly
greater extent than ER-negative lines such as MDA-MB-231 [219], and increased
oxidative stress and inflammation may be involved in adipocyte changes in breast
cancer. For example, insulin-like growth factor I receptor is increased in estrogenreceptor-positive breast cancers such as MCF-7, resulting in PI-3K/Akt pathway
activation that is not found in non-estrogen-receptor-positive breast cancers such as
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MDA-MB-231 [220]. PPARalpha activation is higher in MDA-MB-231 cells than in MCF7 cells with implications related to increased proliferation and tumorigenesis [221]. Other
cell lines, including these, with different characteristics should be used to provide
additional understanding and mechanisms for these differences.
In both these murine and human in vitro experiments, we must consider
additional limitations to the experimental design and the impact of these on our results.
The in vivo environment contains additional cell types not included in these more
simplistic in vitro models. Additionally, the two-dimensional nature of our cell culture
models is inherently different than the three-dimensional in vivo environment, which
limits our ability to fully replicate the interactions and processes occurring in vivo. For
example, our in vitro model does not include hypoxic conditions that are known to be
present in tumors in vivo [134], angiogenesis which can regulate thermogenesis in vivo
[222], nor elevated glycolysis which has been shown to occur in cancer and contribute
to cancer-associated cachexia [223, 224]. Future experiments should consider threedimensional cell culture systems (reviewed by [225]) with multiple cell types to allow for
more robust conclusions.

4.4 Conclusion
Together, our results show that cancer conditioned medium and coculture modify
the overall adipocyte gene expression pattern, but do not alter thermogenic gene
expression in murine in vitro studies. This supports prior literature regarding nonthermogenic changes in cancer, and challenges those related to cancer-induced WAT
browning; however, since the in vivo environment is multifaceted, the complexities of
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the cells and signaling within the tumor microenvironment should be explored further
before completely ruling out WAT browning effects from the E0771 or 4T1 breast cancer
cell lines. In our human in vitro studies, our results using MCF-7 and MDA-MB-231
breast cancer cell lines are more ambiguous, highlighting the importance of individual
variability and susceptibility to breast cancer-mediated changes. Our results, especially
in our murine experiments, suggest that the local WAT browning observed in the
previous chapter are not mediated by factors directly secreted by, or released as a
result of cross talk with, the E0771, 4T1, or LLC cancer cell lines. This suggests that
local WAT browning is the result of interactions with other cells and factors within the
tumor microenvironment. We explore this in the subsequent chapter.
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Chapter 5: The Role of Tumor Microenvironment in Cancer-Mediated White Adipose
Tissue Browning and Plasticity
5.1 Rationale
In the previous chapters, we demonstrate that WAT browning occurs locally in
vivo (Chapter 3), but that cancer conditioned medium and coculture do not alter
thermogenic gene expression in murine in vitro studies (although they do modify the
overall adipocyte gene expression pattern, Chapter 4). These results suggest that the
tumor microenvironment is involved in this process, and we ask here whether several
components – interleukin 6, tumor lysate, and a host of immune cell populations – are
involved in WAT browning and adipocyte plasticity.

5.2 Results
5.2.1 IL6 is minimally secreted by selected murine cancer cell lines, and exposure of
differentiated white adipocytes to exogenous IL6 does not increase Ucp1 gene
expression
Considering that tumor-derived IL6 has been implicated in other models of
cancer-related WAT browning, we asked whether our ER+ murine breast cancer E0771
cell line secreted IL6 into the conditioned medium. Our results demonstrate that the
E0771 cells produce IL6, but at much lower levels than peritoneal cavity inflammatory
cells as measured by intracellular flow cytometry (Figure 45A,B) and qPCR (Figure
45C). We also demonstrate similar expression patterns in other cancer cell lines: 4T1
breast cancer cells and LLC cells, with LLC cells expressing significantly less Il6 mRNA
than stimulated murine peritoneal cavity cells (Figure 46).
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As IL6 may come from a variety of cell types within the tumor microenvironment
in vivo, we next sought to determine whether our mature adipocytes in vitro have the
necessary receptor machinery – interleukin 6 signal transducer (IL6ST, also referred to
as glycoprotein 130, or GP130) and membrane-bound interleukin 6 receptor alpha
(IL6RA) – for IL6 signaling to occur. Flow cytometry demonstrates that differentiated
white and beige adipocytes express abundant IL6ST (aka GP130, or CD130), as
evidenced by increased staining relative to isotype control (Figure 47A). Gene
expression analysis for Il6st supports the flow cytometry data: white and beige
adipocytes express at least the same amount of Il6st (encodes GP130) mRNA
compared to stimulated peritoneal cavity cells (Figure 47B). Interestingly, white and
beige adipocytes do not express IL6RA (CD126) on their cell membranes, evidenced by
less flow cytometry staining than isotype control (Figure 47C). Il6ra mRNA expression is
also decreased in white and beige adipocytes relative to stimulated peritoneal cavity
cells (Figure 47D).
With the above information, we investigated if exogenous IL6 exposure, with or
without supplementation with soluble IL6RA, would induce gene expression changes
indicative of WAT browning in vitro. Increased Socs3 (suppressor of cytokine signaling
3) gene expression (Figure 48A) and increased phosphorylated STAT3 protein at the
tyrosine 705 residue (Figure 48B) following 30 minutes of exposure to IL6 and
IL6+IL6RA demonstrate the bioactivity of IL6 and IL6RA in our experimental model. To
our surprise, exposure of white adipocytes to IL6 or IL6+IL6RA for three days did not
increase Ucp1 mRNA expression but instead resulted in a downward trend in
expression (Figure 49A). A similar trend in Cidea expression was observed (Figure
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49B). The IL6+IL6RA treated group expressed significantly more Tnfrsf9 mRNA
compared to control white adipocytes but had no changes in Ppargc1a expression
(Figure 49B). Lep mRNA expression was significantly decreased with IL6+IL6RA
treatment, but no changes were observed for Cfd or Fasn (Figure 49C). No change in
any of the measured lipolysis markers was observed in the white adipocytes treated
with IL6+IL6RA (Figure 49D).
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Figure 45. E0771 cells do not produce excessive IL6
Peritoneal cavity cells and E0771 cells were stimulated to induce endogenous IL6 production as
described in methods. (A) Intracellular flow cytometry curves showing staining data for IL6 stain and
isotype control. (B) Quantification of intracellular IL6 from flow cytometry MFIs. (C) Quantitative PCR for
Il6 mRNA expression. Please note y-axis scale in (B) and (C) is log2. n = 2 for peritoneal cavity cells; n =
3 for E0771 cells. Statistical tests: (B) Unpaired t-test, (C) Mann-Whitney test. MFI = Mean Fluorescent
Intensity.
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Figure 46. E0771, 4T1, and LLC cells do not produce excessive IL6
Peritoneal cavity cells, immortalized SVF preadipocytes (‘mIWPA’ in image), and different cancer cells
(E0771, 4T1, and LLC) were stimulated to induce endogenous IL6 production as described in methods.
(A) Quantification of intracellular IL6 from flow cytometry MFIs. (B) Quantitative PCR for Il6 mRNA
expression. Please note y-axis scale in (B) is log2. n = 2 for peritoneal cavity cells; n = 3 for all other cells.
Statistical tests: Kruskal-Wallis (nonparametric ANOVA) test with Dunn’s test for multiple comparisons.
MFI = Mean Fluorescent Intensity.
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Figure 47. Differentiated white and beige adipocytes express abundant IL6ST, but not IL6RA
Flow cytometry for (A) cell-surface IL6ST (GP130, CD130) or (C) IL6RA (CD126) in white and beige
adipocytes. Dashed line represents average MFI staining for each respective isotype control. Quantitative
PCR for (B) Il6st (Gp130) or (D) Il6ra (Cd126) for peritoneal cavity cells and white and beige adipocytes. n
= 2 for peritoneal cavity cells; n = 5 SVF cell lines for white and beige adipocytes. Please note y-axis
scale in (B) and (D) is log2. Statistical tests: (A) and (C) Mann-Whitney test, (B) and (D) Kruskal-Wallis
and Dunn’s multiple comparisons tests. MFI = Mean Fluorescent Intensity.
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Figure 48. Both IL6 and IL6+IL6RA treatment induces STAT3 signaling in mature white adipocytes,
with IL6+IL6RA treatment inducing most robust signaling.
Differentiated white adipocytes were treated for 30 minutes with CL316,243 (noted as ‘CL’ in images), IL6
40 ng/mL + IL6RA 200 ng/mL (noted ‘IL6+IL6RA’ in images), and controls as described in methods. (A)
Quantitative PCR for Socs3. Please note y-axis scale is log2. n = 3 primary SVF cell lines. Error bars =
standard deviation. Statistical tests: Friedman and Dunn’s multiple comparisons tests. (B) Western blot of
phosphorylated STAT3 (‘p-STAT3’ with different residues indicated in image), total STAT3, UCP1, and
TBP protein.
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Figure 49. Neither exogenous IL6 or IL6+IL6RA administration causes WAT browning in vitro, but
alters white adipocyte mRNA expression
Differentiated white adipocytes were treated for 3 days with CL316,243 (noted as ‘CL’ in images), IL6 40
ng/mL (noted as ‘IL6’ in images), IL6 40 ng/mL + IL6RA 200 ng/mL (noted ‘IL6+IL6RA’ in images), and
controls as described in methods. Quantitative PCR for (A) Ucp1, (B) markers of beige adipocytes, (C)
markers of white adipocytes, (D) markers of lipolysis. Please note y-axis scale is log2. n = 3 primary SVF
cell lines. Error bars = standard deviation. Statistical tests: (A) Kruskal-Wallis and Dunn’s multiple
comparisons tests, (B), (C), and (D) Two-way ANOVA and Dunnett’s multiple comparisons tests.
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5.2.2 Preliminary data: potential role of tumor lysate and/or tumor-isolated CD11b+ cells
on WAT browning
After demonstrating that IL6 alters some adipocyte-related gene expression, but
does not directly mediate WAT browning, we asked if the immune system component of
the tumor microenvironment is involved in these processes. Using our primary inguinal
SVF adipogenesis cell culture system, we exposed mature white adipocytes from two
different SVF cell strains to a variety of conditions (refer to methods section 2.10)
including tumor lysate and CD11b+ cells from several allograft and spontaneous murine
breast tumors for 3 days. Mature beige adipocytes express appropriately more Ucp1
than white adipocytes (Figure 50A, C); however, results exposure to experimental
conditions are quite variable: some of the tumor lysate conditions altered Ucp1 mRNA
expression in white adipocytes positively or negatively, and to varying degrees,
depending on the SVF strain (Figure 50B, D).
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Figure 50. Tumor lysate and tumor-derived CD11b+ cells alter Ucp1 expression in white
adipocytes in vitro
Quantitative PCR for Ucp1 mRNA expression. (A) and (C) Primary SVF were differentiated to mature
white and beige adipocytes. (B) and (D) Mature white adipocytes were exposed to CL 316,243 (‘CL’ in
image), IL6, TNF, and various tumor lysates (‘MMTV early,’ ‘MMTV late,’ ‘PyMT Lys,’ and ‘E0771 Lys’ in
image) and CD11b cells (‘PyMT CD11b’ and ‘E0771 CD11b’ in image) for 3 days as described in
methods. Please note y-axis scales are log2. (A) and (C) n=6 wells; (B) and (D) n = 2-3 wells per group.
Statistical tests: (A) and (C) Mann-Whitney test; (B) and (D) Kruskal-Wallis (nonparametric ANOVA) test
with Dunn’s test for multiple comparisons.
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5.2.3 Preliminary data: immune cell populations shift in adipose tissue in mice with
breast cancer
We next wanted to explore which immune cell populations within the breast
tumor microenvironment may be most important. After injecting wild-type and Rag1
deficient (Rag1-/-) BALB/c mice with 4T1 breast cancer cells (refer to methods section
2.11), we found that there were no significant changes in body weight in the mice
between inoculation with cancer cells or saline control and euthanization (Figure 51A),
nor were there any significant changes in rectal temperature at time of euthanization
(Figure 51B). We harvested inguinal WAT (where the tumor cells were injected) from
these mice to look at differences in gene expression of several key adipocyte markers
between naïve mice and mice with tumor.
Compared to wild-type naïve mice, inguinal WAT from wild-type mice with 4T1
tumors expressed increased, though not significantly, Ucp1, Cidea, Prdm16, and
Ppargc1a mRNA (Figure 51C, gray bars). In the Rag1-deficient mouse strain,
compared to the Rag1-/- naïve mice, inguinal WAT from Rag1-/- mice with 4T1 tumors
did not have changes in Ucp1 expression, but had increased Cidea and Ptk2b
expression and decreased Ppargc1a expression – although again, none of these
changes were statistically significant (Figure 51C, black bars).
We analyzed adipose tissue (inguinal WAT, axillary WAT, gonadal WAT, and
interscapular BAT) and the tumors themselves via flow cytometry to quantify immune
cell populations. There were no trends or changes in percentage of CD45+ cells
between naïve or mice with tumor in either mouse strain (Figure 52A). Neutrophils
comprised a larger percentage of all live cells in all adipose tissue pads in both mouse
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strains with tumor (Figure 52B), and there was a less impressive increase in dendritic
cell population in the right inguinal, axillary, and gonadal fat pads in mice with tumor
(Figure 52C). Conversely, in most adipose tissue pads, T cell and B cell populations
were larger in naïve (non tumor-burdened) mice (Figure 52D, E). There was a trend
toward an increased pan-macrophage population in many of the WAT pads of mice with
tumor, especially in the right inguinal WAT where 4T1 cells were injected (Figure 53A).
Looking at the subpopulations of macrophages, there appears to be an increase in
major histocompatibility complex class II (MHCII)-/lymphocyte antigen 6 complex
(Ly6C)- and MHCII-/Ly6C+ macrophages, a decrease in MHCII+/Lys6C- macrophages,
and no clear change in MHCII+/Ly6C+ macrophages (Figure 53B-E).
When we analyzed the percentages of immune cell population of all living and
CD45+ cells, the trends just described above are even more apparent: mice with 4T1
cancer cells, regardless of wild-type or Rag1-/- strain, have a larger percentage of
neutrophils and dendritic cells (Figure 54A-B), a smaller percentage of T cells and B
cells (Figure 54C-D), and similar or increased percentage of pan-macrophages (Figure
54E) in all or many adipose tissue pads. The increase in pan-macrophages is, again,
most striking in the right inguinal WAT (Figure 54E, Figure 55A show same information).
Of the live, CD45+, pan-macrophage cell population, we continue to see an increase in
MHCII-/Ly6C- and MHCII-/Ly6C+ macrophages, a decrease in MHCII+/Lys6Cmacrophages, and no clear change in MHCII+/Ly6C+ macrophages in both wild-type
and Rag1-/- mice with 4T1 breast cancer cells (Figure 55B-E).
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Figure 51. Weight, temperature, and Ucp1 mRNA expression data from 4T1 allograft studies in
wild-type and Rag1-/- mice
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or
injected with control PBS and euthanized after tumor growth as described in methods. (A) Change in
weight between inoculation and euthanization, (B) rectal temperature of mice at time of euthanization, (C)
Quantitative PCR for several genes in right inguinal WAT (where injections occurred). For (C), fold
changes were calculated with respect to each genotype’s naïve expression levels, and please note y-axis
scale is log2. For all groups, n=2-5. Statistical tests: (A) and (B) Kruskal-Wallis (nonparametric ANOVA)
test with Dunn’s test for multiple comparisons; (C) two-way ANOVA with Tukey's multiple comparisons
test
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Figure 52. Various immune cell population percentages of live cells from 4T1 allograft studies in
wild-type and Rag1-/- mice
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry
results for (A) CD45+ cells, (B) Neutrophils, (C) Dendritic cells, (D) T cells, (E) B cells. For all groups,
n=4-5 mice.
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Figure 53. Macrophage population percentages of live cells from 4T1 allograft studies in wild-type
and Rag1-/- mice
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry
results for (A) Pan-macrophages, (B) MHCII-/Ly6C-, (C) MHCII-/Ly6C+, (D) MHCII+/Ly6C-, (E)
MHCII+/Ly6C+. For all groups, n=4-5 mice.
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Figure 54. Various immune cell population percentages of CD45+ live cells from 4T1 allograft
studies in wild-type and Rag1-/- mice
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry
results for (A) Neutrophils, (B) Dendritic cells, (C) T cells, (D) B cells, (E) Pan-macrophages. For all
groups, n=4-5 mice.
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Figure 55. Macrophage population percentages of CD45+ live cells from 4T1 allograft studies in
wild-type and Rag1-/- mice
Wild-type (‘WT’ in image) and Rag1-/- mice of both male and female sex were inoculated with 4T1 cells or
injected with control PBS and euthanized after tumor growth as described in methods. Flow cytometry
results for (A) Pan-macrophages, (B) MHCII-/Ly6C-, (C) MHCII-/Ly6C+, (D) MHCII+/Ly6C-, (E)
MHCII+/Ly6C+. For all groups, n=4-5 mice.
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5.3 Discussion
Since our results from Chapter 4 demonstrate that cancer cells induce changes
to white adipocytes but do not cause WAT browning, we wanted to explore other
possible mediators of these WAT browning changes demonstrated in Chapter 3.
In their studies of a murine model of cachectic colon cancer, Petruzzelli and colleagues
concluded that tumor-secreted IL6 is a direct driver of WAT browning [112]. We first
investigated whether E0771, 4T1, and LLC cells secrete IL6 into the conditioned
medium. All cells were treated with PMA and ionomycin, which overstimulate cytokine
production, as well as brefeldin A and monensin, which act to inhibit intracellular protein
and trap proteins in the endoplasmic reticulum. This method allowed us to make
comparisons in maximum IL6 production of each cell type.
Compared with stimulated murine peritoneal cavity cells which contain
inflammatory cells, E0771 cells produce significantly less IL6 when measured by
intracellular flow cytometry (Figure 45A-B) and express over 100-fold less Il6 mRNA
(Figure 45C). When we tested IL6 expression in other cancer cell lines, we found that
4T1 and LLC cells both secrete more IL6 than E0771 cells, although still less than
stimulated murine peritoneal cavity cells (Figure 46A), while mRNA expression of Il6
was significantly decreased in LLC cells (Figure 46B). The expression and secretion of
IL6 directly by breast cancer cells is variable, depending heavily on breast cancer cell
type [226, 227]. Moreover, it is well established that IL6 is physiologically produced by
non-adipocyte cells within adipose tissues [228], and can be modulated by breast
adipose tissue in models of breast cancer [229]. Based on this information, and since
tumor-derived IL6 has been directly implicated in other models of cancer-related WAT
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browning [112], we asked whether it possesses the ability of generating white to brown
transdifferentiation in our primary adipocyte cell culture system, regardless of its cell
origin.
Since IL6 may come from a variety of cell types within the tumor
microenvironment in vivo, we investigated whether our mature adipocytes in vitro have
the necessary receptor machinery to ensure IL6-mediated signal transduction could
occur. IL6 binds to either membrane-bound or soluble interleukin 6 receptor alpha
(IL6RA, also referred to as CD126), and this IL6:IL6RA complex then associates with
membrane-bound interleukin 6 signal transducer IL6ST (IL6ST, also referred to as
GP130 or CD130) to induce signal transduction via the JAK/STAT3 pathway [230].
IL6ST expression is virtually ubiquitous, while expression of membrane-bound IL6RA is
more cell-specific [231]. We confirmed that IL6ST is expressed in our mature,
differentiated adipocytes, both on the membrane surface as measured by flow
cytometry and by transcript levels with qPCR (Figure 47A-B). Interestingly, flow
cytometry data for IL6RA was less than the isotype control, suggesting lack of, or
minimal, receptor expression (Figure 47C). Our expression levels of IL6ra mRNA are
consistent with this finding; while mRNA was detectable, it was 64- to 128-fold lower
than stimulated peritoneal cavity cells (Figure 47D). Since soluble IL6RA is produced by
breast cancer cells [232] and by monocytes and macrophages [231], these results
prompted the inclusion of soluble IL6RA in our IL6 exposure experiments to mimic the
tumor microenvironment and to ensure that signal transduction could occur.
With this information, we investigated whether exogenous IL6 exposure, with or
without supplemented soluble IL6RA, would induce gene expression changes indicative
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of WAT browning in vitro. We observed an increase in Socs3 (suppressor of cytokine
signaling 3) gene expression (Figure 48A) and STAT3 protein phosphorylation at the
tyrosine 705 residue (Figure 48B) following just 30 minutes of exposure to both IL6 and
IL6+IL6RA, not surprisingly more robust in the IL6+IL6RA group.
The suppressors of cytokine signaling (SOCS) family are molecules that inhibit
JAK and STAT activation, regulated by its own signaling pathway: when STAT3
signaling is increased, transcription of SOCS3 is induced to act as negative feedback on
the signaling pathway [145]. We demonstrate substantially increased Socs3 expression
in both IL6 and IL6+IL6RA treatment groups, which indicates that the JAK-STAT
pathways is activated by these two treatment groups. The addition of IL6RA to the IL6
treatment results in an even more robust increase in Socs3 expression – over 1024-fold
that of the white adipocyte control – which tells us that IL6RA supplementation is useful
to maximize this this signaling pathway in vitro. The phosphorylation of tyrosine 705 is
canonical, while phosphorylation of serine 727 is a noncanonical pathway implicated in
several physiologic states [233]. Tyr705 is associated with JAK signaling, while Ser727
is associated with MAPK signaling [234]. We are not surprised that the tyrosine 705
residue is phosphorylated, as JAK/STAT3 signaling is an established pathway in
adipocyte plasticity. The lack of significant increases in serine 727 residue
phosphorylation in the CL 316,243, IL6, or IL6+IL6RA treatment groups suggests
MAPK/STAT3 signaling is not putative for WAT browning. Taking our Socs3 mRNA
expression data and STAT3 phosphorylation data together, these results confirm the
bioactivity of IL6 and IL6RA via the JAK/STAT3 signaling pathway in our experimental
model.
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To our surprise, exposure of white adipocytes to IL6 or IL6+IL6RA for three days
did not increase Ucp1 or Cidea mRNA expression but instead resulted in a downward
trend in expression (Figure 49A-B), similar to our observations in cancer conditioned
medium (Figure 34A-B, Figure 37A-B) and coculture experiments (Figure 36A-B, Figure
39A-B). The IL6+IL6RA treated group expressed significantly more Tnfrsf9 mRNA
compared to control white adipocytes but had no significant changes in Cidea or
Ppargc1a expression (Figure 49B), similar to our coculture results. Together, these
results suggest that IL6-induced changes to adipocytes in vivo may be dependent on
soluble receptors from other cells and additional signaling within the tumor
microenvironment. Lep mRNA expression was significantly decreased with IL6+IL6RA
treatment, similar to our observations in cancer conditioned medium and coculture
experiments, but no changes were observed for Cfd or Fasn (Figure 49C). No change in
any of the measured lipolysis markers was observed in white adipocytes treated with
IL6+IL6RA (Figure 49D).
These results, especially the lack of increased Ucp1 expression, contrast the
findings of previous studies that implicate IL6 as a direct causative agent of WAT
browning [112]. We found this, especially the expression of IL6 by LLC cells, to be
interesting, as LLC cell-derived parathyroid hormone related peptide (PTHrp), but not
IL6, has been implicated as a direct mediator of WAT browning in cancer [113], yet we
demonstrate in Chapter 4 that our LLC-conditioned medium, which presumably contains
both PTHrP and, based on our results here, at least detectable amounts of IL6, does
not induce white to beige transdifferentiation. However, it is important to recognize the
differences in our current study and design limitations that may account for these
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discrepancies. IL6’s role in WAT browning was implicated in a model of colon cancer,
which is inherently different than breast cancer and the specific cancer cell line used in
our studies. Other molecules, such as PTHrp, have been implicated in different models
of CAC [113], so it is possible that other pathways may be driving the process of WAT
browning in breast cancer. Whether IL6 exerts its effects directly or indirectly is still
contested within the literature [235], so it is entirely possible that IL6’s role in WAT
browning in breast cancer may be indirect. It would be interesting to test whether
constitutively-active STAT3 would yield different results, as that could provide useful
information regarding the time-dependent nature of this signaling pathway. Additionally,
other cytokines related to IL6 signaling should be explored, such as oncostatin M which
interacts with gp130 [236], to better understand these signaling pathways in vivo.
To begin testing what processes may be involved in vivo, we exposed mature
white adipocytes from two SVF cell strains to different tumor lysates and tumor-isolated
CD11b+ cells. Tumor lysates inherently contain a variety of cells, including the tumor
cells themselves as well as stromal cells and immune cells. In breast cancer, tumor
lysate is being investigated as a vaccine because it contains multiple tumor-associated
antigens which can induce a variety of immune cell responses [237]. A host of immune
cell populations have been implicated in adipose tissue plasticity (reviewed by [238]).
CD11b is part of the complement receptor type 3 (CR3, or macrophage-1 antigen
MAC1) molecule expressed by monocytes/macrophages, granulocytes, and natural
killer cells [239], and is implicated in cancer [240-242]. It appears that tumor lysate may
increase Ucp1 mRNA expression regardless of whether it came from early or late stage
MMTV tumors, PyMT allograft tumors, or E0771 allograft tumors, although these results
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were extremely variable. Cd11b exposure may also induce Ucp1 expression, but the
range was not as large as that in the tumor lysate groups (Figure 50). Ucp1 mRNA
increased in beige vs white cultured adipocytes, although this varied from 32- to 64-fold
more between the two SVF (and was only significantly different in one of the two strains,
Figure 50A). Furthermore, the effect of CL 316,243 was extremely variable between
these two SVF strains – in the second strain, CL 316,243 exposure for 3 days resulted
in higher Ucp1 expression than beige control (Figure 50D). It is highly likely that this
variability accounted for, at least part, some of the differences we saw in our exposure
groups’ results.
To work towards identifying cell populations that are crucial for WAT browning in
breast cancer, we used two different BALB/c mouse strains, wild type and Rag1-/-, and
injected 4T1 breast cancer cells in the right inguinal WAT pad to induce allograft tumor
formation. When we isolated the WAT from the right inguinal fat pad where tumor cell
were injected and probed for Ucp1 mRNA expression, wild-type mice with 4T1 tumors
expressed roughly 2-fold more Ucp1 mRNA, 4-fold more Cidea mRNA, 3-fold more
Prdm16, and 2-fold more Ppargc1a (Figure 51C, gray bars) – all markers for
thermogenic adipose tissue activity – which suggests that WAT browning occurs in this
model. In Rag1-/- mice with 4T1 tumors, inguinal WAT did not have changes in Ucp1
expression compared to naïve controls, but had increased Cidea and Ptk2b (proteintyrosine kinase 2-beta) expression and decreased Ppargc1a expression (Figure 51C,
black bars).
V(D)J recombination-activating protein 1 (RAG1) is essential for variable (V),
diversity (D), and joining (J) recombination for immunoglobulins and T cell receptors
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(TCRs) in developing T and B cells [243], and deficiency of RAG1 in mice results in lack
of mature T and B cell populations [244]. Other immune cell populations such as
macrophages, dendritic cells, and natural killer cells remain intact and functional,
making this mouse model ideal for providing information on which cell types may or may
not be involved in WAT browning in breast cancer. While wild type mice with tumor have
increased expression of several thermogenic genes (Ucp1, Cidea, Ppargc1a, and
Prdm16), the Rag1-/- mice only had increased expression of Cidea. This suggests that B
and T cell involvement, either directly or indirectly, may be necessary for fully functional
transdifferentiation towards the thermogenic adipose tissue phenotype. Ptk2b was
increased in the inguinal WAT of Rag1-/- mice with tumor. PTK2B is a nonreceptor
protein kinase involved in responses to stimuli in several organ systems and a host of
metabolic processes, including cultured beige adipocyte differentiation in our lab’s
murine immortalized SVF cell culture model [183]. In whole-body mouse studies,
PTK2B (also known as PYK2) was shown to be important for glucose and weight
homeostasis, as whole-body knock-out resulted in exacerbated weight gain and glucose
intolerance on high fat diet [245]. In breast cancer (and others), most literature refers to
PYK2 as an oncogene expressed by breast cancer cells with a variety of essential
processes related to the development and progression of tumors (reviewed extensively
by [246]). While we did not measure protein levels of PTK2B or its phosphorylation, we
hypothesize that the increased Ptk2b expression by adipocytes is a maladaptive
response to the presence of tumor, which aids in the growth and progression of breast
cancer. For all of these results, it is important to note that the small scale of this
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preliminary experiment warrants experimental replication, with a larger sample size, to
determine whether any of these changes are significantly meaningful.
We next used flow cytometry to isolate and quantify the different immune cell
populations within the right inguinal WAT (where 4T1 tumors grew) as well as distal
WAT and BAT depots. Cells which are positive for CD45, also known as leukocyte
common antigen 45, are white blood cells, excluding red blood cells. Of live cells, there
did not appear to be any significant changes in the percentage of leukocytes (CD45+
cells) between naïve mice and mice with tumor. In the Rag1-/- mice, there appears to be
a slight increase in the percentage of CD45+ cells in mice with tumor in the inguinal and
axillary WAT, but with our small sample size and large variability, significance cannot be
determined. Similar trends are observed when we quantify each cell type as a
percentage of live cells (Figure 52 and Figure 53) or of CD45+ live cells (Figure 54 and
Figure 55), so for our discussion, we focus on the CD45+ live results as the results are
more physiologically relevant to our questions since CD45+ cells are white blood cells.
The percentage of neutrophils and dendritic cells increases in adipose tissue
pads of mice with tumor from both genotypes. Neutrophils can exhibit pro- or antiinflammatory characteristics in cancer in an environment-dependent manner (reviewed
by [247]). Furthermore, a 2017 study using human breast cancer samples found that
tumor-associated neutrophils are present in human breast cancer and are most
commonly present in triple negative subtypes [248]. Dendritic cells are known to be
present in the breast cancer microenvironment [249], although their function has been
shown to be dependent on local factors and may be subtype-specific [250]. Taken
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together, it is not surprising that there are more neutrophils and dendritic cells in
adipose tissues in our breast cancer allograft model.
There is, as inherently expected with the Rag1-/- mice, a decrease in the
percentage of T and B cells in naïve Rag1-/- mice compared to wild-type naïve mice.
Interestingly in both groups, the percentage of T and B cells in adipose tissue of mice
with tumor decreased in both mouse strains. This is opposite of what we observe in
neutrophil and dendritic cells. Most studies demonstrate an increase in T cell (especially
T regulatory cells) and B cell populations in breast cancer [251-254]. It is possible that
the decreased population levels that we see in the adipose tissue is the result of
migration into the tumors themselves, but this is speculative.
There were no noticeable changes in the percentage of macrophages in adipose
tissue pads between naïve wild type and naïve Rag1-/- mice, which again is expected
since Rag1-/- is related to only T and B cell maturation [244]. In several adipose tissue
depots in both genotypes, there are more macrophages (pan-macrophages) in the mice
with tumor compared to naïve controls. This trend is most notable in the right inguinal
WAT, which is where 4T1 cells were injected. This suggests that the local tumor
microenvironment elicits as more location-specific increase in macrophage infiltration,
which adds to prior literature demonstrating other immune cell infiltration in cancer [255,
256].
Macrophages are often necessary for various aspects of tumor progression
(recently reviewed by [257]) and are associated with poor prognosis in many cancers
[258]. In general, macrophages often begin as inflammatory and later transition to a
more anti-inflammatory role [259]. While the historical classification of macrophages as
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M1 “inflammatory” and M2 “anti-inflammatory” has recently been challenged [260], prior
studies demonstrate that macrophage phenotype can change in cancer. Considering
that macrophages can be activated into various phenotypes [260], we looked at different
sub-classes of macrophages based on MHCII and Ly6C expression in the adipose
tissue pads.
While there are inconsistent trends in the percentage of MHCII +/Ly6C+
macrophages, there is a decrease in the percentage of MHCII +Lys6C- macrophages,
especially in right inguinal WAT. The percentage of both Ly6C-positive and -negative
MHCII-negative macrophages was increased in the fat pads of mice with tumor. In a
mouse model of hepatocellular carcinoma, Wang and colleagues demonstrate temporal
changes in macrophage phenotype: macrophages expressing MHCII were found early
in tumorigenesis, while macrophages lacking MHCII increased in number with tumor
progression; furthermore, they demonstrated that the early, MHCII+ macrophages were
associated with tumor progression [261]. In mice, Ly6C expression is representative of
pro-inflammatory monocytes/macrophages (reviewed by [262]). Taken together with our
results, we found a general decrease in MHCII-positive cells and increase in MHCIInegative cells. The increase in MHCII-negative cells was most pronounced with the
Ly6C-negative subtype, as this cell population increased by about 10% in adipose
tissue in mice with tumor across both phenotypes (Figure 55). Our data therefore
suggest, like prior literature, a shift towards anti-inflammatory macrophages (M2, or M2like) in breast cancer.
Recently, alternatively activated macrophages have been implicated in WAT
browning in burns [263]. In a murine model of high fat diet-induced obesity, an
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increased M2-macrophage population resulting from of knock-down of receptor
interacting protein 140 (RIP140) was found to induce WAT browning and protect mice
from high fat diet-induced obesity and insulin resistance [264], and obesity-driven
inflammation, which is mostly pro-inflammatory, has been shown to inhibit beige
adipogenesis [265]. Although the mechanism remains controversial [266, 267],
alterations in macrophage phenotype are clearly involved in the WAT browning process.
Taken together with our results demonstrating an increase in anti-inflammatory
macrophages in adipose tissues of mice with cancer, we believe that WAT browning in
cancer is likely mediated by this cell population in vivo.
There are several shortcomings to these experiments that future work can
address. Experimental replication with a larger sample size powered to detect
significant changes will be necessary. While our results point towards macrophages as
a key driver of WAT browning in breast cancer, we cannot rule out other immune cell
populations, especially those we did not measure in these preliminary studies. Other
populations, such as eosinophils and T cells, have been shown to be involved in WAT
browning (reviewed by [238]), so additional work must be done to explore the role of
these cell types, both individually and in unison, in WAT browning. Additionally, these
mice were raised in the barrier facilities at VCU, which is a ‘cleaner’ vivarium
environment; it would be interesting to repeat these experiments in mice housed outside
of this barrier vivarium to provide a more realistic environment that humans experience
daily. Lastly, as the cell type(s) involved in this process are identified, individual
molecular drivers and their mechanisms must be elucidated for future translation to
alleviating WAT browning and CAC in patients.
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5.4 Conclusion
In these experiments, we investigated the role of several cancer cell lines, and
IL6, in an in vitro model of WAT browning. Our results demonstrate that E0771, 4T1,
and LLC cells secrete detectable IL6 in vitro, but not abundantly. We show that while
IL6 treatment induce changes to white adipocyte gene expression patterns, WAT
browning does not occur directly via IL6 signaling, pointing to other cell types and/or
interactions with cells within the tumor microenvironment as the potential driver of these
thermogenic changes. We show a potential change in Ucp1 expression after white
adipocyte exposure to breast tumor lysate and tumor-isolated CD11b+ cells, and then
moved in vivo to explore specific cell populations that may be driving WAT browning.
Our results support prior literature regarding immune cell population changes in cancer
and demonstrate an increase in anti-inflammatory macrophages in adipose tissue of
mice with tumor. Further investigations are needed to understand the mechanisms
behind these changes, the mechanisms by which these immune cell population induce
WAT browning in cancer, and to test the effects on whole body energy expenditure and
the development and progression of cancer-associated cachexia.
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Chapter 6: Human Subjects Research – Maladaptive Adipose Tissue Activity in Cancer

6.1 Rationale
In the last several chapters, we have demonstrated WAT browning and altered
adipocyte gene expression in breast cancer and mechanistically determined that
immune cell population changes may be the source of WAT browning in breast cancer
using murine and human in vitro and in vivo techniques. While the exact mechanisms of
WAT browning in breast cancer are not yet elucidated, we wanted to begin to explore
the translational potential of this work. A recent 2018 study demonstrated that BAT
activity is greater in patients with active cancer compared with BAT+ individuals without
active cancer [268]. In another study, researchers analyzed 1740 patients with PET/CT
scans and found that only 30 (1.72%) showed activated brown adipose tissue activity;
however, of those 30 BAT+ scans, 21 of them (70%) were in patients with cancer, while
the other 9 (30%) were in patients without malignancy. Using data collected regarding
the neoplastic status of each cancer patient (N0, N1, N2, N3) with multiple linear
regression analysis, the authors demonstrated a significant association between BAT
metabolic activity and neoplastic status, irrespective of age, BMI, or gender [107]. In
another study performed in France, researchers took 5 PET/CT images for each of 33
female patients with either stage II or IIIA breast cancer at baseline and then after 1 st,
2nd, 3rd, and 6th courses of chemotherapy. Patients with more BAT uptake had lower
BMI, which suggests a relationship between thermogenic adipose tissue and CAC
[269].
At the Virginia Commonwealth University Health System, we have access to a
large amount of patient clinical data, as well as several different techniques with which
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to measure energy expenditure in humans (Figure 2). We first ask if, via chart review,
we could identify patients with cancer within the VCUHS who have activated BAT on
PET/CT scans. Next, using whole room indirect calorimeters (which our lab has recently
established incredible temporal accuracy for use in metabolic studies [15]), we ask two
main questions: 1) if increased thermogenic adipose tissue activity in cancer is
associated with increased resting energy expenditure, and 2) if increased temperature
can ‘quench’ maladaptive thermogenic adipose tissue activity and decrease energy
expenditure. Please refer to methods section 2.18 and Appendices for all protocols and
pertinent information.

6.2 Results
6.2.1 Preliminary data: the VCUHS has an identifiable population of patients with cancer
who have BAT activity detectable on PET/CT
Within the queried 10 year timeframe in the Montage database and the search
parameters described in methods section 2.18.1, there were 210 results for patients at
least 40 years of age with BAT activity documented. However, there were several cases
of non-cancer-related indications for PET/CT, and several cases of multiple scans for
one patient. After these results were removed, we were left with 164 unique patients at
least 40 years of age with a history of cancer and at least one PET/CT with BAT activity
noted in the report.
Of these 164 unique patients, 122 were female (74.4%), and 42 (25.6%) were
male (Figure 56A). When stratified by age range (starting at age 40 based on inclusion
criteria), we found 44 (26.8%) patients were between 40 and 49 years of age, 61
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(37.2%) between 50-59, 40 (24.4%) between 60-69, 12 (7.3%) between 70-79, 6 (3.7%)
between 80-89, and 1 (0.6%) between 90-99 (Figure 56B).
We also wanted to identify trends in primary cancer diagnosis and presence of
BAT activity in this patient population. Of the 164 unique cases, we found that the
majority (41, or 25%) of patients had a primary diagnosis of lymphoma (Figure 57). The
second most common primary malignancy was breast cancer (34, or 20.7%), and the
third most common was lung cancer (25, or 15.2%). The rest of the patients had a
variety of different primary malignancies, and only 2 individuals had an unknown
primary cancer diagnosis based on preliminary chart review.
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Figure 56. Gender and age in patients with cancer and BAT activity on PET/CT scans
A chart review was performed using the VCUHS medical record and medical imaging systems as
described in methods. Percentage of patients with cancer and BAT activity on PET/CT scan by (A)
gender and (B) age ranges.
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Figure 57. Primary cancer type in patients with cancer and BAT activity on PET/CT scans
A chart review was performed using the VCUHS medical record and medical imaging systems as
described in methods. The y-axis includes all of the primary cancer types noted in patients with cancer
and BAT activity on PET/CT scan, and x-axis is the number of patients with that particular cancer type.
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6.2.2 Preliminary data: measurement of energy expenditure in human subjects with
cancer
We began recruitment of participants for our study using whole-room indirect
calorimetry as described in section 2.18.2. We just completed the first energy recording
session for our first subject: a 54-year-old male with head & neck cancer who had BAT
activity noted on the most recent PET/CT. The raw data are shown in Figure 58 and
described in more detail in the figure legend. After analysis of the raw data, this
subject’s average respiratory exchange ratio was 0.73, and average metabolic rate was
0.88kcal/min (approximately 1267kcal/day).
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Figure 58. Whole-room indirect calorimetry, raw data
Raw data from energy recording using whole room indirect calorimeters from 54 year old male with head
and neck cancer. (A) General information viewed during recording session to ensure calorimeters
maintain appropriate air flow. (B) black line = metabolic rate (MR) in kcal/min; red line = respiratory
exchange ratio (RER or RQ). (C) black line = volume of oxygen (VO2) and red line = volume of carbon
dioxide (VCO2). Large vertical lines indicate time in which subject entered and exited the calorimeters.
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6.3 Discussion
In the first part of this human subjects research, we used a retrospective
approach to search the VCUHS records for our target patient population. We searched
the past 10 years to gain a solid understanding of the prevalence of BAT activity at our
institution. Our preliminary results demonstrate that there is indeed a targetable patient
population at the VCUHS for studying the effects of thermogenic adipose tissue activity
in patients with cancer. We found that the majority of these patients (74.4%) with
cancer and BAT activity on PET/CT were female. This is not surprising, as several
studies have demonstrated that women tend to have greater BAT mass and activity
than men [38, 270, 271].
It is well established that thermogenic capacity decreases with age ([38], and
recently reviewed by [272]); therefore, we chose 40 years as our minimum age as we
believe it will optimize the number of patients with maladaptive thermogenic adipose
tissue activity. We would expect very few patients over the age of 40 to have activated
BAT activity on their PET/CT scans; however, we found 164 patients with what we
hypothesize as maladaptive BAT activity. We were surprised that the number of patients
in the 80-89 and 90-99 ages ranges with cancer and BAT activity were quite low,
because although life expectancy at a given age decreases with age, the risk of dying of
cancer has been shown to peak between ages 40-50 and decrease thereafter [273].
However, this could be due to a younger patient population seen at VCUHS versus
other institutions in the surrounding area. We expected the 40-49 age range to contain
the majority of BAT+ cases; however, we observed that most patients with cancer and
BAT activity on PET were between 50 and 59 years of age. This adds stronger support
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to our hypothesis that maladaptive activation of thermogenic adipose tissue occurs in
cancer.
Our results demonstrate that lymphoma is the most common primary malignancy
in this patient population. Of the 41 patients classified as having lymphoma as their
primary malignancy, 13 had Hodgkin’s lymphoma, 12 had non-Hodgkin’s lymphoma,
and 16 were not specified. Considering that interscapular BAT is in the same
anatomical region as many lymph node changes, we are not certain that all of these
patients have BAT activity versus cancerous FDG uptake. While CAC has been shown
to affect patients across all cancer types [128], it has been previously reported that
cancers such as gastric and esophageal have a higher prevalence of CAC compared to
breast cancer (although we argue that the clinical implications of CAC in breast cancer
are quite important, see Table 1). Interestingly, we found that the 2 nd most common
primary cancer in our patient population was breast cancer, with lung cancer being the
3rd most common. This suggests that maladaptive activation of thermogenic adipose
tissue can certainly occur in breast cancer, strengthening the rationale behind our use
of breast cancer as model for our in vitro molecular studies.
Several factors may have influenced our results. We must consider the potential
for variability in training that may skew the prevalence of BAT activity towards
lymphoma, breast, and lung cancers. As all three of these cancers are anatomically
closer to interscapular region than other cancers such as colon cancer, it is possible the
BAT activity may be under-represented in these results. Many factors may contribute to
site-specific variations in patient population characteristics; regardless, it is clear that
within the VCUHS, there are identifiable patients who have cancer with and without BAT
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activity that we can recruit for energy characterization studies. We will continue to
collect additional data on these patients as described in the methods, such as ethnicity,
BMI, weight, diabetes status, and thyroid function testing. In the 2009 study
demonstrating that approximately 25% of patients with breast cancer have cachexia, the
authors did not provide additional subanalyses on sex or ethnicity in each cancer type
[128]. While breast cancer is far more common in women than in men, it would be
interesting to know whether any of the breast cancer patients in this study were men,
and if so, if any of them had cachexia. Additionally, information regarding ethnicity
would be extremely helpful to provide information regarding potential racial differences
in breast cancer-related CAC. We hope that our data collection and analyses within our
patient population will provide useful information in these areas. We know that thyroid
function contributes to energy expenditure (reviewed in [274]), and BAT activity has
been found to be more prevalent in lean individuals regardless of age [270]. It will be
interesting to determine if this trend persists in this particular patient population as well.
The clinical implication of increased BAT activity relative to calorie utilization is
not yet conclusive – estimates during cold exposure range from 15-25 kcal/day [108] to
several hundred [275, 276]. While the prevalence of maladaptive thermogenic adipose
tissue activity has been explored in several small studies as described in this chapter’s
rationale, the clinical relevance and implications of this increased activity is not well
understood. We therefore developed a pilot study protocol using whole room indirectly
calorimetry to determine whether BAT activity increases REE in human subjects with
cancer at our institution. Our preliminary results from our first participant demonstrate
our capacity to measure resting energy expenditure in patients with cancer using the
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whole-room indirect calorimeters (Figure 58). Our first subject’s average resting
metabolic rate at 24ºC was approximately 1267kcal/day. While this appears low when
taken at face-value, it is crucial that this information be considered along with individual
body weight at the time of study. We will be sure to calculate metabolic rate (kcal/day)
per unit body weight (kg) for each subject to ensure appropriate comparisons in energy
expenditure between the BAT-positive and BAT-negative groups.
We expect that patients with cancer with BAT activity on the PET/CT scans will
have greater energy expenditure than those patients with cancer without BAT activity.
Additionally, when we compare intra-individual energy expenditure differences, we
expect that for patients with cancer who are BAT+, their resting energy expenditure will
be decreased after exposure to the warmer temperature condition (27ºC, or 80.6ºF)
compared to the ‘room temperature’ condition (24ºC or 75.2ºF). If the data support
these hypotheses, our results would suggest that maladaptive browning does occur,
and that warm temperature may have utility as a simple and safe therapeutic adjuvant.
Although we have recruited one participant, we are far from our goal of 36
patients. This highlights that clinical research and subject recruitment often takes longer
than expected. Regardless, as we continue to recruit more subjects, we expect our
results to provide a useful point-estimate difference in energy expenditure between
BAT+ and BAT- patients with cancer, which is currently lacking in the literature. We
have not analyzed the serum or urine samples obtained from this first patient, as we
plan to analyze all samples together to minimize possible sources of result variability.
However, we expect that our results, when combined with energy expenditure data, will
provide useful clinical data for patients with cancer with or at risk for developing CAC.
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Even once our recruitment is completed, it is important to note several limitations
to this pilot study as we interpret our results and as subsequent studies are considered.
First, we cannot say with certainty whether patients who had BAT activity on their
PET/CT scan used for inclusion criteria continue to have measurable BAT activity by the
time they are recruited into the study. BAT FDG uptake is not always consistent within a
series of scans of a given patient [269, 277]. Ideally, we would have patients undergo
repeat PET/CT before beginning any energy expenditure recordings. In this pilot study,
we were financially limited and needed to utilize PET/CT scans that were already
performed; however, in any larger studies that develop, funding should be requested to
obtain these repeat PET/CT scans to confirm whether participants do or do not have
activated BAT. Next, there is debate as to whether or not outdoor temperature and
other related factors impact BAT activity on PET/CT scans, and if confers any change to
energy expenditure; some studies demonstrate no significant relationship between BAT
FDG uptake and outdoor temperature [269] while others demonstrate an association
between photoperiod and seasonal variation with BAT activity [278]. We do our best to
ensure patients complete their visits within the same season to decrease variability
within a subject but individuals who enroll at different times of the year may have
different results due to seasonal variability. It is also important to note that our study
(and others) utilizing FDG uptake by BAT as a means to identify candidates inherently
under-represents our ideal patient population: PET/CT is believed to underestimate the
true prevalence of BAT activity (reviewed by [279]), and is not able to capture the more
diffuse activity of beige adipose tissue activity in large WAT depots. Several methods
are under development utilizing magnetic resonance or ultrasound (reviewed by [280]);
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however, until these are validated and implemented in a widespread and cost-efficient
manner, FDG PET/CT is still the ‘gold standard,’ even with its limitations.

6.4 Conclusion
In this Chapter, we utilized human subjects research to begin to understand the
clinical and translational implications of maladaptive thermogenic adipose tissue activity
in patients with cancer. Our results demonstrate that within the VCUHS, there exists a
patient population comprised of individuals with cancer, at least 40 years of age, with
brown adipose tissue activation. We argue that this BAT activity represents maladaptive
adipocyte plasticity. Furthermore, though still in the early stages of recruitment and data
collection, we demonstrate that our institution’s whole-room indirect calorimeters are
capable of measuring resting energy expenditure in patients with cancer. We expect to
generate useful data quantifying the difference in energy expenditure between patients
with cancer with and without BAT activity. Analysis of secondary endpoints will provide
useful clinical data aimed towards improving quality of life in patients with cancer,
especially those with or at risk for developing cancer-associated cachexia.
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Chapter 7: Human Subjects Research – Unusual Case of Autoimmune Diabetes
Mellitus in the Setting of Extra-Adrenal Paraganglioma with Loss of Succinate
Dehydrogenase Expression
Please note that the majority of the material within this Chapter comes from our recently
published manuscript, DOI 10.4158/ACCR-2018-0072. The final, definitive version of
this paper has been published in AACE Clinical Case Reports: November/December
2018, Vol. 4, No. 6. [281]

7.1 Rationale
Even if cancer is not directly adjacent to adipose tissue, cancer can influence
thermogenic adipose tissue activity as well as normal adipose tissue functions such as
glycemic control. Recently, a case of hypermetabolic BAT was found in a patient with
paraganglioma [282]. Paragangliomas are referred to as ‘extra-adrenal
pheochromocytomas,’ originating from chromaffin cells in the sympathetic and/or
parasympathetic ganglia [283]. Functional pheochromocytomas and paragangliomas
are often associated with impaired glycemic control and exacerbation of pre-existing
diabetes mellitus [284]. Here we present a unique case of autoimmune diabetes with
glycemic control that follows the course of diagnosis and management for a
norepinephrine-secreting paraganglioma.

7.2 Results (case report and bench laboratory findings)
A 55-year-old African American man with history of nephrolithiasis presented to
an outside institution with flank pain and hypertension. Computerized tomography (CT)
imaging with contrast revealed a heterogeneous retroperitoneal mass measuring 4.5 x
218

5.4 x 4.9 cm, located anterior to, and abutting, the inferior vena cava and abdominal
aorta (Figure 59A). Further evaluation was consistent with paraganglioma: his plasma
normetanephrines were 260 pg/mL (normal 0-145 pg/mL) and blood pressure was
160/90 mmHg (Figure 60). There is no known family history of paraganglioma, and only
his mother has hypertension. He was started on Prazosin for control of hypertension in
preparation for surgery.
Concurrently at the time of paraganglioma presentation and diagnosis, his blood
glucose levels were elevated and anti-glutamic acid decarboxylase-65 (anti-GAD65)
antibodies were 97.9 U/mL (normal 0-1.5 U/mL). He was therefore diagnosed with latent
autoimmune diabetes of adults (LADA) and started a basal-bolus insulin regimen of
Lispro 5U with meals and Detemir 25U at bedtime with prompt improvement in his
hyperglycemia. Three months after initial diagnosis, the patient underwent a successful
surgery, but review of the resected tumor by surgical pathology demonstrated the
presence of positive margins. Additionally, there was involvement of an adjacent lymph
node and foci of vascular space invasion. Immunostaining demonstrated loss of
succinate dehydrogenase subunit B (SDHB) expression in the paraganglioma cells
(Figure 61).
At post-surgery follow up, the patient reported normal blood pressure recordings
and denied symptoms of catecholamine excess. He had self-decreased his insulin
therapy because of reported improved glucose levels. Prandial insulin was
discontinued.
Six months after surgery, the patient continued to report stable blood pressure
without medication and no symptoms or signs of catecholamine excess. Point of care
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HbA1c was 5.5% (37 mmol/mol) (normal < 5.6% or < 38 mmol/mol), and home
measurements indicated post-prandial glucose levels ranging 120-140 mg/dL. Basal
insulin was discontinued at this visit. Blood tests revealed normal catecholamine levels,
but markedly elevated anti-GAD65 (above the assay’s detection limit of 5000 U/mL) and
anti-insulin antibodies of 137 µU/mL (normal 0 µU/mL) (Figure 60).
Eleven months after surgery, the patient was still normotensive and euglycemic
without medication, with a point of care HbA1c of 5.7% (39 mmol/mol). However, CT
imaging with contrast of the abdomen and pelvis showed a “small focus of ill-defined
soft tissues” near the bifurcation of the abdominal aorta, soft tissue thickening at site of
resected mass, and an enlarged left periaortic lymph node.
Eighteen months after surgery, the patient presented with unintentional weight
loss, increased home glucose readings, and hypertension. Normetanephrines were
significantly elevated at 841 pg/mL (normal 0-145 pg/mL), and HbA1c at 7.2% (55
mmol/mol). CT and subsequent 18F-FDG positron emission tomography (PET)/CT
imaging confirmed disease recurrence with metastasis to para-aortic lymph nodes
(Figure 59B, C). Basal-bolus insulin regimen was resumed.
Two years after surgery, he has not experienced hypertensive crises but
complains of fatigue and hyperhidrosis. Glycemic control had significantly worsened
since the last visit, and his basal and bolus insulin doses were increased to Glargine
12U/day, and Lispro 5U before breakfast and 7U before lunch and dinner. He is also
taking Benazepril 5mg and Hydrochlorothiazide 25mg daily for management of
hypertension. He is undergoing cytoreductive therapy with Vincristine 1.4 mg/m 2,
Dacarbazine 600 mg/m2, and Cyclophosphamide 750 mg/m2 (Figure 60).
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Archival (formalin fixed, paraffin embedded) paraganglioma tissue obtained
during the initial surgery was recut and mounted onto slides for IHC. Staining for GAD65
was negative in the paraganglioma (Figure 62).
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Figure 59. CT and PET/CT images at paraganglioma diagnosis and recurrence
Computed tomography images demonstrate the location of the paraganglioma at the time of first
diagnosis (A) and at the time of recurrence (B). Recurrence was also imaged with positron emission
tomography/computed tomography (C). White arrows point to the paraganglioma.
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Figure 60. Timeline of events and corresponding lab results
The symbol “-” designates no medication at that time. Blank cells designate no value obtained at that
time.
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Figure 61. Loss of succinate dehydrogenase in paraganglioma
Immunohistochemistry imaging of the paraganglioma demonstrating loss of succinate dehydrogenase
subunit B expression and positive fumarate hydratase staining for comparison. Scale bar in black is
200μm.
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Figure 62. Lack of GAD65 expression in paraganglioma
Immunohistochemistry imaging of the paraganglioma (top) and control pancreas (bottom) with
hematoxylin and eosin and glutamic acid decarboxylase-65 at low and high magnifications. Low
magnification scale bar is 1 mm; high magnification scale bar is 200μm.
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7.3 Discussion
Functional pheochromocytomas and paragangliomas are classified into three
major phenotypes: adrenergic, noradrenergic, and dopaminergic [285]. Most functional
paragangliomas are noradrenergic, whereas many pheochromocytomas can be
adrenergic because of the presence of phenylethanolamine N-methyltransferase in the
adrenal medulla [286]. Because of excess catecholamine secretion, functional
pheochromocytomas and paragangliomas are often accompanied with hyperglycemia.
The mechanisms by which catecholamines induce this glucose intolerance include
insulin resistance [287] with decreased glucose uptake into muscle and adipose tissue
[288], decreased insulin release [289, 290], and stimulation of glucagon secretion [291].
We could not address the possibility of germline SDH mutations [292] since the patient
declined genetic testing; however, it is well-documented that SDH mutations in
paragangliomas confer an aggressive tumor phenotype and increased metastatic
potential [293-295], so the clinical course of this patient’s tumor burden is not surprising.
Cases have been presented demonstrating that in patients who already had type 2
diabetes, paraganglioma resection dramatically improved their glycemic control [296].
However, to the best of our knowledge, this is the first description of a new diagnosis of
autoimmune diabetes in the setting of a paraganglioma. The patient’s age at
presentation, autoantibody positivity, and insulin dependence all meet the conventional
requirements for the diagnosis of LADA [297]. It is interesting that the timing of
autoimmune diabetes diagnosis matches that of the paraganglioma diagnosis, and that
the waxing and waning of poor glycemic control seems to correlate with the timing of
paraganglioma surgical debulking and subsequent recurrence. We postulate three
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possible explanations: one, this patient has two concurrent, but unrelated, diagnoses of
paraganglioma and LADA; two, the recurrence of poor glycemic control is caused
primarily by the norepinephrine secreted by the paraganglioma; and three, this patient’s
paraganglioma elicits an autoimmune response that targets the pancreatic beta cells
leading to autoimmune diabetes.
We cannot rule out the possibility that this patient’s glycemic trends are the result
of the ‘honeymoon phase,’ or period of ‘remission,’ that can occur in patients with type 1
diabetes, during which patients are often able to halt most or all of their insulin therapy
and maintain euglycemia [298]. In the pediatric population, this period of remission can
vary between three months to 13 years (reviewed by [298]). In adults, some cases
report remission lasting beyond 14 months after cessation of insulin regimens [299], and
this patient’s period of euglycemia without insulin fits within that timeframe.
Closely related to the first possible explanation, we do not expect this patient’s
glucose intolerance to be solely attributable to norepinephrine secretion by the
paraganglioma. Norepinephrine excess can contribute to hyperglycemia, but less
significantly than epinephrine because of differences in receptor affinities [296].
Additionally, the patient’s anti-GAD65 antibodies were elevated at the time of
paraganglioma diagnosis, and then were substantially increased at the time of
confirmation of disease recurrence. The patient had no neuromuscular symptoms or
signs that could be associated with Stiff-person syndrome [300]. The presence of antiGAD antibodies is clearly indicative of autoimmune-related diabetes, which to the best
of our knowledge, is not attributable to norepinephrine excess.
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Lastly, while we do not have anti-GAD65 levels preceding the diagnosis, or
during the period of euglycemia post-surgery, their trend is suggestive of an
autoimmune process which would result in loss of beta cell function, a condition which
has not been described before in the setting of a paraganglioma. The patient’s
improvement in glycemic control after surgical debulking could be the result of removal
of antigen within the paraganglioma, whose burden increased as the tumor recurred
and metastasized. Although our IHC results did not show GAD65 antigen present within
the paraganglioma tissue, which supports one of the first two proposed hypotheses, we
cannot exclude a tumor-induced autoimmune process toward other epitopes not
recognized by the antibody utilized in our IHC. Interestingly, GAD65 expression in a
small cell lung cancer has been reported in a case of LADA with high anti-GAD65 titers,
indicative of a paraneoplastic syndrome [301]. The extraordinary rise in plasma antibody
titer concomitant with the relapse of tumor is consistent with an increase in exposure to
the antigen. This would support the hypothesis of a novel form of paraneoplastic
autoimmune diabetes in the setting of paragangliomas, and should be further evaluated
in future work.
While not directly adjacent to adipose tissue, these results clearly demonstrate
the role of tumor and tumor microenvironment on whole-body energy and glucose
homeostasis, which inherently includes adipose tissue.

7.4 Conclusion
Catecholamine excess can cause hyperglycemia in patients with functional
paragangliomas. This is a unique case of autoimmune diabetes diagnosed in the setting
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of a functional paraganglioma, with glycemic control closely related to paraganglioma
disease burden. Further research and testing should be done in patients with
pheochromocytomas and paragangliomas to investigate a possible autoimmune role in
certain cases. Additionally, this work highlights the importance of understanding the
implications of cancer on whole-body energy and glucose homeostasis.
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Summary

The role of adipose tissue in CAC is complex. Our results show that adipose
tissue plasticity occurs in breast cancer. First, we demonstrate in murine models of
breast cancer as well as in human samples of breast cancer that white adipose tissue,
in the presence of tumor, undergoes WAT browning to a beige adipose tissue
phenotype. We show that this effect is localized and seems to occur earlier in cancer
progression (Figure 63A).
Next, we moved into in vitro models of adipogenesis and cancer to investigate
the role of cancer secreted factors, as well as cancer:adipocyte cross-talk, on adipocyte
plasticity. We show in both human and mice cell culture that cancer secreted factors
and cross-talk decrease mRNA expression of classic WAT-related genes. In mice, we
show that cross-talk specifically results in an increase in lipolysis-related mRNA
expression, and in humans, cancer secreted factors reduce white adipocyte lipid droplet
size. Regarding WAT browning, our results strongly suggest that in mice, neither cancer
secreted factors nor cross talk with adipocytes is able to induce WAT browning;
however, in human cell culture, our results are less conclusive (Figure 63B).
We demonstrate that IL6+IL6RA, regardless of its source, is able to induce IL6mediated signaling through STAT3 phosphorylation; however, that signaling alone is not
sufficient to directly induce WAT browning. The last part of our bench laboratory
experiments, we present preliminary data suggesting that immune cell population shifts
within the white adipose tissue of mice with breast cancer tumors may be source of
WAT browning (Figure 63B).
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Lastly, we show that the VCUHS has an identifiable population of patients with
cancer over the age of 40 with brown adipose tissue activity on PET/CT scan. Our pilot
clinical study is currently underway to test our hypothesis that this increased brown
adipose tissue activity is maladaptive in this patient population, and to show the effects
of these changes on whole body energy expenditure as well as other relevant
secondary endpoints.
In conclusion, we have demonstrated that adipose tissue plasticity occurs in
breast cancer and certain components are caused by different drivers with the tumor
microenvironment. We predict that further exploration of the exact mechanisms and
translational implications will provide useful information to lead to new therapeutic
treatments for patients with cancer-associated cachexia.
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Figure 63. Summary of work
(A) Local WAT browning occurs in murine and human breast cancer, and in murine models we
demonstrate that this occurs earlier in tumor progression. (B) Using in vitro cell culture models, we
demonstrate that cancer secreted factors, cross talk between cancer cells and adipocytes, IL6+IL6RA,
and immune cell population shifts are capable of inducing as host of effects related to adipocyte plasticity.
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